WO2010148649A1 - 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists - Google Patents

5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists Download PDF

Info

Publication number
WO2010148649A1
WO2010148649A1 PCT/CN2010/000939 CN2010000939W WO2010148649A1 WO 2010148649 A1 WO2010148649 A1 WO 2010148649A1 CN 2010000939 W CN2010000939 W CN 2010000939W WO 2010148649 A1 WO2010148649 A1 WO 2010148649A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxy
phenyl
methylethyl
oxadiazol
chloro
Prior art date
Application number
PCT/CN2010/000939
Other languages
French (fr)
Inventor
Guanghui Deng
Xichen Lin
Qinghua Meng
Feng Ren
Jianing Xiang
Heng Xu
Baowei Zhao
Haibo Zhang
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0911126A external-priority patent/GB0911126D0/en
Priority claimed from GB0918473A external-priority patent/GB0918473D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to US13/379,431 priority Critical patent/US20120101134A1/en
Priority to EP10791156A priority patent/EP2445891A4/en
Priority to JP2012516485A priority patent/JP2012530728A/en
Publication of WO2010148649A1 publication Critical patent/WO2010148649A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to novel compounds having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
  • Sphingosine 1 -phosphate is a bioactive lipid mediator formed by the phosphorylation of sphingosine by sphingosine kinases and is found in high levels in the blood. It is produced and secreted by a number of cell types, including those of hematopoietic origin such as platelets and mast cells (Okamoto et al 1998 J Biol Chem 273(42):27104; Sanchez and HIa 2004, J Cell Biochem 92:913). It has a wide range of biological actions, including regulation of cell proliferation, differentiation, motility, vascularisation, and activation of inflammatory cells and platelets (Pyne and Pyne 2000, Biochem J. 349: 385).
  • S1P1 Edg-1
  • S1P2 Edg-5
  • S1P3 Edg-3
  • S1P4 Edg-6
  • S1P5 S1P5
  • S1P1 receptor Proposed roles for the S1P1 receptor include lymphocyte trafficking, cytokine induction/suppression and effects on endothelial cells (Rosen and Goetzl 2005 Nat Rev Immunol. 5:560). Agonists of the S1 P1 receptor have been used in a number of autoimmune and transplantation animal models, including Experimental Autoimmune Encephalomelitis (EAE) models of MS, to reduce the severity of the induced disease (Brinkman et al 2003 JBC 277:21453; Fujino et al 2003 J Pharmacol Exp Ther 305:70; Webb et al 2004 J Neuroimmunol 153:108; Rausch et al 2004 J Magn Reson Imaging 20:16).
  • EAE Experimental Autoimmune Encephalomelitis
  • This activity is reported to be mediated by the effect of S1P1 agonists on lymphocyte circulation through the lymph system.
  • Treatment with S1P1 agonists results in the sequestration of lymphocytes within secondary lymphoid organs such as the lymph nodes, inducing a reversible peripheral lymphopoenia in animal models (Chiba et al 1998, J Immunology 160:5037, Forrest et al 2004 J Pharmacol Exp Ther 309:758; Sanna et al 2004 JBC 279:13839).
  • S1P1 gene deletion causes embryonic lethality.
  • Experiments to examine the role of the S1P1 receptor in lymphocyte migration and trafficking have included the adoptive transfer of labelled S1P1 deficient T cells into irradiated wild type mice. These cells showed a reduced egress from secondary lymphoid organs (Matloubian et al 2004 Nature 427:355).
  • S1P1 has also been ascribed a role in endothelial cell junction modulation (Allende et al 2003 102:3665, Blood Singelton et al 2005 FASEB J 19:1646). With respect to this endothelial action, S1P1 agonists have been reported to have an effect on isolated lymph nodes which may be contributing to a role in modulating immune disorders. S1P1 agonists caused a closing of the endothelial stromal 'gates' of lymphatic sinuses which drain the lymph nodes and prevent lymphocyte egress (Wei wt al 2005, Nat. Immunology 6:1228).
  • the immunosuppressive compound FTY720 (JP11080026-A) has been shown to reduce circulating lymphocytes in animals and man, have disease modulating activity in animal models of immune disorders and reduce remission rates in relapsing remitting Multiple Sclerosis (Brinkman et al 2002 JBC 277:21453, Mandala et al 2002 Science 296:346, Fujino et al 2003 J Pharmacology and Experimental Therapeutics 305:45658, Brinkman et al 2004 American J Transplantation 4:1019, Webb et al
  • the present invention therefore provides as novel compounds of formula (I) or a salt thereof:
  • X is CH or N
  • Y is CR 5 or N
  • Z is C ( o- 5) alkyl optionally interrupted by O, S or N 1 and optionally substituted by C ( i-
  • B is a 5-membered heteroaryl ring selected from:
  • R 1 is C (1-4) alkoxy
  • R 2 is cyano or chloro
  • R 3 is hydrogen, halogen, trifluoromethyl, C ( i -5) alkyl, C ⁇ alkoxy or CN;
  • R 4 is hydrogen, halogen, trifluoromethyl, C ⁇ alkyl or C d ⁇ alkoxy
  • R 5 is hydrogen, halogen, trifluoromethyl, C (1 . 3) alkyl or C(i-3 ) alkoxy, with the proviso that the compound is not 3-(3-(5-(3-cyano-4-isopropoxyphenyl)-1 ,2,4-oxadiazol-3-yl)-
  • X is CH. In another embodiment X is N. In one embodiment Y is CR 5 , wherein R 5 is hydrogen or halogen. In another embodiment Y is CR 5 , wherein R 5 is hydrogen or fluorine. In a further embodiment R 5 is hydrogen. In a further embodiment Y is N.
  • Z is C ⁇ alkyl optionally interrupted by O and optionally substituted by C (1 . 3) alkyl. In another embodiment Z is C (2-5) alkyl optionally substituted by methyl. In a further embodiment Z is OC ⁇ alkyl.
  • Z is C (0- 5)alkyl. In another embodiment Z is C (2) alkyl substituted by methyl. In a further embodiment Z is OC ⁇ alkyl. In another embodiment Z is C (1 . 2)NC(i. 2 )alkyl optionally substituted by methyl on the N atom.
  • B is (a), (b), (c), (d) or (T).
  • B is (f).
  • R 1 is C ( i -4) alkoxy. In another embodiment R 1 is ispropoxy.
  • R 2 is cyano. In another embodiment R 2 is chloro.
  • R 3 is hydrogen, methyl, ethyl, propyl, methoxy, chloro or triflouromethyl.
  • R 4 is hydrogen or fluoro.
  • R 5 is hydrogen
  • X is CH or N; Y is CR 5 or N;
  • Z is C (2 - 5) alkyl optionally interrupted by O and optionally substituted by Co ⁇ alkyl;
  • R 1 is C ( i- 4) alkoxy
  • R 2 is cyano or chloro
  • R 3 is hydrogen, methyl, ethyl, methoxy, chloro or triflouromethyl
  • R 4 is hydrogen
  • R 5 is hydrogen
  • X is CH or N
  • Y is CR 5 or N
  • Z is C (2 - 5) alkyl optionally substituted by methyl or Z is OC ⁇ alkyl;
  • R 1 is ispropoxy;
  • R 2 is cyano or chloro;
  • R 3 is hydrogen, methyl, ethyl, methoxy, chloro or triflouromethyl
  • R 4 is hydrogen
  • R 5 is hydrogen.
  • X is CH or N;
  • Y is CR 5 or N;
  • Z is C ( o-5)alkyl optionally interrupted by O or N and optionally substituted by C ( i -3) alkyl;
  • B is (a), (b), (C), (d) or (f);
  • R 1 is C( 1-4) alkoxy;
  • R 2 is cyano or chloro;
  • R 3 is hydrogen, methyl, ethyl, propyl, methoxy, chloro or triflouromethyl;
  • R 4 is hydrogen or fluoro; and
  • R 5 is hydrogen.
  • X is CH or N; Y is CR 5 or N;
  • Z is C(o-5)alkyl, C ⁇ alkyl substituted by methyl, OC ⁇ alkyl or C ⁇ NC ⁇ alkyl optionally substituted by methyl on the N atom.
  • B is (a), (b), (c), (d) or (f);
  • R 1 is ispropoxy;
  • R 2 is cyano or chloro;
  • R 3 is hydrogen, methyl, ethyl, propyl, methoxy, chloro or triflouromethyl
  • R 4 is hydrogen or fluoro
  • R 5 is hydrogen
  • alkyl as a group or part of a group e.g. alkoxy or hydroxyalkyl refers to a straight or branched alkyl group in all isomeric forms.
  • C ( i -6 ) alkyl refers to an alkyl group, as defined above, containing at least 1 , and at most 6 carbon atoms Examples of such alkyl groups include methyl, ethyl, propyl, /so-propyl, ⁇ -butyl, iso- butyl, sec-butyl, or terf-butyl. Examples of such alkoxy groups include methoxy, ethoxy, propoxy, /so-propoxy, butoxy, /so-butoxy, sec-butoxy and te/f-butoxy.
  • halogen refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) and the term “halo” refers to the halogen: fluoro (-F), chloro (-Cl), bromo(-Br) and iodo(-l).
  • compounds of formula (I) may exist as stereoisomers.
  • the invention extends to all optical isomers such as stereoisomeric forms of the compounds of formula (I) including enantiomers, diastereoisomers and mixtures thereof, such as racemates.
  • the different stereoisomer ⁇ forms may be separated or resolved one from the other by conventional methods or any given isomer may be obtained by conventional stereoselective or asymmetric syntheses.
  • Suitable compounds of formula (I) are:
  • compositions of formula (I) include any pharmaceutically acceptable salt, ester or salt of such ester of a compound of formula (I) which, upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolic or residue thereof.
  • the compounds of formula (I) can form salts. It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in J. Pharm. Sci., 1977, 66, 1-19, such as acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid.
  • inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid
  • organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-tolu
  • Salts may also be prepared from pharmaceutically acceptable bases including inorganic bases and organic bases.
  • Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like.
  • Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary, and tertiary amines; substituted amines including naturally occurring substituted amines; and cyclic amines.
  • Particular pharmaceutically acceptable organic bases include arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tris(hydroxymethyl)aminomethane (TRIS, trometamol) and the like.
  • Salts may also be formed from basic ion exchange resins, for example polyamine resins.
  • salts may be prepared from pharmaceutically acceptable acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, ethanedisulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, pamoic, pantothenic, phosphoric, propionic, succinic, sulfuric, tartaric, p- toluenesulfonic acid, and the like.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, ethanedisulfonic, fumaric, gluconic, glutamic, hydrobro
  • the compounds of formula (I) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated.
  • This invention includes within its scope stoichiometric hydrates or solvates as well as compounds containing variable amounts of water and/or solvent.
  • this invention provided processes for the preparation of a compound of formula (I).
  • certain compounds of formula (I) were prepared by the process in Schemes I to XIV.
  • the first step of the process (Il to III) is carried out in POCI 3 at 90 0 C.
  • suitable reagents include CuBr 2 and 1 ,1-dimethylethyl nitrite were used at low temperature (O 0 C).
  • the Suzuki coupling reaction (IV to V) may be performed employing suitable reagents including Pd(PPh 3 ) 4 and K 3 PO 4 in a suitable solvent such as DMF or DME under microwave condition.
  • the last step of the process (V to I) is carried out by treatment with basic (such as sodium hydroxide in a suitable solvent such as isopropanol) conditions and may be carried out at room temperature.
  • intermediate (Vl) can be converted to (I) by reductive amination reaction with amino acids in the presence of a suitable reducing reagent such as NaBH(OAc) 3 in a suitable solvent (methanol or CH 2 CI 2 ) at room temperature.
  • a suitable reducing reagent such as NaBH(OAc) 3 in a suitable solvent (methanol or CH 2 CI 2 ) at room temperature.
  • the amino ester instead of the amino acid was used for the reductive amination process, the ester should be hydrolyzed to the corresponding acid by treatment with basic (such as sodium hydroxide in a suitable solvent such as isopropanol) conditions to get compound I.
  • the first two steps (VII to Xl) are Suzuki coupling reactions, and suitable palladium catalysts (such as PdCI 2 (dppf) and Pd(PPh 3 J 4 ), bases (such as Cs 2 CO 3 and K 3 PO 4 ), and solvents (such as DMF and DME) need to be selected to provide good yield.
  • suitable palladium catalysts such as PdCI 2 (dppf) and Pd(PPh 3 J 4
  • bases such as Cs 2 CO 3 and K 3 PO 4
  • solvents such as DMF and DME
  • Representative compounds of formula (VIII) can be prepared as described in the experimental section. Hydrolysis of the ethyl ester in intermediate Xl provide compound I.
  • reagents include Pd(PPh 3 ) 4 and K 3 PO 4 in a solvent such as DMF or DME under microwave condition.
  • suitable reagent HCI in suitable solvent dioxane or TMSCI in acetonitrile at room temperature.
  • the last step (XVI to I) is similar with process (Vl to I) in scheme II.
  • reagents include PdCI 2 (dppf) and Cs 2 CO 3 in a solvent such as CH 3 CN or DME under microwave condition.
  • the second step of the process (XVII to XVIII) is carried out by treatment with Br 2 in a suitable solvent such as HOAc at room temperature.
  • the last two steps (XIX to I) are similar with process (IV to I) in scheme I.
  • Scheme X In the first step of Suzuki coupling process (XVIlI to XXlM) suitale reagents include PdCI 2 (dppf) and Cs 2 CO 3 in a solvent such as DME under microwave condition. Formula (XXIII) can be converted to (XXIV) by treatment with suitable reagent BrZn(CH 2 ) 3 COOEt in a suitable solvent such as THF at elevated temperature. The last step (XXIV to I) is similar with process (V to I) in scheme I.
  • suitable reagents include EDCI, HOBT and TBAF.
  • the second step of Negishi coupling process(XXV to XXVI) suitale reagents include Pd 2 (dba) 3 and Cs 2 CO 3 in a solvent such as THF.
  • the last step of the process (XXVI to I) is carried out by treatment with basic (such as sodium hydroxide in a suitable solvent such as /-propanol or THF) conditions and may be carried out at 60- 9O 0 C.
  • Scheme XII The first step of process (Il to XXVIII) is similar with process (Il to XXV) in scheme Xl.
  • Compounds of formula (XXVII) can be prepared as described in the experimental section.
  • the last step of the process (XXVIII to I) is carried out by treatment with basic (such as sodium hydroxide in a suitable solvent such as isopropanol) conditions and may be carried out at room temperature.
  • the first step of process (Il to XXXI) is similar with process (Il to XXV) in scheme Xl.
  • the second step of process (XXXI to XXXII) is carried out in suitable solvent such as THF with reagents include ethyl hydroxyacetate, PPh 3 and DIAD.
  • the last step of the process (XXXII to I) is carried out by treatment with basic (such as sodium hydroxide in a suitable solvent such as /-propanol or THF) conditions and may be carried out at 50 0 C
  • compositions may be prepared conventionally by reaction with the appropriate acid or acid derivative.
  • potencies and efficacies of the compounds of this invention for the S1 P1 receptor can be determined by GTPYS assay or S1P1 Tango assay performed on the human cloned receptor as described herein.
  • Compounds of formula (I) have demonstrated agonist activity at the S1P1 receptor, using functional assays described herein.
  • the compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment of multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia- reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependant diabetes.
  • Compounds of formula (I) and their pharmaceutically acceptable salts may also be of use in the treatment of Parkinson's Disease, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, spinal muscular atrophy, polyglutamine expansion disorders, vascular dementia, Down's syndrome, HIV dementia, dementia, ocular diseases including glaucoma, aged related macular degeneration, cataracts, traumatic eye injury, diabetic retinopathy, traumatic brain injury, stroke, tauopathies and hearing loss. It is to be understood that "treatment” as used herein includes prophylaxis as well as alleviation of established symptoms.
  • the invention also provides a compound of formula (I) and a pharmaceutically acceptable salt thereof, for use as therapeutic substances, in particular in the treatment of the conditions or disorders mediated via the S1P1 receptor.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as therapeutic substances in the treatment of multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non- insulin dependant diabetes.
  • the invention further provides a method of treatment of conditions or disorders in mammals including humans which can be mediated via the S1P1 receptor, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides for the use of compounds of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of the conditions or disorders mediated via the S1P1 receptor
  • the invention provides a method of treatment of multiple sclerosis, which comprises administering to the sufferer a therapeutically safe and effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
  • a pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
  • the present invention provides a process for preparing a pharmaceutical composition, the process comprising mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); tabletting lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); and acceptable wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • tabletting lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium starch glycollate
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e.g. lecithin or acacia), non-aqueous vehicles (which may include edible oils e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils), preservatives (e.g.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salts thereof and a sterile vehicle.
  • Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose, utilising a compound of the invention or pharmaceutically acceptable derivatives thereof and a sterile vehicle, optionally with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen- free water, before use.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.
  • compounds of formula (I) or pharmaceutically acceptable salts thereof may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops).
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.
  • the composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • the dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors.
  • suitable unit doses may be 0.05 to 1000 mg, 1.0 to 500mg or 1.0 to 200 mg and such unit doses may be administered more than once a day, for example two or three times a day.
  • Compounds of formula (I) or pharmaceutically acceptable salts thereof may be used in combination preparations.
  • the compounds of the invention may be used in combination with cyclosporin A, methotrexate, steriods, rapamycin, proinflammatory cytokine inhibitors, immunomodulators including biologicals or other therapeutically active compounds.
  • the subject invention also includes isotopically-labeled compounds, which are identical to those recited in formulas I and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 3 H, 11 C, 14 C, 18 F, 123 I and 125 I.
  • Isotopically-labeled compounds of the present invention for example those into which radioactive isotopes such as 3 H, 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
  • 11 C and 8 F isotopes are particularly useful in PET (positron emission tomography), and 125 I isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging.
  • substitution with heavier isotopes such as deuterium, i.e., 2 H can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances, lsotopically labelled compounds of formula (I) can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labelled reagent for a non-isotopically labeled reagent.
  • the intermediates for the preparation of the examples may not necessarily have been prepared from the specific batch of precursor described.
  • Tricyclohexylphosphine 0.550 g
  • Pd 2 (dba) 3 (0.144 g) in ⁇ /, ⁇ /-dimethylformamide (DMF) (12 mL) were stirred under nitrogen for 30 min.
  • 4 I 4,4 ⁇ 4',5,5,5' l 5'-octamethyl-2,2'-bi-1 l 3,2- dioxaborolane
  • potassium acetate (0.770 g) were added to the reacion mixture under nitrogen at room temperature.
  • the reaction vessel was sealed and heated under microwave at 180 0 C for 90 min.
  • Example-4 4-[3-(5- ⁇ 5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl ⁇ -1,2,4-oxadiazol-3-yl)-2- methylphenyl]butanoic acid (E4)
  • Example-13 a-p-tS ⁇ S-chloro-e-KI-methylethyOoxyl-a-pyridiny ⁇ -I ⁇ . ⁇ oxacliazol-a-yl) ⁇ - ethylphenyljpropanoic acid (E13)
  • Example-36 4-[3-(5- ⁇ 3-chloro-4-t(1 -methylethyl)oxy]phenyl ⁇ -1 ,2,4-oxadiazol-3-yl)-2- propylphenyl]butanoic acid (E36)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)

Abstract

5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.

Description

5 -MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1 -PHOSPHATE RECEPTOR AGONISTS
The present invention relates to novel compounds having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
Sphingosine 1 -phosphate (S1 P) is a bioactive lipid mediator formed by the phosphorylation of sphingosine by sphingosine kinases and is found in high levels in the blood. It is produced and secreted by a number of cell types, including those of hematopoietic origin such as platelets and mast cells (Okamoto et al 1998 J Biol Chem 273(42):27104; Sanchez and HIa 2004, J Cell Biochem 92:913). It has a wide range of biological actions, including regulation of cell proliferation, differentiation, motility, vascularisation, and activation of inflammatory cells and platelets (Pyne and Pyne 2000, Biochem J. 349: 385). Five subtypes of S1P responsive receptor have been described, S1P1 (Edg-1), S1P2 (Edg-5), S1P3 (Edg-3), S1P4 (Edg-6), and S1P5 (Edg-8), forming part of the G-protein coupled endothelial differentiation gene family of receptors (Chun et al 2002 Pharmacological Reviews 54:265, Sanchez and HIa 2004 J Cellular Biochemistry, 92:913). These 5 receptors show differential mRNA expression, with S1P1-3 being widely expressed, S1P4 expressed on lymphoid and hematopoietic tissues and S1P5 primarily in brain and to a lower degree in spleen. They signal via different subsets of G proteins to promote a variety of biological responses (Kluk and HIa 2002 Biochem et Biophysica Acta 1582:72, Sanchez and HIa 2004, J Cellular Biochem 92:913).
Proposed roles for the S1P1 receptor include lymphocyte trafficking, cytokine induction/suppression and effects on endothelial cells (Rosen and Goetzl 2005 Nat Rev Immunol. 5:560). Agonists of the S1 P1 receptor have been used in a number of autoimmune and transplantation animal models, including Experimental Autoimmune Encephalomelitis (EAE) models of MS, to reduce the severity of the induced disease (Brinkman et al 2003 JBC 277:21453; Fujino et al 2003 J Pharmacol Exp Ther 305:70; Webb et al 2004 J Neuroimmunol 153:108; Rausch et al 2004 J Magn Reson Imaging 20:16). This activity is reported to be mediated by the effect of S1P1 agonists on lymphocyte circulation through the lymph system. Treatment with S1P1 agonists results in the sequestration of lymphocytes within secondary lymphoid organs such as the lymph nodes, inducing a reversible peripheral lymphopoenia in animal models (Chiba et al 1998, J Immunology 160:5037, Forrest et al 2004 J Pharmacol Exp Ther 309:758; Sanna et al 2004 JBC 279:13839). Published data on agonists suggests that compound treatment induces loss of the S1P1 receptor from the cell surface via internalisation (Graler and Goetzl 2004 FASEB J 18:551; Matloubian et al 2004 Nature 427:355; Jo et al 2005 Chem Biol 12:703) and it is this reduction of S1P1 receptor on immune cells which contributes to the reduction of movement of T cells from the lymph nodes back into the blood stream.
S1P1 gene deletion causes embryonic lethality. Experiments to examine the role of the S1P1 receptor in lymphocyte migration and trafficking have included the adoptive transfer of labelled S1P1 deficient T cells into irradiated wild type mice. These cells showed a reduced egress from secondary lymphoid organs (Matloubian et al 2004 Nature 427:355).
S1P1 has also been ascribed a role in endothelial cell junction modulation (Allende et al 2003 102:3665, Blood Singelton et al 2005 FASEB J 19:1646). With respect to this endothelial action, S1P1 agonists have been reported to have an effect on isolated lymph nodes which may be contributing to a role in modulating immune disorders. S1P1 agonists caused a closing of the endothelial stromal 'gates' of lymphatic sinuses which drain the lymph nodes and prevent lymphocyte egress (Wei wt al 2005, Nat. Immunology 6:1228).
The immunosuppressive compound FTY720 (JP11080026-A) has been shown to reduce circulating lymphocytes in animals and man, have disease modulating activity in animal models of immune disorders and reduce remission rates in relapsing remitting Multiple Sclerosis (Brinkman et al 2002 JBC 277:21453, Mandala et al 2002 Science 296:346, Fujino et al 2003 J Pharmacology and Experimental Therapeutics 305:45658, Brinkman et al 2004 American J Transplantation 4:1019, Webb et al
2004 J Neuroimmunology 153:108, Morris et al 2005 EurJ Immunol 35:3570, Chiba
2005 Pharmacology and Therapeutics 108:308, Kahan et al 2003, Transplantation 76:1079, Kappos et a) 2006 New Eng J Medicine 335:1124). This compound is a prodrug that is phosphorylated in vivo by sphingosine kinases to give a molecule that has agonist activity at the S1P1 , S1P3, S1P4 and S1P5 receptors. Clinical studies have demonstrated that treatment with FTY720 results in bradycardia in the first 24 hours of treatment (Kappos et al 2006 New Eng J Medicine 335:1124). The bradycardia is thought to be due to agonism at the S1P3 receptor, based on a number of cell based and animal experiments. These include the use of S1P3 knock- out animals which, unlike wild type mice, do not demonstrate bradycardia following FTY720 administration and the use of S1P1 selective compounds. (Hale et al 2004 Bioorganic & Medicinal Chemistry Letters 14:3501, Sanna et al 2004 JBC 279:13839, Koyrakh et al 2005 American J Transplantation 5:529)
Hence, there is a need for S1P1 receptor agonist compounds with selectivity over S1P3 which might be expected to show a reduced tendency to induce bradycardia.
The following patent applications describe oxadiazole derivatives as S1P1 agonists: WO03/105771, WO05/058848, WO06/047195, WO06/100633, WO06/115188, WO07/024922, WO07/116866, WO08/076356, WO08/074821 , WO09/043889, WO09/043890, and US09/0076070.
The following patent application describes indole-oxadiazole derivatives as antipicomaviral agents: WO96/009822. The following patent applications describe indole-carboxylic acid derivatives as leukotriene receptor antagonists, pesticides and agrochemical fungicides respectively: WO06/090817, EP 0 439 785 and DE 39 39 238.
International patent applications WO08/074821 and WO08/76356 describe oxadiazole-indole derivatives as S1 P1 agonists.
The following patent applications describe oxadiazole and other 5-membered heteroaromatic ring derivatives as S1P1 agonists: WO05/082089, WO06/131336, WO08/029306, WO08/029370, and WO09/011850.
The Chemical Abstracts Registry disloses a compound of 3-(3-(5-(3-cyano-4- isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methylphenyl)propanoic acid without any associated activity or use (Chem Abs 1025928-99-7, 6 June 2008).
A structurally novel class of compounds has now been found which provides agonists of the S1P1 receptor.
The present invention therefore provides as novel compounds of formula (I) or a salt thereof:
Figure imgf000006_0001
(I)
wherein
X is CH or N;
Y is CR5 or N;
Z is C(o-5)alkyl optionally interrupted by O, S or N1 and optionally substituted by C(i-
3)alkyl or OH;
B is a 5-membered heteroaryl ring selected from:
Figure imgf000006_0002
(a) (b) (C) (d) (e)
Figure imgf000006_0003
(f)
R1 is C(1-4)alkoxy;
R2 is cyano or chloro;
R3 is hydrogen, halogen, trifluoromethyl, C(i-5)alkyl, C^alkoxy or CN;
R4 is hydrogen, halogen, trifluoromethyl, C^alkyl or Cd^alkoxy; and
R5 is hydrogen, halogen, trifluoromethyl, C(1.3)alkyl or C(i-3)alkoxy, with the proviso that the compound is not 3-(3-(5-(3-cyano-4-isopropoxyphenyl)-1 ,2,4-oxadiazol-3-yl)-
5-methylphenyl)propanoic acid.
In one embodiment X is CH. In another embodiment X is N. In one embodiment Y is CR5, wherein R5 is hydrogen or halogen. In another embodiment Y is CR5, wherein R5 is hydrogen or fluorine. In a further embodiment R5 is hydrogen. In a further embodiment Y is N.
In one embodiment Z is C^alkyl optionally interrupted by O and optionally substituted by C(1.3)alkyl. In another embodiment Z is C(2-5)alkyl optionally substituted by methyl. In a further embodiment Z is OC^alkyl.
In one embodiment Z is C(0-5)alkyl. In another embodiment Z is C(2)alkyl substituted by methyl. In a further embodiment Z is OC^alkyl. In another embodiment Z is C(1. 2)NC(i.2)alkyl optionally substituted by methyl on the N atom.
In one embodiment B is (a), (b), (c), (d) or (T).
In one embodiment B is (f).
In one embodiment R1 is C(i-4)alkoxy. In another embodiment R1 is ispropoxy.
In one embodiment R2 is cyano. In another embodiment R2 is chloro.
In one embodiment R3 is hydrogen, methyl, ethyl, propyl, methoxy, chloro or triflouromethyl. In one embodiment R4 is hydrogen or fluoro.
In one embodiment R5 is hydrogen.
In one embodiment
X is CH or N; Y is CR5 or N;
Z is C(2-5)alkyl optionally interrupted by O and optionally substituted by Co^alkyl;;
B is (f);
R1 is C(i-4)alkoxy;
R2 is cyano or chloro; R3 is hydrogen, methyl, ethyl, methoxy, chloro or triflouromethyl;
R4 is hydrogen; and
R5 is hydrogen.
In another embodiment X is CH or N;
Y is CR5 or N;
Z is C(2-5)alkyl optionally substituted by methyl or Z is OC^alkyl;
B is (f);
R1 is ispropoxy; R2 is cyano or chloro;
R3 is hydrogen, methyl, ethyl, methoxy, chloro or triflouromethyl;
R4 is hydrogen; and
R5 is hydrogen. In one embodiment X is CH or N; Y is CR5 or N; Z is C(o-5)alkyl optionally interrupted by O or N and optionally substituted by C(i-3)alkyl; B is (a), (b), (C), (d) or (f); R1 is C(1-4)alkoxy; R2 is cyano or chloro;
R3 is hydrogen, methyl, ethyl, propyl, methoxy, chloro or triflouromethyl; R4 is hydrogen or fluoro; and R5 is hydrogen.
In another embodiment
X is CH or N; Y is CR5 or N;
Z is C(o-5)alkyl, C^alkyl substituted by methyl, OC^alkyl or C^NC^alkyl optionally substituted by methyl on the N atom.
B is (a), (b), (c), (d) or (f);
R1 is ispropoxy; R2 is cyano or chloro;
R3 is hydrogen, methyl, ethyl, propyl, methoxy, chloro or triflouromethyl;
R4 is hydrogen or fluoro; and
R5 is hydrogen.
The term "alkyl" as a group or part of a group e.g. alkoxy or hydroxyalkyl refers to a straight or branched alkyl group in all isomeric forms. The term "C(i-6) alkyl" refers to an alkyl group, as defined above, containing at least 1 , and at most 6 carbon atoms Examples of such alkyl groups include methyl, ethyl, propyl, /so-propyl, π-butyl, iso- butyl, sec-butyl, or terf-butyl. Examples of such alkoxy groups include methoxy, ethoxy, propoxy, /so-propoxy, butoxy, /so-butoxy, sec-butoxy and te/f-butoxy.
As used herein, the term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) and the term "halo" refers to the halogen: fluoro (-F), chloro (-Cl), bromo(-Br) and iodo(-l).
In certain of the compounds of formula (I), dependent upon the nature of the substituent there are chiral carbon atoms and therefore compounds of formula (I) may exist as stereoisomers. The invention extends to all optical isomers such as stereoisomeric forms of the compounds of formula (I) including enantiomers, diastereoisomers and mixtures thereof, such as racemates. The different stereoisomer^ forms may be separated or resolved one from the other by conventional methods or any given isomer may be obtained by conventional stereoselective or asymmetric syntheses.
Certain of the compounds herein can exist in various tautomeric forms and it is to be understood that the invention encompasses all such tautomeric forms.
Suitable compounds of formula (I) are:
3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- methylphenyl]propanoic acid
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl] butanoic acid
(2f?)-3-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-2- methylphenyl]-2-methylpropanoic acid
4-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-2- methylphenyl]butanoic acid
3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- methylphenyl]propanoic acid 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- methylphenyl]butanoic acid
4-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-3-methyl-2- pyridinyl]butanoic acid
S-p-chloro-S-CS^δ-chloro-e-KI-methylethyOoxyJ-S-pyridinyl^i ^^-oxadiazol-S- yl)phenyl]propanoic acid
4-[2-chloro-3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3- yl)phenyl]butanoic acid
3-[2-chloro-3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3- yl)phenyl]propanoic acid 4-[2-chloro-3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3- yl)phenyl]butanoic acid e-^-chloro-S-CS-IS-cyano^-lli-methylethyOoxyjphenyl^i^^-oxadiazol-S- yl)phenyl]hexanoic acid
3-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyljpropanoic acid 4-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyriclinyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyl]butanoic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- ethylphenyl]butanoic acid 3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-
(methyloxy)phenyl]propanoic acid
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-
(methyloxy)phenyl]butanoic acid
3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- (methyloxy)phenyl]propanoic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1>2,4-oxadiazol-3-yl)-2-
(methyloxy)phenyl]butanoic acid
3-[4-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- pyridinyl]propanoic acid 4-[4-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- pyridinyl]butanoic acid
3-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 l2,4-oxadiazol-3-yl)-2- fluorophenyl]propanoic acid
4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- fluorophenyl]butanoic acid
3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-
(trifluoromethyl)phenyl]propanoic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2l4-oxadiazol-3-yl)-2-
(trifluoromethyl)phenyl]butanoic acid 3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-methylbenzoic acid
{[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl>1 ,2,4-oxadiazol-3-yl)-2- methylphenyl]oxy}acetic acid
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- ethylphenyl]butanoic acid
S-IS-Cδ^S-chloro^-KI-methylethyOoxylphenyiy-i ^^-oxadiazol-S-yl)^- ethylphenyl]propanoic acid
3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-5-fluoro-2-
(methyloxy)phenyl]propanoic acid 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5-fluoro-2-
(methyloxy)phenyl]butanoic acid ^[S-CS^S-chloro-e-KI-methylethyOoxyJ-S-pyricliny^-i ^^-oxadiazol-S-yO-δ-fluoro^- (methyloxy)phenyl]butanoic acid
3-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-5-fluoro-2- (methyloxy)phenyl]propanoic acid 3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5-fluoro-2- (methyloxy)phenyl]propanoic acid
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-5-fluoro-2-
(methyloxy)phenyl]butanoic acid
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- propylphenyl]butanoic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- propylphenyl]butanoic acid
4-{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- ethylphenyl]oxy}butanoic acid 4-{[3-(5-{3-chloro-4-[(1-methylethyl)oxy]pheny^1,2,4-oxadiazol-3-yl)-2- ethylphenyl]oxy}butanoic acid
{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyl]oxy}acetic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3,4-oxadiazol-2-yl)-2- ethylphenyljbutanoic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3,4-thiadiazol-2-yl)-2- ethylphenyl]butanoic acid
/\/-{[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3,4-thiadiazol-2-yl)-2- ethylphenyl]methyl}-Λ/-methylglycine 4-[3-(3-{3-cyano-4-[(1-methylethyl)oxy]pheny^1 ,2,4-thiadiazol-5-yl)-2- ethylphenyl]butanoic acid
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2- ethylphenyl]butanoic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2- ethylphenyl]butanoic acid
Λ/-{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2- ethylphenyl]methyl}-Λ/-methylglycine
Λ/-{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadiazol-3-yl)-2- ethylphenyl]methyl}-b-alanine Λ/-{2-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadiazol-3-yl)-2- ethylphenyl]ethyl}-Λ/-methylglycine 4-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2-ethylphenyl] butanoic acid
4-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-5-fluoro-2- (methyloxy)phenyl]bυtanoic acid 4-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl] butanoic acid
Λ/-{2-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2-ethylphenyl] ethyl}-Λ/-methylglycine
Λ/-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl] methyl}-Λ/-methylglycine
Λ/-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl] methyl}-/\/-methylglycine
/V-{2-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl] ethyl}-Λ/-methylglycine Λ/-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2-ethylphenyl] methyl}- Λ/-methyl-β-alanine
4-[4-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-3-ethyl-2- pyridinyl]butanoic acid
Λ/-{2-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2- ethylphenyl]ethyl}-Λ/-methyl-b-alanine
S-IS-Cδ-iS-chloro^-KI-methylethyOoxyJphenyl^i^^-oxadiazol-S-yOphenyllpropanoic acid or salts thereof.
Pharmaceutically acceptable derivatives of compounds of formula (I) include any pharmaceutically acceptable salt, ester or salt of such ester of a compound of formula (I) which, upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolic or residue thereof.
The compounds of formula (I) can form salts. It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in J. Pharm. Sci., 1977, 66, 1-19, such as acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid. The present invention includes within its scope all possible stoichiometric and non-stoichiometric forms. Salts may also be prepared from pharmaceutically acceptable bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary, and tertiary amines; substituted amines including naturally occurring substituted amines; and cyclic amines. Particular pharmaceutically acceptable organic bases include arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tris(hydroxymethyl)aminomethane (TRIS, trometamol) and the like. Salts may also be formed from basic ion exchange resins, for example polyamine resins. When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, ethanedisulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, pamoic, pantothenic, phosphoric, propionic, succinic, sulfuric, tartaric, p- toluenesulfonic acid, and the like.
The compounds of formula (I) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated. This invention includes within its scope stoichiometric hydrates or solvates as well as compounds containing variable amounts of water and/or solvent.
Included within the scope of the invention are all salts, solvates, hydrates, complexes, polymorphs, prodrugs, radiolabeled derivatives, stereoisomers and optical isomers of the compounds of formula (I). In a further aspect, this invention provided processes for the preparation of a compound of formula (I). In one aspect, certain compounds of formula (I) were prepared by the process in Schemes I to XIV.
Figure imgf000014_0001
Figure imgf000014_0002
Scheme I
The first step of the process (Il to III) is carried out in POCI3 at 90 0C. In the second step of the process (III to IV) suitable reagents include CuBr2 and 1 ,1-dimethylethyl nitrite were used at low temperature (O 0C). The Suzuki coupling reaction (IV to V) may be performed employing suitable reagents including Pd(PPh3)4 and K3PO4 in a suitable solvent such as DMF or DME under microwave condition. The last step of the process (V to I) is carried out by treatment with basic (such as sodium hydroxide in a suitable solvent such as isopropanol) conditions and may be carried out at room temperature.
In another aspect, compounds of formula (I) can be prepared by the process in Scheme Il to XIV.
Figure imgf000014_0003
Scheme Il
The Suzuki coupling reation in scheme Il (IV to Vl) is similar as that described in scheme I. In the next step, intermediate (Vl) can be converted to (I) by reductive amination reaction with amino acids in the presence of a suitable reducing reagent such as NaBH(OAc)3 in a suitable solvent (methanol or CH2CI2) at room temperature. If the amino ester (instead of the amino acid) was used for the reductive amination process, the ester should be hydrolyzed to the corresponding acid by treatment with basic (such as sodium hydroxide in a suitable solvent such as isopropanol) conditions to get compound I.
Figure imgf000015_0001
VII IX
Figure imgf000015_0002
Xl
Scheme III
In scheme III, the first two steps (VII to Xl) are Suzuki coupling reactions, and suitable palladium catalysts (such as PdCI2(dppf) and Pd(PPh3J4), bases (such as Cs2CO3 and K3PO4), and solvents (such as DMF and DME) need to be selected to provide good yield. Representative compounds of formula (VIII) can be prepared as described in the experimental section. Hydrolysis of the ethyl ester in intermediate Xl provide compound I.
Figure imgf000016_0002
DMF
Figure imgf000016_0001
R1 K3PO4, Pd(Ph3P)4, DMF
XII
Figure imgf000016_0003
XIII
Scheme IV Steps in scheme IV (X to XIII to I) are similar with process (VII to Xl to I) in scheme III.
Figure imgf000016_0004
Scheme V
The two steps (XII to XIV to I) in scheme V are similar with process (IV to Vl to I) in scheme II.
Figure imgf000016_0005
XII XV
Figure imgf000016_0006
XVI Scheme Vl
In the first step of Suzuki coupling process (XII to XV) suitale reagents include Pd(PPh3)4 and K3PO4 in a solvent such as DMF or DME under microwave condition. In the second step of the process (XV to XVI) suitable reagent HCI in suitable solvent dioxane or TMSCI in acetonitrile at room temperature. The last step (XVI to I) is similar with process (Vl to I) in scheme II.
Br21 NaOAc HOAc
Figure imgf000017_0001
Figure imgf000017_0002
XVII XVIII
Figure imgf000017_0003
Scheme VII
In the first step of Suzuki coupling process (X to XVII) suitale reagents include PdCI2(dppf) and Cs2CO3 in a solvent such as CH3CN or DME under microwave condition. The second step of the process (XVII to XVIII) is carried out by treatment with Br2 in a suitable solvent such as HOAc at room temperature. The last two steps (XIX to I) are similar with process (IV to I) in scheme I.
Figure imgf000017_0004
Scheme VIII
The two steps (XVIII to I) are similar with process (IV to I) in scheme II.
Figure imgf000018_0001
XXI
Figure imgf000018_0002
Scheme IX The two steps (XVIII to I) are similar with process (XII to I) in scheme Vl.
OEt
Figure imgf000018_0003
XVlIl XXIII
Figure imgf000018_0004
Scheme X In the first step of Suzuki coupling process (XVIlI to XXlM) suitale reagents include PdCI2(dppf) and Cs2CO3 in a solvent such as DME under microwave condition. Formula (XXIII) can be converted to (XXIV) by treatment with suitable reagent BrZn(CH2)3COOEt in a suitable solvent such as THF at elevated temperature. The last step (XXIV to I) is similar with process (V to I) in scheme I.
Figure imgf000019_0001
Figure imgf000019_0002
XXVI
Scheme Xl In the first step of the process (Il to XXV) suitable reagents include EDCI, HOBT and TBAF. The second step of Negishi coupling process(XXV to XXVI) suitale reagents include Pd2(dba)3 and Cs2CO3 in a solvent such as THF. The last step of the process (XXVI to I) is carried out by treatment with basic (such as sodium hydroxide in a suitable solvent such as /-propanol or THF) conditions and may be carried out at 60- 9O 0C.
Figure imgf000019_0003
Scheme XII The first step of process (Il to XXVIII) is similar with process (Il to XXV) in scheme Xl. Compounds of formula (XXVII) can be prepared as described in the experimental section. The last step of the process (XXVIII to I) is carried out by treatment with basic (such as sodium hydroxide in a suitable solvent such as isopropanol) conditions and may be carried out at room temperature.
Figure imgf000020_0001
XXIX XXX
Figure imgf000020_0002
Scheme XIII The first step of process (Il to XXIX) is similar with process (Il to XXV) in scheme Xl. In the last two steps, formula (XXX) can be converted to (I) by oxidation in suitable conditions.
Figure imgf000020_0003
XXXI XXXII
Figure imgf000020_0004
Scheme XIV
The first step of process (Il to XXXI) is similar with process (Il to XXV) in scheme Xl. The second step of process (XXXI to XXXII) is carried out in suitable solvent such as THF with reagents include ethyl hydroxyacetate, PPh3 and DIAD. The last step of the process (XXXII to I) is carried out by treatment with basic (such as sodium hydroxide in a suitable solvent such as /-propanol or THF) conditions and may be carried out at 50 0C
Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.
The potencies and efficacies of the compounds of this invention for the S1 P1 receptor can be determined by GTPYS assay or S1P1 Tango assay performed on the human cloned receptor as described herein. Compounds of formula (I) have demonstrated agonist activity at the S1P1 receptor, using functional assays described herein.
Compounds of formula (I) including 3-(3-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4- oxadiazol-3-yl)-5-methylphenyl)propanoic acid and their pharmaceutically acceptable salts are therefore of use in the treatment of conditions or disorders which are mediated via the S1 P1 receptor.
In particular the compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment of multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia- reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependant diabetes.
Compounds of formula (I) and their pharmaceutically acceptable salts are therefore of use in the treatment of multiple sclerosis.
Compounds of formula (I) and their pharmaceutically acceptable salts may also be of use in the treatment of Parkinson's Disease, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, spinal muscular atrophy, polyglutamine expansion disorders, vascular dementia, Down's syndrome, HIV dementia, dementia, ocular diseases including glaucoma, aged related macular degeneration, cataracts, traumatic eye injury, diabetic retinopathy, traumatic brain injury, stroke, tauopathies and hearing loss. It is to be understood that "treatment" as used herein includes prophylaxis as well as alleviation of established symptoms.
Thus the invention also provides a compound of formula (I) and a pharmaceutically acceptable salt thereof, for use as therapeutic substances, in particular in the treatment of the conditions or disorders mediated via the S1P1 receptor. In particular the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as therapeutic substances in the treatment of multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non- insulin dependant diabetes. The invention further provides a method of treatment of conditions or disorders in mammals including humans which can be mediated via the S1P1 receptor, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Compounds of formula (I) and their pharmaceutically acceptable salts are of use as therapeutic substances in the treatment of multiple sclerosis.
In another aspect, the invention provides for the use of compounds of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of the conditions or disorders mediated via the S1P1 receptor
The invention provides a method of treatment of multiple sclerosis, which comprises administering to the sufferer a therapeutically safe and effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.
In order to use the compounds of formula (I) and pharmaceutically acceptable salts thereof in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. In a further aspect, the present invention provides a process for preparing a pharmaceutical composition, the process comprising mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); tabletting lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); and acceptable wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated according to methods well known in normal pharmaceutical practice.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e.g. lecithin or acacia), non-aqueous vehicles (which may include edible oils e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils), preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid), and, if desired, conventional flavourings or colorants, buffer salts and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salts thereof and a sterile vehicle. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose, utilising a compound of the invention or pharmaceutically acceptable derivatives thereof and a sterile vehicle, optionally with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen- free water, before use. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
The compounds of formula (I) or pharmaceutically acceptable salts thereof may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
The compounds of formula (I) or pharmaceutically acceptable salts thereof may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. For intranasal administration, the compounds of formula (I) or pharmaceutically acceptable salts thereof, may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device. Thus compounds of formula (I) or pharmaceutically acceptable salts thereof may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
The compounds of formula (I) or pharmaceutically acceptable salts thereof may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops). Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.
The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, 1.0 to 500mg or 1.0 to 200 mg and such unit doses may be administered more than once a day, for example two or three times a day.
Compounds of formula (I) or pharmaceutically acceptable salts thereof may be used in combination preparations. For example, the compounds of the invention may be used in combination with cyclosporin A, methotrexate, steriods, rapamycin, proinflammatory cytokine inhibitors, immunomodulators including biologicals or other therapeutically active compounds.
The subject invention also includes isotopically-labeled compounds, which are identical to those recited in formulas I and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 3H, 11C, 14C, 18F, 123I and 125I.
Compounds of the present invention and pharmaceutically acceptable saltss of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the present invention. Isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H, 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. 11C and 8F isotopes are particularly useful in PET (positron emission tomography), and 125I isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances, lsotopically labelled compounds of formula (I) can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labelled reagent for a non-isotopically labeled reagent.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The following Descriptions and Examples illustrate the preparation of compounds of the invention.
Abbreviations g - grams mg - milligrams ml - millilitres min - minute ul - microlitres
MeCN - acetonitrile
MeOH - methanol
EtOH - ethanol Et2O- diethyl ether
EtOAc- ethyl acetate
DABCO - 1 ,4-diazabiclo[2,2,2]octane
DCM- dichloromethane
DIAD- diisopropyl azodicarboxylate
DME- 1 ,2-bis(methyloxy)ethane
DMF- Λ/,Λ/-dimethylformamide
DMSO- dimethylsulphoxide
EDAC- Λ/-(3-Dimethylaminopropyl)-Λ/'-ethylcarbodiimide hydrochloride
EDC- Λ/-(3-Dimethylaminopropyl)-Λ/'-ethylcarbodiimide hydrochloride
EDCI- Λ/-(3-Dimethylaminopropyl)-Λ/'-ethylcarbodiimide hydrochloride
HOBT/HOB1 t - Hydroxybenzotriazole
IPA- isopropylalcohol
NCS- Λ/-chlorosuccinimide
PyBOP- Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate
THF- tetrahydrofuran dba- dibenzylidene acetone
RT- room temperature
0C- degrees Celsius
M- Molar
H- proton
S- singlet d- doublet t- triplet q- quartet
MHz- megahertz
MeOD- deuterated methanol
LCMS- Liquid Chromatography Mass Spectrometry
LC/MS - Liquid Chromatography Mass Spectrometry
MS- mass spectrometry
ES- Electrospray
MH+- mass ion + H+
MDAP- mass directed automated preparative liquid chromatography. sat. - saturated
Chromatography Unless stated otherwise, all chromatography was carried out using silica columns.
General chemistry section
The intermediates for the preparation of the examples may not necessarily have been prepared from the specific batch of precursor described.
Description for D1 3-bromo-N-hydroxy-2-methylbenzenecarboximidamide (D1 )
Figure imgf000028_0001
A mixture of 3-bromo-2-methylbenzonitrile (3.0 g), sodium bicarbonate (2.57 g) and hydroxylamine hydrochloride (2.13 g) in ethanol (100 ml) was stirred at 650C overnight. The inorganic precipitate was filtered off. The solid was washed thoroughly with ethanol. The filtrate was concentrated. The obtained solid was dried in vacuo to afford S-bromo-N-hydroxy^-methylbenzenecarboximidamide (D1) (3.27 g). MS (ES): C8H9BrN2O requires 229; found 230.1 (M+H+).
Description for D2
3-(3-bromo-2-methylphenyl)-5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4- oxadiazole (D2)
Figure imgf000028_0002
3-Chloro-4-[(1-methylethyl)oxy]benzoic acid (5.0 g), EDCI (11.16 g), HOBT (7.87 g) were dissolved in THF (100 ml). After the mixture was stirred for 10 mins at RT, a solution of 3-bromo-N-hydroxy-2-methylbenzenecarboximidamide (D1) (4.27 g) in THF (100 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (24.36 g), the reaction mixture was refluxed for 3 days. The organic phase was washed three times with water (5OmL), dried over sodium sulphate and evaporated in vacuo to give the crude product as an orange solid. The crude product was added to a silica gel column and was eluted with hexane:DCM =9:1 LCMS confirmed as the desired compound 3-(3-bromo-2-methylphenyl)-5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazole (D2) (5.55 g). MS (ES): C18H16BrCIN2O2 requires 407; found 408.2 (M+H+).
Description for D3 ethyl 3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadia2ol-3-yl)-2- methylphenyl]propanoate (D3)
Figure imgf000029_0001
To a suspension of 3-(3-bromo-2-methylphenyl)-5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazole (D2) (140 mg), Pd(PPh3)4 (60 mg) in THF (15 ml) stirred under nitrogen at room temperature was added a solution of bromo[3- (ethyloxy)-3-oxopropyl]zinc (0.5 M in THF, 5 ml) in one charge of 1 minute. The reaction mixture was stirred at 40 0C for 2 hours. The mixture was cooled to room temperature. The solvent was evaporated off and EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 3-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl]propanoate (D3) (126 mg), applied to next step directly. MS (ES): C23H25CIN2O4 requires 429; found 430.1 (M+H+).
Description for D4 ethyl 4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,274-oxadiazol-3-yl)-2- methylphenyl] butanoate (D4)
Figure imgf000029_0002
To a suspension of 3-(3-bromo-2-methylphenyl)-5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazole (D2) (140 mg), Pd(PPh3)4 (64 mg) in THF
(15 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-
(ethyloxy)-4-oxobutyl]zinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at 40 0C for 2 hours. The mixture was cooled to room temperature.
Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1)2,4- oxadiazol-3-yl)-2-methylphenyl]butanoate (D4) (141 mg), applied to next step directly. MS (ES): C24H27CIN2O4 requires 443; found 444.1 (M+H+).
Description for D5
5-[3-(3-bromo-2-methylphenyl)-1,2,4-oxadiazol-5-yl]-3-chloro-2-[(1- methylethyl)oxy]pyridine (D5)
Figure imgf000030_0001
δ-chloro-β-KI-methylethyOoxyl-S-pyridinecarboxylic acid (6.65 g), EDCI (14.78 g), HOBT (10.42 g) were dissolved in THF (100 ml). After the mixture was stirred for 10 mins at RT, a solution of 3-bromo-N-hydroxy-2-methylbenzenecarboximidamide (D1) (4.95 g) in THF (50 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (32.3 g), the reaction mixture was heated to 80 0C for 2 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (Hexane:DCM=9:1) to afford a off white solid. LCMS confirmed as the desired compound 5-[3-(3-bromo-2-methylphenyl)- 1,2,4-oxadiazol-5-yl]-3-chloro-2-[(1-methylethyl)oxy]pyridine (D5) (6.86 g). δH (CDCI3, 400 MHz): 1.46 (6H, d), 2.49 (3H, S)1 4.71 (1H, m), 7.38 (1H, d), 8.00 (1H, dd), 8.35 (1H, d), 8.40 (1H, d), 8.88 (1 H, d).MS (ES): C17H15BrCIN3O2 requires 407; found 408.2 (M+H+).
Description for D6 methyl (2/?)-3-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4- oxadiazol-3-yl)-2-methylphenyl]-2-methylpropanoate (D6)
Figure imgf000030_0002
To a suspension of 5-[3-(3-bromo-2-methylphenyl)-1 ,2,4-oxadiazol-5-yl]-3-chloro-2- [(1-methylethyl)oxy]pyridine (138 mg), Pd(PPh3)4 (59 mg) in THF (15 ml) stirred under nitrogen at room temperature was added a solution of bromo[2-methyl-3- (methyloxy)-3-oxopropyl]zinc (0.5 M in THF, 3.4 ml) in one portion. The reaction mixture was stirred at 60 0C for 3 hours. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford methyl (2R)-3-[3-(5-{5-chloro-6-[(1- methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl]-2- methylpropanoate (146 mg), applied to next step directly. MS (ES): C23H25CIN2O4 requires 429; found 430.1 (IvHH+)-
Description for D7 ethyl 4-[3-(5-{5-chloro-6-[(1 -methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-
2-methylphenyl]butanoate (D7)
Figure imgf000031_0001
To a suspension of 5-[3-(3-bromo-2-methylphenyl)-1,2,4-oxadiazol-5-yl]-3-chloro-2- [(i-methylethyl)oxyj pyridine (300 mg), Pd(PPh3)* (127 mg) in THF (15 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-(ethyloxy)-4- oxobutyl]zinc (0.5 M in THF, 12 ml) in one portion. The reaction mixture was stirred at 50 0C for 0.5 hours. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4- oxadiazol-3-yl)-2-methylphenyl]butanoate (231 mg), applied to next step directly. MS (ES): C23H26CIN3O4 requires 444; found 445.1 (M+H+).
Description for D8
5-[3-(3-bromo-2-methylphenyl)-1,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (D8)
Figure imgf000031_0002
3-cyano-4-[(1-methylethyl)oxy]benzoic acid (0.8 g), EDCI (1.49 g), HOBT (1.19 g) were dissolved in THF (10 ml_). After the mixture was stirred for 10 mins at RT, a solution of 3-bromo-N-hydroxy-2-methylbenzenecarboximidamide (0.84 g) in THF (10 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (3.73 g), the reaction mixture was heated to 80 0C for 2 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (PE:EA=10:1) to afford a off white solid. LCMS confirmed as the desired compound 5-[3-(3-bromo-2-methylphenyl)-1 ,2,4-oxadiazol- 5-yl]-2-[(1-methylethyl)oxy]benzonitrile
(0.96 g). MS (ES): C19H16BrN3O2 requires 397; found 398.2 (M+H+).
Description for D9 ethyl 3-[3-(5-{3-cyano-4-[(1 -methyiethy l)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- methylphenyl]propanoate (D9)
Figure imgf000032_0001
To a suspension of 5-[3-(3-bromo-2-methylphenyl)-1 ,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (150 mg), Pd2(dba)3 (52 mg), tris(1,1-dimethylethyl)phosphane (33 mg), Cs2CO3 (37 mg)in THF (5 ml) stirred under nitrogen at room temperature was added a solution of bromo[3-(ethyloxy)-3-oxopropyl]zinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for 1.5 hours. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- methylphenyl]propanoate (146 mg), applied to next step directly. MS (ES): C24H25N3O4 requires 419; found 420.1 (M+H+).
Description for D10 ethyl 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- methylphenyl]butanoate (D10)
Figure imgf000033_0001
To a suspension of 5-[3-(3-bromo-2-methylphenyl)-1 ,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (150 mg), Pd2(dba)3 (52 mg), tris(1,1- dimethylethyl)phosphane (33 mg), Cs2CO3 (37 mg) in THF ( 5 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-(ethyloxy)-4- oxobutyl]zinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for 1.5 hours. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4- oxadiazol-3-yl)-2-methylphenyl]butanoate (153 mg), applied to next step directly. MS (ES): C25H27N3O4 requires 433; found 434.1 (M+H+).
Description for D11 2-bromo-Λ/-hydroxy-3-methyl-4-pyridinecarboximidamide (D11)
Figure imgf000033_0002
A mixture of 2-bromo-3-methyl-4-pyridinecarbonitrile (3.0 g), sodium bicarbonate (2.57 g) and hydroxylamine hydrochloride (2.13 g) in ethanol (100 ml) was heated at reflux for overnight. The inorganic precipitate was filtered off. The solid was washed thoroughly with ethanol. The filtrate was concentrated. The obtained solid was dried in vacuo to afford 2-bromo-Λ/-hydroxy-3-methyl-4-pyridinecarboximidamide (3.27 g). MS (ES): C7H8BrN2O requires 230; found 231.1 (M+H+).
Description for D12 2-bromo-4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-3- methylpyridine (D12)
Figure imgf000033_0003
3-Chloro-4-[(1-methylethyl)oxy]benzoic acid (0.5 g), EDCI (1.16 g), HOBT (0.8 g) were dissolved in THF (10 ml). After the mixture was stirred for 10 mins at RT, a solution of 2-bromo-Λ/-hydroxy-3-methyl-4-pyridinecarboximidamide (0.32 g) in THF (50 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF ( 2.4 g), the reaction mixture was heated to 80 0C for 1 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (Hexane:DCM=9:1) to afford a off white solid. LCMS confirmed as the desired compound 2-bromo-4-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-3-methylpyridine (0.54 g). δH (CDCI3, 400 MHz): 1.49 (6H, d), 2.78 (3H, s), 4.73-4.74 (1H, m), 7.08 (1 H, d), 7.87 (1H, d), 8.05-8.08 (1H, dd), 8.24(1 H, d), 8.38 (1H, d). MS (ES): C17Hi5BrCIN3O2 requires 409; found 410.2 (M+H+).
Description for D13 ethyl 4-[4-(5-{3-chloro-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-3- methyl-2-pyridinyl]butanoate (D13)
Figure imgf000034_0001
To a suspension of 2-bromo-4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4- oxadiazol-3-yl)-3-methylpyridine (130 mg), Pd(PPh3)4 (37 mg) in THF (5 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-(ethyloxy)-4- oxobutyl]zinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for 40 mins. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 mL (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[4-(5-{3-chloro-4- [(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-3-methyl-2-pyridinyl]butanoate (135 mg), applied to next step directly. MS (ES): C23H26CIN3O4 requires 444; found 445.1 (M+H+).
Description for D14 3-bromo-2-chloro-Λ/-hydroxybenzenecarboximidamide (D14)
Figure imgf000035_0001
A mixture of 3-bromo-2-chlorobenzonitrile (2.0 g), sodium bicarbonate (1.55 g) and hydroxylamine hydrochloride (1.28 g) in ethanol (50 ml.) was heated at reflux for overnight. The inorganic precipitate was filtered off. The solid was washed thoroughly with ethanol. The filtrate was concentrated. The obtained solid was dried in vacuo to afford 3-bromo-2-chloro-Λ/-hydroxybenzenecarboximidamide (2.13 g). MS (ES): C7H6BrCIN2O requires 248; found 249.1 (M+H+).
Description for D15 5-[3-(3-bromo-2-chlorophenyl)-1 ,2,4-oxadiazol-5-yl]-3-chloro-2-[(1 - methylethyl)oxy]pyridine (D15)
Figure imgf000035_0002
5-chloro-6-[(1-methylethyl)oxy]-3-pyridinerarboxylic acid (2.6 g), EDCI (4.62 g), HOBT (3.69 g) were dissolved in THF (50 ml). After the mixture was stirred for 10 mins at RT, a solution of 3-bromo-2-chloro-Λ/-hydroxybenzenecarboximidamide (2.13 g) in THF (50 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (12.6 g), the reaction mixture was heated to 80 °C for 3 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (Hexane: DCM= 10:1) to afford a off white solid. LCMS confirmed as the desired compound 5-[3-(3-bromo-2-chlorophenyl)-1,2,4- oxadiazol-5-yl]-3-chloro-2-[(1-methylethyl)oxy]pyridine (3.25 g). δH (CDCI3, 400 MHz): 1.46 (6H, d), 5.49-5.52 (1 H, m), 7.30 (1 H, dd), 7.82-7.85 (1 H1 dd), 7.90-7.92 (1 H, dd), 8.39 (1H, d), 8.88 (1H, d).MS (ES): Ci6Hi2BrCI2N3O2 requires 427; found 428.2 (M+H+).
Description for D16 ethyl 3-[2-chloro-3-(5-{5-chloro-6-[(1 -methylethyl)oxy]-3-pyridinyl}-1 ,2,4- oxadiazol-3-yl)phenyl]propanoate (D16)
Figure imgf000036_0001
To a suspension of 5-[3-(3-bromo-2-chlorophenyl)-1,2,4-oxadiazol-5-yϊJ-3-chloro-2- [(1-methylethyl)oxy]pyridine (100 mg), Pd2(dba)3 (32 mg), P(o-tol)3 (21 mg) in THF (3 ml) stirred under nitrogen at room temperature was added a solution of bromo[3- (ethyloxy)-3-oxopropyl]zinc (0.5 M in THF, 1.2 ml) in one portion. The reaction mixture was stirred at room temperature for 0.5 hours. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml_ (three times), dried over sodium sulphate and evaporated to afford ethyl 3-[2-chloro-3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4- oxadiazol-3-yl)phenyl]propanoate (146 mg), applied to next step directly. MS (ES): C2iH2iCI2N3O4 requires 449; found 450.1 (M+H+).
Description for D17 ethyl 4-[2-chloro-3-(5-{5-chloro-6-[(1 -methylethyl)oxy]-3-pyridinyl}-1 ,2,4- oxadiazol-3-yl)phenyl]butanoate (D17)
Figure imgf000036_0002
To a suspension of 5-[3-(3-bromo-2-chlorophenyl)-1,2,4-oxadiazol-5-yl]-3-chloro-2- [(1-methylethyl)oxy]pyridine (150 mg), Pd2(dba)3 (64 mg), tris(1 ,1- dimethylethyl)phosphane (40 mg), Cs2CO3 (45 mg) in THF (5 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-(ethyloxy)-4- oxobutyljzinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at 40 0C for 0.5 hours. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml_ (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[2-chloro-3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}- 1 ,2,4- oxadiazol-3-yl)phenyl]butanoate (147 mg), applied to next step directly. MS (ES): C22H23CI2N3O4 requires 463; found 464.1 (M+H+).
Description for D18 S-p-CS-bromo^-chlorophenyO-i^^-oxadiazol-δ-yll^-KI- methylethyl)oxy]benzonitrile (D18)
Figure imgf000037_0001
3-cyano-4-[(1-methylethyl)oxy]benzoic acid (1.05 g), EDCI (1.96 g), HOBT (1.57 g) were dissolved in THF (50 ml). After the mixture was stirred for 10 mins at RT1 a solution of S-bromo-N-hydroxy^-methylbenzenecarboximidamide (1.2 g) in THF (10 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (4.87 g), the reaction mixture was heated to 80 0C for 2 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (PE:EA=5:1) to afford a off white solid. LCMS confirmed as the desired compound 5-[3-(3-bromo-2-chlorophenyl)-1 ,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (1.03 g). MS (ES): C18Hi3BrCIN3O2 requires 417; found 418.2 (M+H+).
Description for D19 ethyl 3-[2-chloro-3-(5-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3- yl)phenyl]propanoate (D19)
Figure imgf000037_0002
To a suspension of 5-[3-(3-bromo-2-chlorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (150 mg), Pd2(dba)3 (49 mg), tris(1,1- dimethylethyl)phosphane (31 mg), Cs2CO3 (35 mg)in THF (5 ml) stirred under nitrogen at room temperature was added a solution of bromo[3-(ethyloxy)-3- oxopropyl]zinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for 1.5 hours. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 3-[2-chloro- 3-(5-{3-cyano-4-[( 1 -methylethyl)oxy]phenyl}- 1 ,2 ,4-oxadiazol-3-y l)pheny IJpropanoate (159 mg), applied to next step directly. MS (ES): C23H22CIN3O4 requires 439; found 440.1 (M+H+).
Description for D20 ethyl 4-[2-chloro-3-(5-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3- yl)phenyl]butanoate (D20)
Figure imgf000038_0001
To a suspension of 5-[3-(3-bromo-2-chlorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (150 mg), Pd2(dba)3 (49 mg), tris(1,1- dimethylethyl)phosphane (31 mg), Cs2CO3 (35 mg) in THF ( 5 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-(ethyloxy)-4- oxobutyljzinc (0,5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for 2 hours. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml_ (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[2-chloro-3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)phenyl]butanoate (142 mg), applied to next step directly. MS (ES): C24H24CIN3O4 requires 453; found 454.1 (M+H+).
Description for D21 ethyl β-p-chloro-a-tS-fa-cyano^-KI-methylethyOoxylpheny^-i^^-oxadiazol-a- yl)phenyl]hexanoate (D21)
Figure imgf000038_0002
To a suspension of 5-[3-(3-bromo-2-chlorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (150 mg), Pd2(dba)3 (49 mg), tris(1,1- dimethylethyl)phosphane (31 mg), Cs2CO3 (35 mg) in THF ( 5 ml) stirred under nitrogen at room temperature was added a solution of bromo[6-(ethyloxy)-6- oxohexyljzinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for 2 hours. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 6-[2-chloro-3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)phenyl]hexanoate (167 mg), applied to next step directly. MS (ES): C26H28ClN3O4 requires 481; found 482.1 (M+H+).
Description for D22 3-bromo-2-ethyl-W-hydroxybenzenecarboximidamide (D22)
Figure imgf000039_0001
A mixture of 3-bromo-2-ethylbenzonitrile (1.5 g), sodium bicarbonate (1.20 g) and hydroxylamine hydrochloride (1.0 g) in ethanol (65 ml) was heated at reflux for overnight. The inorganic precipitate was filtered off. The solid was washed thoroughly with ethanol. The filtrate was concentrated. The obtained solid was dried in vacuo to afford 3-bromo-2-ethyl-Λ/-hydroxybenzenecarboximidamide (1.62 g). MS (ES):
C9H11BrN2O requires 242; found 243.1 (M+H+).
Description for D23
5-[3-(3-bromo-2-ethylphenyl)-1,2,4-oxadiazol-5-yl]-3-chloro-2-[(1- methylethyl)oxy]pyridine (D23)
Figure imgf000039_0002
δ-chloro-β-^i-methylethyOoxyl-S-pyridinecarboxylic acid (2.0 g), EDCI (3.56 g), HOBT (2.84 g) were dissolved in THF (50 ml). After the mixture was stirred for 10 mins at RT, a solution of 3-bromo-2-ethyl-Λ/-hydroxybenzenecarboximidamide (1.62 g) in THF (50 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (12.6 g), the reaction mixture was heated to 80 0C for 2 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (Hexane: DCM= 10:1) to afford a off white solid. LCMS confirmed as the desired compound 5-[3-(3-bromo-2-ethylphenyl)-1 ,2,4- oxadiazol-5-yl]-3-chloro-2-[(1-methylethyl)oxy]pyridine (2.41 g). δH (CDCI3, 400 MHz): 1.28(3H1 t), 1.46 (6H, d), 3.13-3.17(2H, m), 5.48-5.52 (1H, m), 7.18-7.22 (1 H, dd), 7.73-7.75 (1H, dd), 7.87-7.89 (1H, dd), 8.38 (1H, d), 8.88 (1H, d).MS (ES): C18Hi7BrCIN3O2 requires 421; found 422.2 (M+H+).
Description for D24 ethyl 3-[3-(5-{5-chloro-6-[(1 -methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-
2-ethylphenyl]propanoate (D24)
Figure imgf000040_0001
To a suspension of 5-[3-(3-bromo-2-ethylphenyl)-1,2,4-oxadiazol-5-yl]-3-chloro-2-[(1- methylethyl)oxy]pyridine (120 mg), Pd2(dba)3 (39 mg), P(o-tol)3 (26 mg) in THF (3 ml) stirred under nitrogen at room temperature was added a solution of bromo[3- (ethyloxy)-3-oxopropyl]zinc (0.5 M in THF1 1.7 ml) in one portion. The reaction mixture was stirred at room temperature for overnight. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 3-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)- 2-ethylphenyl]propanoate (108 mg), applied to next step directly. MS (ES): C23H26CIN3O4 requires 443; found 444.1 (M+H+).
Description for D25 ethyl 4-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)- 2-ethylphenyl]butanoate (D25)
Figure imgf000040_0002
To a suspension of 5-[3-(3-bromo-2-ethylphenyl)-1,2,4-oxadiazol-5-yl]-3-chloro-2- [(1-methylethyl)oxy]pyridine (180 mg), Pd2(dba)3 (58 mg), P(o-tol)3 (39 mg)in THF (5 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-
(ethyloxy)-4-oxobutyl]zinc (0.5 M in THF, 2.5 ml) in one portion. The reaction mixture was stirred at 40 °C for overnight. The mixture was cooled to room temperature.
Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}- 1,2,4-oxadiazol-3-yl)-2-ethylphenyl]butanoate (174 mg), applied to next step directly. MS (ES): C24H28CIN3O4 requires 457; found 458.1 (M+H+).
Description for D26
5-[3-(3-bromo-2-ethylphenyl)-1 ,2,4-oxadiazol-5-yl]-2-[(1 - methylethyl)oxy]benzonitrile (D26)
Figure imgf000041_0001
3-cyano-4-[(1-methylethyl)oxy]benzoic acid (0.91 g), EDCI (1.70 g), HOBT (1.36 g) were dissolved in THF (50 ml). After the mixture was stirred for 10 mins at RT, a solution of 3-bromo-2-ethyl-Λ/-hydroxybenzenecarboximidamide (0.98 g) in THF (10 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF
(4.22 g), the reaction mixture was heated to 80 0C for 3 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc
(100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (PE:EA=5:1) to afford a off white solid. LCMS confirmed as the desired compound 5-[3-(3-bromo-2-ethylphenyl)-1 ,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (0.65 g). MS (ES): C20H18BrN3O2 requires 411 ; found
412.2 (M+H+).
Description for D27 ethyl 4-[3-(5-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- ethylphenyl]butanoate (D27)
Figure imgf000041_0002
To a suspension of 5-[3-(3-bromo-2-ethylphenyl)-1,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (150 mg), Pd2(dba)3 (50 mg), tris(1,1- dimethylethyOphosphane (31 mg), Cs2CO3 (35 mg) in THF ( 5 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-(ethyloxy)-4- oxobutyl]zinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for overnight. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4- oxadiazol-3-yl)-2-ethylphenyl]butanoate (152 mg), applied to next step directly. MS (ES): C26H29N3O4 requires 447; found 448.1 (M+H+).
Description for D28 3-bromo-A/-hydroxy-2-(methyloxy)benzenecarboximidamide (D28)
Figure imgf000042_0001
A mixture of 3-bromo-2-(methyloxy)benzonitrile (1.3 g), sodium bicarbonate (1.03 g) and hydroxylamine hydrochloride (0.85 g) in ethanol (50 ml) was heated at reflux for overnight. The inorganic precipitate was filtered off. The solid was washed thoroughly with ethanol. The filtrate was concentrated. The obtained solid was dried in vacuo to afford 3-bromo-Λ/-hydroxy-2-(methyloxy)benzenecarboximidamide (1.37 g). MS (ES): C8H9BrN2O2 requires 244; found 245.1 (M+H+).
Description for D29
3-[3-bromo-2-(methyloxy)phenyl]-5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}- 1,2,4-oxadiazole (D29)
Figure imgf000042_0002
3-Chloro-4-[(1-methylethyl)oxy]benzoic acid (1.63 g), EDCI (2.90 g), HOBT (2.32 g) were dissolved in THF (50 ml). After the mixture was stirred for 10 mins at RT, a solution of 3-bromo-Λ/-hydroxy-2-(methyloxy)benzenecarboximidamide (1.37 g) in THF (50 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (1.98 g), the reaction mixture was heated to 80 0C for 4 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (Hexane:DCM=9:1) to afford a off white solid. LCMS confirmed as the desired compound 3-[3-bromo-2-(methyloxy)phenyl]-5-{3-chloro-4- [(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazole(2.53 g). MS (ES): C18H16BrCIN2O3 requires 422; found 423.2 (M+H+).
Description for D30 ethyl 3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- (methyloxy)phenyl]propanoate (D30)
Figure imgf000043_0001
To a suspension of 3-[3-bromo-2-(methyloxy)phenyl]-5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazole (150 mg), Pd2(dba)3 (49 mg), P(o-tol)3 (32 mg) in THF (5 ml) stirred under nitrogen at room temperature was added a solution of bromo[3-(ethyloxy)-3-oxopropyl]zinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at 40 0C for 2 hours. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 3-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-(methyloxy)phenyl]propanoate (153 mg), applied to next step directly. MS (ES): C22H24CIN3O5 requires 445; found 446.1
(M+H+).
Description for D31 ethyl 4-[3-(5-{3-chloro-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-
(methy loxy)phenyl]butanoate (D31 )
To a suspension of 3-[3-bromo-2-(methyloxy)phenyl]-5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazole (150 mg), Pd2(dba)3 (48 mg), P(o-tol)3(32 mg) in THF (5 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-(ethyloxy)-4-oxobutyl]zinc (0.5 M in THF, 2 ml_) in one portion. The reaction mixture was stirred at 40 0C for overnight. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-(methyloxy)phenyl]butanoate (160 mg), applied to next step directly. MS (ES): C24H27CIN2O5 requires 459; found 460.1 (M+H+).
Description for D32
5-{3-[3-bromo-2-(methyloxy)phenyl]-1,2,4-oxadiazol-5-yl}-2-[(1- methylethyl)oxy]benzonitrile (D32)
Figure imgf000044_0001
3-cyano-4-[(1-methylethyl)oxy]benzoic acid (0.8 g), EDCI (1.49 g), HOBT (1.19 g) were dissolved in THF (10 ml). After the mixture was stirred for 10 mins at RT, a solution of 3-bromo-/V-hydroxy-2-(methyloxy)benzenecarboximidamide (1.1 g) in THF (10 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (4.87 g), the reaction mixture was heated to 80 0C for 2 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (PE:EA=9:1) to afford a off white solid. LCMS confirmed as the desired compound 5-{3-[3-bromo-2-(methyloxy)phenyl]-1 ,2,4-oxadiazol-5-yl}- 2-[(1-methylethyl)oxy]benzonitrile (1.03 g). MS (ES): C19H16BrN3O3 requires 413; found 414.2 (M+H+).
Description for D33 ethyl 3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- (methyloxy)phenyl]propanoate (D33)
Figure imgf000044_0002
To a suspension of 5-{3-[3-bromo-2-(methyloxy)phenyl]-1,2,4-oxadiazol-5-yl}-2-[(1- methylethyl)oxy]benzonitrile (150 mg), Pd2(dba)3 (52 mg), tris(1,1- dimethylethyl)phosphane (33 mg), Cs2CO3 (37 mg)in THF (5 ml_) stirred under nitrogen at room temperature was added a solution of bromo[3-(ethyloxy)-3- oxopropyl]zinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for 2 hours. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 3-[3-(5-{3-cyano- 4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-(methyloxy)phenyl]propanoate (147 mg), applied to next step directly. MS (ES): C24H2SN3O5 requires 435; found 436.1 (M+H+).
Description for D34 ethyl 4-[3-(5-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-
(methyloxy)phenyl]butanoate (D34)
Figure imgf000045_0001
To a suspension of 5-{3-[3-bromo-2-(methyloxy)phenyl]-1,2,4-oxadiazol-5-yl}-2-[(1- methylethyl)oxy]benzonitrile (150 mg), Pd2(dba)3 (49 mg), tris(1,1- dimethylethyl)phosphane (31 mg), Cs2CO3 (35 mg) in THF ( 5 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-(ethyloxy)-4- oxobutyl]zinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for 2 hours. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4- oxadiazol-3-yl)-2-(methyloxy)phenyl]butanoate (139 mg), applied to next step directly. MS (ES): C25H27N3O5 requires 449; found 450.1 (M+H+).
Description for D35 2-brorno-A/-hydroxy-4-pyridinecarboximidamide (D35)
Figure imgf000045_0002
A mixture of 2-bromo-4-pyridinecarbonitrile (0.7 g), sodium bicarbonate (0.65 g) and hydroxylamine hydrochloride (0.53 g) in ethanol (50 ml) was heated at reflux for overnight. The inorganic precipitate was filtered off. The solid was washed thoroughly with ethanol. The filtrate was concentrated. The obtained solid was dried in vacuo to afford 2-bromo-Λ/-hydroxy-4-pyridinecarboximidamide (0.78 g). MS (ES): C6H6BrN3O requires 215; found 216.1 (M+H+).
Description for D36
5-[3-(2-bromo-4-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile(D36)
Figure imgf000046_0001
3-cyano-4-[(1-methylethyl)oxy]benzoic acid (0.8 g), EDCI (1.49 g), HOBT (1.19 g) were dissolved in THF (10 ml). After the mixture was stirred for 10 mins at RT, a solution of 2-bromo-Λ/-hydroxy-4-pyridinecarboximidamide (0.78 g) in THF (10 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (4.22 g), the reaction mixture was heated to 80 0C for 3 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (PE:EA=8:1) to afford a off white solid. LCMS confirmed as the desired compound 5-[3-(2-bromo-4-pyridinyl)-1 ,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (0.95 g). MS (ES): Ci7Hi3BrN4O2 requires 384; found 385.2 (M+H+).
Description for D37 ethyl 3-[4-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- pyridinyl]propanoate (D37)
Figure imgf000046_0002
To a suspension of 5-[3-(2-bromo-4-pyridinyl)-1 ,2,4-ox1adiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (150 mg), Pd2(dba)3 (50 mg), tris(1,1- dimethylethyl)phosphane (106 mg), Cs2CO3 (35 mg)in THF (5 ml) stirred under nitrogen at room temperature was added a solution of bromo[3-(ethyloxy)-3- oxopropyl]zinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for 1.5 hours. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 3-[4-(5-{3- cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-pyridinyl]propanoate
(158 mg), applied to next step directly. MS (ES): C22H22N4O4 requires 406; found 407.1 (M+H+).
Description for D38 ethyl 4-[4-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- pyridinyl]butanoate (D38)
Figure imgf000047_0001
To a suspension of 5-[3-(2-bromo-4-pyridinyl)-1 ,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (150 mg), Pd2(dba)3 (52 mg), tris(1,1- dimethylethyl)phosphane (33 mg), Cs2CO3 (37 mg) in THF (5 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-(ethyloxy)-4- oxobutyl]zinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for 1.5 hours. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[4-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4- oxadiazol-3-yl)-2-pyridinyl]butanoate (139 mg), applied to next step directly. MS (ES): C23H24N4O4 requires 420; found 421.1 (M+H+).
Description for D39
3-bromo-4-fluoro-A/-hydroxybenzenecarboximidamide (D39)
Figure imgf000047_0002
A mixture of 3-bromo-4-fluorobenzonitrile (2 g), sodium bicarbonate (1.68 g) and hydroxylamine hydrochloride (1.39 g) in ethanol (50 ml) was heated at reflux for overnight. The inorganic precipitate was filtered off. The solid was washed thoroughly with ethanol. The filtrate was concentrated. The obtained solid was dried in vacuo to afford 3-bromo-4-fluoro-Λ/-hydroxybenzenecarboxinnidamide (2.02 g). MS (ES): C7H6BrFN2O requires 232; found 233.1 (M+H+).
Description for D40 5-[3-(3-bromo-4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (D40)
Figure imgf000048_0001
3-cyano-4-[(1-methylethyl)oxy]benzoic acid (1.6 g), EDCI (3.0 g), HOBT (2.4 g) were dissolved in THF (10 ml). After the mixture was stirred for 10 mins at RT, a solution of 2-bromo-Λ/-hydroxy-4-pyridinecarboximidamide (2.2 g) in THF (10 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (9.66 g), the reaction mixture was heated to 80 0C for 3 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (PE:EA=5:1) to afford a off white solid. LCMS confirmed as the desired compound 5-[3-(3-bromo-4-fluorophenyl)-1 ,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (1.1 g). MS (ES): Ci8H13BrFN3O2 requires 401; found 402.2 (M+H+).
Description for D41 ethyl 3-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1(2,4-oxadiazol-3-yl)-2- fluorophenyl]propanoate (D41)
Figure imgf000048_0002
To a suspension of 5-[3-(3-bromo-4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (150 mg), Pd2(dba)3 (51 mg), tris(1,1- dimethylethyl)phosphane (92 mg), Cs2CO3 (36 mg)in THF (7 ml) stirred under nitrogen at room temperature was added a solution of bromo[3-(ethyloxy)-3- oxopropyl]zinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for 1.5 hours. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 3-[5-(5-{3- cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-fluorophenyl]propanoate (168 mg), applied to next step directly. MS (ES): C23H22FN3O4 requires 423; found 424.1 (M+H+).
Description for D42 ethyl 4-[5-(5-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- fluorophenyl]butanoate (D42)
Figure imgf000049_0001
To a suspension of 5-[3-(3-bromo-4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (150 mg), Pd2(dba)3 (52 mg), tris(1,1- dimethylethyl)phosphane (36 mg), Cs2CO3 (37 mg) in THF (5 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-(ethyloxy)-4- oxobutyljzinc (0.5 M in THF, 2 ml) in one portion. The reaction mixture was stirred at room temperature for 1.5 hours. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4- oxadiazol-3-yl)-2-fluorophenyl]butanoate (168 mg), applied to next step directly. MS (ES): C24H24FN3O4 requires 437; found 437.1 (M+H+).
Description for D43 3-bromo-Λ/-hydroxy-2-(trifluoromethyl)benzenecarboximidamide (D43)
Figure imgf000049_0002
A mixture of 3-brorno-2-(trifluoromethyl)benzonitrile (0.96 g), sodium bicarbonate (0.65 g) and hydroxylamine hydrochloride (0.54 g) in ethanol (30 ml) was heated at reflux for overnight. The inorganic precipitate was filtered off. The solid was washed thoroughly with ethanol. The filtrate was concentrated. The obtained solid was dried in vacuo to afford 3-bromo-Λ/-hydroxy-2-(trifluoromethyl)benzenecarboximidamide (1.06 g). MS (ES): C8H6BrF3N2O requires 282; found 283.1 (M+H+). Description for D44
5-{3-[3-bromo-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-2-[(1- methylethyl)oxy]benzonitrile (D44)
Figure imgf000050_0001
3-cyano-4-[(1-methylethyl)oxy]benzoic acid (0.66 g), EDCI (1.24 g), HOBT (1 g) were dissolved in THF (10 ml). After the mixture was stirred for 10 mins at RT, a solution of 3-bromo-Λ/-hydroxy-2-(trifluoromethyl)benzenecarboximidamide (1.06 g) in THF (10 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (4.19 g), the reaction mixture was heated to 80 0C for 3 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (PE:EA=5:1) to afford a off white solid. LCMS confirmed as the desired compound 5-{3-[3-bromo-2-(trifluoromethyl)phenyl]-1 ,2,4-oxadiazol-5- yl}-2-[(1-methylethyl)oxy]benzonitrile (0.62 g). MS (ES): C19H13BrF3N3O2 requires 451; found 452.2 (M+H+).
Description for D45 ethyl 3-[3-(5-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- (trifluoromethyl)phenyl]propanoate (D45)
Figure imgf000050_0002
To a suspension of 5-{3-[3-bromo-2-(trifluoromethyl)phenyl]-1 ,2,4-oxadiazol-5-yl}-2- [(1-methylethyl)oxy]benzonitrile (115 mg), Pd2(dba)3 (35 mg), tris(1,1- dimethylethyl)phosphane (22 mg), Cs2CO3 (25 mg)in THF (7 ml) stirred under nitrogen at room temperature was added a solution of bromo[3-(ethyloxy)-3- oxopropyl]zinc (0.5 M in THF, 1.5 ml) in one portion. The reaction mixture was stirred at room temperature for 2 hours. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 3-[3-(5-{3-cyano- 4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- (trifluoromethyl)phenyl]propanoate (121 mg), applied to next step directly. MS (ES): C24H23F3N4O4 requires 488; found 489.1 (M+H+).
Description for D46 ethyl 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- (trifluoromethyl)phenyl]butanoate (D46)
Figure imgf000051_0001
To a suspension of 5-{3-[3-bromo-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-2- [(1-methylethyl)oxy]benzonitrile (115 mg), Pd2(dba)3 (35 mg), tris(1,1- dimethylethyl)phosphane (15 mg), Cs2CO3 (25 mg) in THF (7 ml) stirred under nitrogen at room temperature was added a solution of bromo[4-(ethyloxy)-4- oxobutyl]zinc (0.5 M in THF, 1.5 ml) in one portion. The reaction mixture was stirred at room temperature for 1.5 hours. The mixture was cooled to room temperature. Evaporate off the solvent, EtOAc (25 ml) was added. The organic phase was washed with 2M sodium hydroxide solution 25 ml (three times), dried over sodium sulphate and evaporated to afford ethyl 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4- oxadiazol-3-yl)-2-(trifluoromethyl)phenyl]butanoate (108 mg), applied to next step directly. MS (ES): C24H23F3N4O4 requires 488; found 489.1 (M+H+).
Description for D47
Λ/-hydroxy-3-(hydroxymethyl)-2-methylbenzenecarboximidamide (D47)
Figure imgf000051_0002
A mixture of 3-(hydroxymethyl)-2-methylbenzonitrile (2.0 g), sodium bicarbonate (3.42 g) and hydroxylamine hydrochloride (2.83 g) in ethanol (40 ml) was heated at reflux for overnight. The inorganic precipitate was filtered off. The solid was washed thoroughly with ethanol. The filtrate was concentrated. The obtained solid was dried in vacuo to afford Λ/-hydroxy-3-(hydroxymethyl)-2-methylbenzenecarboximidamide (2.08 g). MS (ES): C9Hi2N2O2 requires 180; found 181.1 (M+H+).
Description for D48 5-{3-[3-(hydroxymethyl)-2-methylphenyl]-1,2,4-oxadiazol-5-yl}-2-[(1 methylethyl)oxy]benzonitrile (D48)
Figure imgf000052_0001
3-cyano-4-[(1-methylethyl)oxy]benzoic acid (1.32 g), EDCI (2.4 g), HOBT (2 g) were dissolved in THF (50 ml). After the mixture was stirred for 10 mins at Room Temperature, LCMS show one intermediate was formed. Evaporate off the solvent, EtOAc(50 ml) was added, organic layer was washed by water (50 ml) 3 times, combine the organic layer, evaporate off the solvent, THF(50 ml) readded, in the resulting solution a solution of 5-bromo-2-fluoro-Λ/- hydroxybenzenecarboximidamide (0.73 g) in THF (10 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (4.19 g), the reaction mixture was heated to 80 0C for 3 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (PE:EA=5:1) to afford a off white solid. LCMS confirmed as the desired compound 5- {3-[3-(hydroxymethyl)-2-methylphenyl]-1 ,2,4-oxadiazol-5-yl}-2-[(1- methylethyl)oxy]benzonitrile (1.05 g). δH (CDCI3, 400 MHz): 1.48 (6H, d), 2.62 (3H, s), 4.11-4.16(1H, m), 4.79-4.84(1 H, m), 7.13 (1 H, d), 7.35-7.39(1H, dd), 7.58 (1H, d), 7.89 (1H1 d), 8.34-8.36 (1H, dd), 8.44 (1H, d).MS (ES): C20Hi9N3O3 requires 349; found 350.2 (M+H+).
Description for D49 5-[3-(3-formyl-2-methylphenyl)-1 ,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (D49)
Figure imgf000052_0002
5-{3-[3-(hydroxymethyl)-2-methylphenyl]-1,2,4-oxadiazol-5-yl}-2-[(1- methylethyl)oxy]benzonitrile(66 mg) were well dissolved in DCM (3 ml). In the resulting solution was added Dess-Martin periodinane (99 mg), stirred for 1 hour, LCMS show complete conversion, filter off the solid, evaporate off the solvent . LCMS confirmed as the desired compound 5-[3-(3-formyl-2-methylphenyl)-1,2,4- oxadiazol-5-yl]-2-[(1-methylethyl)oxy]benzonitrile (64 mg). MS (ES): C20Hi7N3O3 requires 347; found 348.2 (M+H+).
Description for D50 W,3-dihydroxy-2-methylbenzenecarboximidamide (D50)
Figure imgf000053_0001
A mixture of 3-hydroxy-2-methylbenzonitrile (0.9 g), sodium bicarbonate (0.78 g) and hydroxylamine hydrochloride (0.64 g) in ethanol (40 ml) was heated at reflux for overnight. The inorganic precipitate was filtered off. The solid was washed thoroughly with ethanol. The filtrate was concentrated. The obtained solid was dried in vacuo to afford Λ/,3-dihydroxy-2-methylbenzenecarboximidamide (0.71 g). MS (ES): Ci0H12N2O3 requires 208; found 209.1 (M+H+).
Description for D51
3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-2- methylphenol (D51)
Figure imgf000053_0002
S-chloro-β-KI-methylethyOoxyJ-S-pyridinecarboxylic acid (1.5 g), EDCI (2.67 g),
HOBT (2.13 g) were dissolved in THF (50 ml). After the mixture was stirred for 10 mins at Room Temperature, LCMS show one intermediate was formed. Evaporate off the solvent, EtOAc(50 ml) was added, organic layer was washed by water (50 ml) 3 times.combine the organic layer, evaporate off the solvent, THF(50 ml) readded, in the resulting solution a solution of Λ/,3-dihydroxy-2-methylbenzenecarboximidamide (0.71 g) in THF (10 ml) was added slowly. The obtained mixture was stirred for further 2 hours at room temperature. LCMS show only one intermediate was found. After addition of TBAF (7.28 g), the reaction mixture was heated to 80 0C for 3 days. The reaction was cooled down to room temperature, Evaporate off the solvent and added with EtOAc (100 ml). The organic solution was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, residue was purified by flash column (PE:EA=5:1) to afford a off white solid. LCMS confirmed as the desired compound 5-{3-[3-(hydroxymethyl)-2-methylphenyl]- 1 ,2,4-oxadiazol-5-yl}-2-[(1-methylethyl)oxy]benzonitrile (0.49 g). δH (CDCI3, 400 MHz): 1.48 (6H, d), 2.55 (3H, s), 5.48-5.51 (1H, m), 6.97 (1H, d), 7.21-7.25 (1H, dd), 7.58 (1H, d), 8.40 (1H, d), 8.88 (1H, d).MS (ES): Ci7H16CIN3O3 requires 345; found 346.2 (M+H+).
Description for D52 ethyl {[3-(5-{5-chloro-6-t(1 -methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-2- methylphenyl]oxy}acetate (D52)
Figure imgf000054_0001
To a solution of 3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 )2,4-oxadiazol-3- yl)-2-methylphenol (45 mg), PPh3 (109 mg) and DIAD (84 mg) in Tetrahydrofuran (THF) (4 ml) stirred under nitrogen at room temp, in the resulting solution was added a solution of ethyl hydroxyacetate (29 mg) in one charge during 1 min. The reaction mixture was stirred at 22 0C for 1 hour . LCMS show complete conversion. Evaporate off the solvent, afford the desired compound ethyl {[3-(5-{5-chloro-6-[(1- methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-2-methylphenyl]oxy}acetate (47 mg). MS (ES): C21H22CIN3O5 requires 431 ; found 432.2 (M+H+).
Description for D53
3-(3-bromo-2-ethylphenyl)-5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4- oxadiazole (D53)
Figure imgf000054_0002
3-chloro-4-[(1-methylethyl)oxy]benzoic acid (105 mg), EDCI (190 mg), HOBT (150 mg) were dissolved in THF (3 mL). After the mixture was stirred at RT for 1 h, a solution of 3-bromo-2-ethyl-Λ/-hydroxybenzenecarboximidamide (D22) (140 mg) in
THF (3 ml) was added slowly. The obtained mixture was stirred for further 2 h at room temperature. LCMS show only one intermediate was found. After addition of
TBAF (742 mg), the reaction mixture was sealed and heated under microwave at 120 °C for 2 h. The reaction was cooled down to room temperature, the solvent was evaporated and EtOAc (100 mL) was added. The organic phase was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, the residue was purified by column chromatography to afford 3-(3-bromo-2-ethylphenyl)-5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazole (D53) (345 mg) as a yellow solid. MS (ES): C19H18BrCIN2O2 requires 420; found 421.1 (M+H+).
Description for D54 ethyl 4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyljbutanoate (D54)
Figure imgf000055_0001
To a suspension of 3-(3-bromo-2-ethylphenyl)-5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazole (D53) (120 mg), tri-t-butylphosphine (17.27 mg) and cesium carbonate (27.8 mg) in tetrahydrofuran (THF) (10 mL) stirred under nitrogen was added Pd2(dba)3 (39.1 mg) and a solution of bromo[3-(ethyloxy)-3- oxopropyl]zinc (0.5 M in THF, 1.707 mL) in one portion. The reaction mixture was stirred at RT for 3 h. The solvent was evaporated off and EtOAc (25 mL) was added. The aqueous phase was extracted with EA for 3 times, the combined organic layers were washed with brine, dried over sodium sulphate and evaporated to afford ethyl 4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyl]butanoate (D54) (173 mg) as a yellow oil, which was used in the next step directly. MS (ES): C25H29CIN2O4 requires 456; found 457.2 (M+H+).
Description for D55 ethyl 3-[3-(5-{3-chloro-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- ethylphenyl]propanoate (D55)
Figure imgf000055_0002
To a suspension of 3-(3-bromo-2-ethylphenyl)-5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazole (D53) (130 mg), tri-t-butylphosphine (19 mg) and cesium carbonate (30 mg) in tetrahydrofuran (THF) (10 ml_) stirred under nitrogen was added Pd2(dba)3 (42.3 mg) and a solution of bromo[3-(ethyloxy)-3- oxopropyljzinc (0.5 M in THF, 2.5 mL) in one portion. The reaction mixture was stirred at RT for 3 h. The solvent was evaporated off and EtOAc (25 mL) was added. The aqueous phase was extracted with EA for 3 times, the combined organic layers were washed with brine, dried over sodium sulphate and evaporated to afford ethyl 3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyl]propanoate (D55) (164 mg) as a yellow oil, which was used in the next step directly. MS (ES): C24H27CIN2O4 requires 442; found 443.2 (M+H+).
Description for D56 3-bromo-5-fluoro-2-(methyloxy)benzonitrile (D56)
Figure imgf000056_0001
To bromine (3.8 mL) was added iron (0.813 g) in one portion. The reaction mixture was stirred at RT for 5 min, and a solution of 5-fluoro-2-(methyloxy)benzonitrile (2 g) in dichloromethane (DCM) (40 mL) was added dropwise. The reaction mixture was stirred at 60 0C for 24 h. LCMS showed trace of the product. More bromine (3.2 mL) was added. Heating continued at 60 0C for 24 h. Aqueous NaHSO3 was added to quench the reaction. The aqueous layer was seperated and extracted with EA for 3 times. The combined organic layers were washed with brine, dried over anhydrous Na2SO4. The dried solution was purified by column chromatography to afford 3- bromo-5-fluoro-2-(methyloxy)benzonitrile (D56) (330 mg) as an off-white solid. δH (CDCI3, 400MHz): 4.04 (3H1 s), 7.29 (1H, q), 7.56 (1H, q).
Description for D57 3-bromo-5-fluoro-Λ/-hydroxy-2-(methyloxy)benzenecarboximidamide (D57)
Figure imgf000056_0002
To a solution of 3-bromo-5-fluoro-2-(methyloxy)benzonitrile (D56) (495 mg) in ethanol (8 mL) was added hydroxylamine hydrochloride (301 mg) and sodium bicarbonate (362 mg). The reaction mixture was stirred at 90 0C overnight. After cooling, the reaction, the mixture was filtered through the celite, and washed by ethanol. The filtrate was concentrated in vacuo to afford 3-bromo-5-fluoro-Λ/-hydroxy- 2-(methyloxy)benzenecarboximidamide (D57) (573 mg) as an off-white solid. MS (ES): C8H8BrFN2O2 requires 262; found 263.0 (M+H+).
Description for D58 5-{3-[3-bromo-5-fluoro-2-(methyloxy)phenyl]-1,2,4-oxadiazol-5-yl}-2-[(1- methylethyl)oxy]benzonitrile (D58)
Figure imgf000057_0001
3-cyano-4-[(1-methylethyl)oxy]benzoic acid (202 mg), EDCI (377 mg), HOBT (301 mg) were dissolved in THF (6 mL). After the mixture was stirred at RT for I h, a solution of 3-bromo-5-fluoro-Λ/-hydroxy-2-(methyloxy)benzenecarboximidamide (D57) (280 mg) in THF (3 ml) was added slowly. The obtained mixture was stirred for further 2 h at room temperature. LCMS show the intermediate was formed. After addition of TBAF (1.17 g), the reaction mixture was sealed and heated under microwave at 120 0C for 2 h. The reaction was cooled down to room temperature, the solvent was evaporated and EtOAc (100 mL) was added. The organic phase was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, the residue was purified by column chromatography to afford 5-{3-[3-bromo-5-fluoro-2-(methyloxy)phenyl]-1,2,4- oxadiazol-5-yl}-2-[(1-methylethyl)oxy]benzonitrile (D58) (345 mg) as a yellow solid. MS (ES): Ci9H15BrFN3O3 requires 431; found 432.1 (M+H+).
Description for D59 ethyl 3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5- fluoro-2-(methyloxy)phenyl]propanoate (D59)
Figure imgf000058_0001
To a suspension of 5-{3-[3-bromo-5-fluoro-2-(methyloxy)phenyl]-1,2,4-oxadiazol-5- yl}-2-[(1-methylethyl)oxy]benzonitrile (D58) (152 mg), tri-t-butylphosphine (21.34 mg) and cesium carbonate (34.4 mg) in tetrahydrofuran (THF) (12 ml_) stirred under nitrogen was added Pd2(dba)3 (48.3 mg) and a solution of bromo[3-(ethyloxy)-3- oxopropyl]zinc (0.5 M in THF, 2.11 mL) in one portion. The reaction mixture was stirred at RT for 3 h. The solvent was evaporated off and EtOAc (25 mL) was added. The aqueous phase was extracted with EA for 3 times, the combined organic layers were washed with brine, dried over sodium sulphate and evaporated to afford ethyl 3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5-fluoro-2- (methyloxy)phenyl]propanoate (D59) (128 mg) as a yellow oil, which was used in the next step directly. MS (ES): C24H24FN3O5 requires 453; found 454.2 (M+H+).
Description for D60 ethyl 4-[3-(5-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-5- fluoro-2-(methyloxy)phenyl]butanoate (D60)
Figure imgf000058_0002
To a suspension of 5-{3-[3-bromo-5-fluoro-2-(methyloxy)phenyl]-1 ,2,4-oxadiazol-5- yl}-2-[(1-methylethyl)oxy]benzonitrile (D58) (156 mg), tri-t-butylphosphine (21.91 mg) and cesium carbonate (35.3 mg) in tetrahydrofuran (THF) (12 mL) stirred under nitrogen was added Pd2(dba)3 (49.6 mg) and a solution of bromo[4-(ethyloxy)-4- oxobutyljzinc (0.5 M in THF, 2.16 mL) in one portion. The reaction mixture was stirred at RT for 4 h. The solvent was evaporated off and EtOAc (25 mL) was added. The aqueous phase was extracted with EA for 3 times, the combined organic layers were washed with brine, dried over sodium sulphate and evaporated, the residue was purified by column chromatography to afford ethyl 4-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2l4-oxadiazol-3-yl)-5-fluoro-2-(methyloxy)phenyl]butanoate (D60) (130 mg) as a yellow oil. MS (ES): C25H26FN3O5 requires 467; found 468.2 (M+H+).
Description for D61
S^S-ia-bromo-S-fluoro^methyloxyJphenylJ-i.a^-oxadiazol-S-yl^a-chloro-a- [(1-methylethyl)oxy]pyridine (D61 )
Figure imgf000059_0001
3-chloro-5-[(1-methylethyl)oxy]-2-pyridinecarboxylic acid (205 mg), EDCI (372 mg), HOBT (299 mg) were dissolved in THF (8 ml_). After the mixture was stirred at RT for 1 h, a solution of 3-bromo-5-fluoro-Λ/-hydroxy-2-
(methyloxy)benzenecarboximidamide (D57) (257 mg) in THF (3 ml) was added slowly. The obtained mixture was stirred for further 2 h at room temperature. LCMS show the intermediate was formed. After addition of TBAF (1.2 g), the reaction mixture was sealed and heated under microwave at 120 0C for 2 h. The reaction was cooled down to room temperature, the solvent was evaporated and EtOAc (100 ml_) was added. The organic phase was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, the residue was purified by column chromatography to afford 5-{3-[3-bromo-5-fluoro-2- (methyloxy)phenyl]-1 ,2,4-oxadiazol-5-yl}-3-chloro-2-[(1-methylethyl)oxy]pyridine (D61) (316 mg) as a yellow solid. MS (ES): Ci7H14BrCIFN3O3 requires 441; found 442.0 (M+H+).
Description for D62 ethyl 4-[3-(5-{5-crιloro-6-[(1-metrιylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)- 5-fluoro-2-(methyloxy)phenyl]butanoate (D62)
Figure imgf000059_0002
To a suspension of 5-{3-[3-bromo-5-fluoro-2-(methyloxy)phenyl]-1,2,4-oxadiazol-5- yl}-3-chloro-2-[(1-methylethyl)oxy]pyridine (D61) (137 mg), tri-t-butylphosphine (18.78 mg) and cesium carbonate (30.3 mg) in tetrahydrofuran (THF) (8 ml_) stirred under nitrogen was added Pd2(dba)3 (42.6 mg) and a solution of bromo[4-(ethyloxy)-4- oxobutyl]zinc (0.5 M in THF, 2.2 mL) in one portion. The reaction mixture was stirred at RT overnight. The solvent was evaporated off and EtOAc (25 mL) was added. The aqueous phase was extracted with EA for 3 times, the combined organic layers were washed with brine, dried over sodium sulphate and evaporated, the residue was purified by column chromatography to afford ethyl 4-[3-(5-{5-chloro-6-[(1- methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-5-fluoro-2-(methyloxy)phenyl] butanoate (D62) (124 mg) as a yellow oil. MS (ES): C23H25CIFN3O5 requires 477; found 478.2 (M+H+).
Description for D63 ethyl 3-[3-(5-{5-chloro-6-[(1 -methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-
5-fluoro-2-(methyloxy)phenyl]propanoate (D63)
To a suspension of 5-{3-[3-bromo-5-fluoro-2-(methyloxy)phenyl]-1 ,2,4-oxadiazol-5- yl}-3-chloro-2-[(1-methylethyl)oxy]pyridine (D61) (142 mg), tri-t-butylphosphine (19.47 mg) and cesium carbonate (31.4 mg) in tetrahydrofuran (THF) (12 mL) stirred under nitrogen was added Pd2(dba)3 (44.1 mg) and a solution of bromo[3-(ethyloxy)-3- oxopropyljzinc (0.5 M in THF, 1.93 mL) in one portion. The reaction mixture was stirred at RT overnight. The solvent was evaporated off and EtOAc (25 mL) was added. The aqueous phase was extracted with EA for 3 times, the combined organic layers were washed with brine, dried over sodium sulphate and evaporated, the residue was purified by column chromatography to afford ethyl 3-[3-(5-{5-chloro-6- [(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-5-fluoro-2-
(methyloxy)phenyl]propanoate (D63) (144 mg) as a yellow oil, which was used in the next step directly. MS (ES): C22H23CIFN3O5 requires 463; found 464.2 (M+H+).
Description for D64 3-[3-bromo-5-fluoro-2-(methyloxy)phenyl]-5-{3-chloro-4-[(1-methylethyl)oxy] phenyl}-1,2,4-oxadiazole (D64)
Figure imgf000061_0001
3-chloro-4-[(1-methylethyl)oxy]benzoic acid (200 mg), EDCI (357 mg), HOBT (285 mg) were dissolved in THF (4 ml_). After the mixture was stirred at RT for 1 h, a solution of 3-bromo-5-fluoro-Λ/-hydroxy-2-(methyloxy)benzenecarboximidamide (D57) (280 mg) in THF (3 ml) was added slowly. The obtained mixture was stirred for further 1 h at room temperature. LCMS show the intermediate was formed. After addition of TBAF (974 mg), the reaction mixture was sealed and heated under microwave at 120 0C for 2 h. The reaction was cooled down to room temperature, the solvent was evaporated and EtOAc (100 mL) was added. The organic phase was washed with saturated aqueous sodium dicarbonate solution (twice) and water (twice). After removal of the solvent, the residue was purified by column chromatography to afford 3-[3-bromo-5-fluoro-2-(methyloxy)phenyl]-5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazole (D64) (240 mg) as a white solid. MS (ES): C18H15BrCIFN2O3 requires 440; found 441.0 (M+H+).
Description for D65 ethyl 3-[3-(5-{3-chloro-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-5- fluoro-2-(methyloxy)phenyl]propanoate (D65)
Figure imgf000061_0002
To a suspension of 3-[3-bromo-5-fluoro-2-(methyloxy)phenyl]-5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazole (D64) (115 mg), tri-t-butylphosphine (17 mg) and cesium carbonate (31 mg) in tetrahydrofuran (THF) (10 mL) stirred under nitrogen was added Pd2(dba)3 (41 mg) and a solution of bromo[3-(ethyloxy)-3- oxopropyljzinc (0.5 M in THF, 1.56 mL) in one portion. The reaction mixture was stirred at RT overnight. The solvent was evaporated off and EtOAc (25 mL) was added. The aqueous phase was extracted with EA for 3 times, the combined organic layers were washed with brine, dried over sodium sulphate and evaporated, the residue was purified by column chromatography to afford ethyl 3-[3-(5-{3-chloro-4- [(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5-fluoro-2-
(methyloxy)phenyl]propanoate (D65) (109 mg) as a yellow oil. MS (ES): C23H24CIFN2O5 requires 462; found 463.2 (M+H+).
Description for D66 ethyl 4-[3-(5-{3-chloro-4-[{1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5- fluoro-2-(methyloxy)phenyl]butanoate (D66)
Figure imgf000062_0001
To a suspension of 3-[3-bromo-5-fluoro-2-(methyloxy)phenyl]-5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazole (D64) (72 mg), tri-t-butylphosphine (9.89 mg) and cesium carbonate (18 mg) in tetrahydrofuran (THF) (8 ml_) stirred under nitrogen was added Pd2(dba)3 (22.39 mg) and a solution of bromo[4-(ethyloxy)-4- oxobutyljzinc (0.5 M in THF, 0.98 mL) in one portion. The reaction mixture was stirred at RT overnight. The solvent was evaporated off and EtOAc (25 mL) was added. The aqueous phase was extracted with EA for 3 times, the combined organic layers were washed with brine, dried over sodium sulphate and evaporated, the residue was purified by column chromatography to afford ethyl 4-[3-(5-{3-chloro-4- [(1-methylethyl)oxy]phenyϊ}-1,2,4-oxadiazol-3-yl)-5-fluoro-2-
(methyloxy)phenyljbutanoate (D66) (72 mg) as a yellow oil. MS (ES): C24H26CIFN2O5 requires 476; found 477.2 (M+H+).
Description for D67 ethyl 4-(3-cyano-2-propylphenyl)butanoate (D67)
Figure imgf000062_0002
To a suspension of 3-bromo-2-propylbenzonitrile (520 mg), tri-t-butylphosphine (141 mg) and cesium carbonate (243 mg) in tetrahydrofuran (THF) (30 mL) stirred under nitrogen was added Pd2(dba)3 (319 mg) and a solution of bromo[4-(ethyloxy)-4- oxobutyl]zinc (0.5 M in THF, 13.92 mL) in one portion. The reaction mixture was stirred at RT overnight. The solvent was diluted with EtOAc, filered through the celite, the filtrate was seperated between aqueous and organic layers. The aqueous phase was extracted with EA for 3 times, the combined organic layers were washed with brine, dried over sodium sulphate and evaporated, the residue was purified by column chromatography to afford ethyl 4-(3-cyano-2-propylphenyl)butanoate (D67) (410 mg) as a yellow oil. MS (ES): C16H2INO2 requires 259; found 260.2 (M+H+).
Description for D68 ethyl 4-{3-[(Z)-(hydroxyamino)(imino)methyl]-2-propylphenyl}butanoate (D68)
Figure imgf000063_0001
To a solution of ethyl 4-(3-cyano-2-propylphenyl)butanoate (D67) (410 mg) in ethanol (5 ml_) was added hydroxylamine hydrochloride (220 mg) and sodium bicarbonate (266 mg). The reaction mixture was stirred at 90 0C overnight. After cooling, the reaction, the mixture was filtered through the celite, and washed by ethanol. The filtrate was concentrated in vacuo to afford ethyl 4-{3-[(Z)- (hydroxyamino)(imino)methyl]-2-propylphenyl}butanoate (D68) (700 mg) as an off- white solid. MS (ES): Ci6H24N2O4 requires 292; found 293.2 (M+H+).
Description for D69 ethyl 4-[3-(5-{3-chloro-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- propylphenyl]butanoate (D69)
Figure imgf000063_0002
3-chloro-4-[(1-methylethyl)oxy]benzoic acid (140 mg), EDCI (250 mg), HOBT (200 mg) were dissolved in THF (8 mL). After the mixture was stirred at RT for 1 h, a solution of ethyl 4-{3-[(Z)-(hydroxyamino)(imino)methyl]-2-propylphenyl}butanoate (D68) (286 mg) in THF (3 ml) was added slowly. The obtained mixture was stirred for further 1 h at room temperature. LCMS show the intermediate was formed. After addition of TBAF (682 mg), the reaction mixture was sealed and heated under microwave at 120 0C for 1.5 h. The reaction was cooled down to room temperature, the solvent was evaporated and water was added. The aqueous layer was extracted with EtOAc for 3 times, the combined organic layers were washed with brine and dried over Na2SO4. After removal of the solvent, the residue was purified by column chromatography to afford ethyl 4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4- oxadiazol-3-yl)-2-propylphenyl]butanoate (D69) (94 mg) as a white solid. MS (ES): C26H3ICIN2O4 requires 470; found 471.3 (M+H+).
Description for D70 ethyl 4-[3-(5-{3.cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- propylphenyl]butanoate (D70)
Figure imgf000064_0001
3-cyano-4-[(1-methylethyl)oxy]benzoic acid (139 mg), EDCI (260 mg), HOBT (207 mg) were dissolved in THF (8 ml_). After the mixture was stirred at RT for 1 h, a solution of ethyl 4-{3-[(Z)-(hydroxyamino)(imino)methyl]-2-propylphenyl}butanoate
(D68) (300 mg) in THF (3 ml) was added slowly. The obtained mixture was stirred for further 1 h at room temperature. LCMS show the intermediate was formed. After addition of TBAF (708 mg), the reaction mixture was sealed and heated under microwave at 120 0C for 2 h. The reaction was cooled down to room temperature, the solvent was evaporated and water was added. The aqueous layer was extracted with
EtOAc for 3 times, the combined organic layers were washed with brine and dried over Na2SO4. After removal of the solvent, the residue was purified by column chromatography to afford ethyl 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4- oxadiazol-3-yl)-2-propylphenyl]butanoate (D70) (136 mg) as a yellow oil. MS (ES):
C27H31N3O4 requires 461; found 462.3 (M+H+).
Description for D71
3-bromophenyl diethylcarbamate (D71)
Figure imgf000065_0001
To a mixture of sodium hydride (4.62 g) and THF (80 mL) at 0 0C under nitrogen was added a solution of 3-bromophenol (10 g) in THF (20 mL) dropwise. The mixture was stirred at this temperture for 0.5 h. Then diethylcarbamic chloride (14.65 mL) in THF (20 mL) was added to the mixture dropwise. The mixture was stirred at room temperature for 2 h. The reaction was quenched by EtOH. Then added water. The organic phase was seperated. The aqueous phase was extracted with EΞA. The combined organic solution was dried over anhydrous sodium sulphate. After concentration, the residue was purified by column chromatography to give 3- bromophenyl diethylcarbamate (D71) (15.4 g) as a oil. MS (ES): CnHi4BrNO2 requires 271; found 272.0 (M+H+).
Description for D72 3-bromo-2-ethylphenyl diethylcarbamate (D72)
Figure imgf000065_0002
To a solution of 3-bromophenyl diethylcarbamate (D71) (7 g) in tetrahydrofuran (THF) at -78 0C was added sec-butyllithium (35.6 mL) and TMEDA (6.99 mL). The resulting mixture was stirred at this temperature for 1.5 h. After that, iodoethane (6.24 mL) was added to the mixture through syringe. The reaction mixture was warmed to room temperature and stirred at this temperature overnight. The reaction was quenched with water. The organic phase was seperated. The aqueous phase was extracted with EA. The combined organic solution was dried over anhydrous sodium sulphate. After filtration and concentration, the residue was purified by column chromatography to give 3-bromo-2-ethylphenyl diethylcarbamate (D72) (4.4 g). MS (ES): Ci3H18BrNO2 requires 299; found 300.1 (M+H+).
Description for D73 3-bromo-2-ethylphenol (D73)
Figure imgf000066_0001
sodium hydroxide (5.86 g) was added into a solution of 3-bromo-2-ethylphenyl diethylcarbamate (D72) (4.4 g) in ethanol (15 ml_). The reaction vessel was sealed and heated under microwave at 120 0C for 90 min. After cooling the reaction, the mixture was quenched with water. Then pH value was adjusted to about 5 using 2N
HCI solution. EtOH was removed. The residue was extracted with EtOAc. The combined organic solution was dried over anhydrous sodium sulphate. After filtration and concentration, the residue was purified by column chromatography to give 3- bromo-2-ethylphenol (D73) (1.37 g). δH (CDCI3, 400MHz): 1.16 (3H, t), 2.82 (2H, m), 5.17 (1H, S)1 6.70 (1H1 dd), 6.90 (1H, t), 7.12 (1H1 dd).
Description for D74 ethyl 4-[(3-bromo-2-ethylphenyl)oxy]butanoate (D74)
Figure imgf000066_0002
To a solution of 3-bromo-2-ethylphenol (D73) (500 mg) and ethyl 4-bromobutanoate (0.395 mL) in Λ/,Λ/-dimethylformamide (DMF) (10 ml_) was added potassium carbonate (447 mg). The reaction mixture was stirred at 65 0C overnight. Water was added to the reaction mixture and then the mixture was extracted with EtOAc. The combined organic solution was dried over anhydous sodium sulphate. After filtration and concentration, the residue was purified by column chromatography to give ethyl 4-[(3-bromo-2-ethylphenyl)oxy]butanoate (D74) (583 mg). MS (ES): Ci4Hi9BrO3 requires 314; found 315.1 (M+H+).
Description for D75 ethyl 4-[(3-cyano-2-ethylphenyl)oxy]butanoate (D75)
Figure imgf000066_0003
To a solution of ethyl 4-[(3-bromo-2-ethylphenyl)oxy]butanoate (D74) (583 mg) in N- methyl-2-pyrrolidone (NMP) (15 mL) was added copper(l) cyanide (199 mg) and copper(l) iodide (70.5 mg). The mixture was stirred at 180 0C for 6 h. After cooling the reaction, water was added to quench the reaction. The mixture was extracted with EtOAc. The combined organic solution was dried over anhydrous Na2SO4. After filtration and concentration, the residue was purified by column chromatography to give ethyl 4-[(3-cyano-2-ethylphenyl)oxy]butanoate (D75) (341.6 mg). MS (ES): Ci5Hi9NO3 requires 261 ; found 262.2 (M+H+).
Description for D76 ethyl 4-({2-ethyl-3-[(Z)-(hydroxyamino)(imino)methyl]phenyl}oxy)butanoate
(D76)
Figure imgf000067_0001
To a solution of ethyl 4-[(3-cyano-2-ethylphenyl)oxy]butanoate (D75) (341 mg) in ethanol (20 mL) was added hydroxylamine hydrochloride (181 mg) and sodium bicarbonate (329 mg). The reaction mixture was stirred at 90 0C overnight. After cooling, the reaction, the mixture was filtered through the celite, and washed by ethanol. The filtrate was concentrated in vacuo to afford ethyl 4-({2-ethyl-3-[(Z)- (hydroxyamino)(imino)methyl]phenyl}oxy)butanoate (D76) (428 mg) as an off-white solid. MS (ES): Ci5H22N2O4 requires 294; found 295.2 (M+H+).
Description for D77 ethyl 4-{[3-(5-{3-cyano-4-[(1 -methylethy l)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- ethylphenyl]oxy}butanoate (D77)
Figure imgf000067_0002
3-cyano-4-[(1-methylethyl)oxy]benzoic acid (100 mg), EDCI (187 mg), HOBT (149 mg) were dissolved in THF (10 mL). After the mixture was stirred at RT for 1 h, a solution of ethyl 4-({2-ethyl-3-[(Z)-(hydroxyamino)(imino)methyl]phenyl}oxy)butanoate (D76) (215 mg) was added. The obtained mixture was stirred for further 2 h at room temperature. LCMS show the intermediate was formed. After addition of TBAF (510 mg), the reaction mixture was sealed and heated under microwave at 120 0C for 2 h. The reaction was cooled down to room temperature, the solvent was evaporated and EtOAc (100 ml_) was added. The organic phase was washed with saturated aqueous sodium dicarbonate solution and water. After removal of the solvent, the residue was purified by column chromatography to afford ethyl 4-{[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-ethylphenyl]oxy}butanoate (D77) (73.5 mg) as a yellow solid. MS (ES): C26H29N3O5 requires 463; found 464.3 (M+H+).
Description for D78 ethyl 4-{[3-(5-{3-chloro-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- ethylphenyl]oxy}butanoate (D78)
Figure imgf000068_0001
3-chloro-4-[(1-methylethyl)oxy]benzoic acid (100 mg), EDCI (179 mg), HOBT (143 mg) were dissolved in THF (10 ml_). After the mixture was stirred at RT for 1 h, a solution of ethyl 4-({2-ethyl-3-[(Z)-(hydroxyamino)(imino)methyl]phenyl}oxy)butanoate (D76) (206 mg) was added. The obtained mixture was stirred for further 2 h at room temperature. LCMS show the intermediate was formed. After addition of TBAF (487 mg), the reaction mixture was sealed and heated under microwave at 120 0C for 2 h. The reaction was cooled down to room temperature, the solvent was evaporated and EtOAc (100 mL) was added. The organic phase was washed with saturated aqueous sodium dicarbonate solution and water. After removal of the solvent, the residue was purified by column chromatography to afford ethyl 4-{[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-ethylphenyl]oxy}butanoate (D78) (84.5 mg). MS (ES): C25H29CIN2O5 requires 472; found 473.2 (M+H+).
Description for D79 [2-({[(3-bromo-2-ethylphenyl)oxy]methyl}oxy)ethyl](trimethyl)silane (D79)
Figure imgf000069_0001
To the solution of 3-bromo-2-ethylphenol (D73) (2.23 g) in dichloromethane (DCM) (50 mL) was added Hunig's base (2.52 mL) followed by SEMCI (2.56 ml_) dropwise under ice-water cooling. After addition, the cooling was removed and the reaction solution was warmed to room temperature overnight. The reaction solution was washed with water (2*10 mL), dried over sodium sulphate, concentrated. The crude product was purified by column chromatography to give [2-({[(3-bromo-2- ethylphenyl)oxy]methyl}oxy)ethyl](trimethyl)silane (D79) (3.24 g).
Description for D80
2-ethyl-3-hydroxybenzonitrile (D80)
Figure imgf000069_0002
A mixture of [2-({[(3-bromo-2-ethylphenyl)oxy]methyl}oxy)ethyl](trimethyl)silane (D79) (2.74 g), copper(l) cyanide (1.111 g) and copper(l) iodide (0.315 g) in Λ/-methyl-2- pyrrolidone (NMP) (10 mL) was stirred at 180 0C for 6 h. LCMS showed no starting material and the protecting group SEM was removed. The mixture was diluted with EtOAc, the organic phase was washed with water and dried over anhydrous sodium sulphate. After filtration and concentration, the residue was purified by column chromatography to give 2-ethyl-3-hydroxybenzonitrile (D80) (514 mg). MS (ES): C9H9NO requires 147; found 148.1 (M+H+).
Description for D81 2-ethyl-3-[({[2-(trimethylsilyl)ethyl]oxy}methyl)oxy]benzonitrile (D81)
Figure imgf000069_0003
To the solution of 2-ethyl-3-hydroxybenzonitrile (D80) (514 mg) in dichloromethane (DCM) (10 mL) was added Hunig's base (0.732 mL) followed by SEMCI (0.743 mL) dropwise under ice-water cooling. After addition, the cooling was removed and the reaction solution was warmed to room temperature overnight. The reaction solution was washed with water (2*10 mL), dried over sodium sulphate, concentrated. The crude product was purified by column chromatography to give 2-ethyl-3-[({[2- (trimethylsilyl)ethyl]oxy}methyl)oxy]benzonitrile (D81) (950 mg). MS (ES): Ci5H23NO2Si requires 277; found 278.2 (M+H+).
Description for D82
2-ethyl-Λ/-hydroxy-3-[({[2-(trimethylsilyl)ethyl]oxy}methyl)oxy] benzenecarboximidamide (D82)
Figure imgf000070_0001
A mixture of 2-ethyl-3-[({[2-(trimethylsilyl)ethyl]oxy}methyl)oxy]benzonitrile (D81) (950 mg), sodium bicarbonate (1.72 g) and hydroxylamine hydrochloride (952 mg) in ethanol (25 ml.) was stirred at reflux overnight until the starting material was consumed completely. The mixture was filtered and the filtrate was concentrated. The obtained oil was purified by C18 column to give 2-ethyl-Λ/-hydroxy-3-[({[2- (trimethylsilyl)ethyl]oxy}methyl)oxy]benzenecarboximidamide (D82) (892 mg). MS (ES): C15H26N2O3Si requires 310; found 311.2 (M+H+).
Description for D83
5-(3-{2-ethyl-3-[({[2-(trimethylsilyl)ethyl]oxy}methyl)oxy]phenyl}-1,2,4- oxadiazol-5-yl)-2-[(1-methylethyl)oxy]benzonitrile (D83)
Figure imgf000070_0002
3-cyano-4-[(1-methylethyl)oxy]benzoic acid (350 mg), EDCI (654 mg), HOBT (522 mg) were dissolved in THF (10 ml_). After the mixture was stirred at RT for 1 h, a solution of 2-ethyl-Λ/-hydroxy-3-[({[2-
(trimethylsilyl)ethyl]oxy}methyl)oxy]benzenecarboximidamide (D82) (794 mg) was added. The reaction mixture was sealed and heated under microwave at 120 0C for 2 h. The reaction was cooled down to room temperature, the solvent was evaporated and EtOAc (100 mL) was added. The organic phase was washed with saturated aqueous sodium dicarbonate solution and water. After removal of the solvent, the residue was purified by column chromatography to afford 5-(3-{2-ethyl-3-[({[2- (trimethylsilyl)ethyl]oxy}methyl)oxy]phenyl}-1,2,4-oxadiazol-5-yl)-2-[(1- methylethyl)oxy]benzonitrile (D83) (364 mg). MS (ES): C26H33N3O4Si requires 479; found 480.3 (M+H+).
Description for D84
Figure imgf000071_0001
To the solution of 5-(3-{2-ethyl-3-[({[2-(trimethylsilyl)ethyl]oxy}methyl)oxy]phenyl}- 1 ,2,4-oxadiazol-5-yl)-2-[(1-methylethyl)oxy]benzonitrile (D83) (364 mg) in HMPA (5 mL) was added TBAF (992 mg) at room temperature. The resulting solution was stirred at 60 0C overnight. After cooling the reaction, the solution was diluted with ethyl acetate (50 mL), washed with water (3*20 mL), dried over sodium sulphate and concentrated. The residue was purified by column chromatography to give 5-[3-(2- ethyl-3-hydroxyphenyl)-1 ,2,4-oxadiazol-5-yl]-2-[(1-methylethyl)oxy]benzonitrile (D84) (224.5 mg). MS (ES): C20H19N3O3 requires 349; found 350.2 (M+H+).
Description for D85 ethyl {[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyl]oxy}acetate (D85)
Figure imgf000071_0002
To a solution of 5-[3-(2-ethyl-3-hydroxyphenyl)-1,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (D84) (30 mg) in Λ/,Λ/-dimethylformamide (DMF) (2 mL) was added ethyl bromoacetate (28.7 mg) and potassium carbonate (23.73 mg). The resulting mixture was heated to 60 0C for overnight. After cooling the reaction, water was added to the mixture, the aqueous layer was extracted with ethyl acetate for 3 times, the organic phases were washed with water, dried over sodium sulphate, concentrated to afford ethyl {[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4- oxadiazol-3-yl)-2-ethylphenyl]oxy}acetate (D85) (37.4 mg) as a yellow oil, which was used for the next step directly. MS (ES): 024H25N3O5 requires 435; found 436.2 (M+H+). Description for D86
5-(5-amino-1 ,3,4-oxadiazol-2-yl)-2-[(1 -methylethyl)oxy]benzonitrile (D86)
Figure imgf000072_0001
To a suspension of 3-cyano-4-[(1-methylethyl)oxy]benzoic acid (2 g) in phosphorus oxychloride (10 mL) was added hydrazinecarboxamide hydrochloride (1.630 g). The reaction mixture was heated at 90 0C for 3 h. The reaction mixture was cooled to room temperature, the solvent was removed in vacuo. The residue was poured into ice carefully and neutralized with 2 M NaOH to pH=7. The aqueous layer was extracted with EtOAc1 the organic layer was dried over sodium sulfate and evaporated in vacuo to afford the crude product 5-(5-amino-1 ,3,4-oxadiazol-2-yl)-2- [(1-methylethyl)oxy]benzonitrile (D86) (1.93 g). The crude product was used directly for the next step.
Description for D87
5-(5-bromo-1 ,3,4-oxadiazol-2-yl)-2-[(1 -methy lethyl)oxy]benzonitrile (D87)
Figure imgf000072_0002
To a mixture of 5-(5-amino-1 ,3,4-oxadiazol-2-yl)-2-[(1-methylethyl)oxy]benzonitrile (D86) (1.93 g) and copper(ll) bromide (3.53 g) in acetonitrile (100 mL), 1 ,1- dimethylethyl nitrite (1.895 mL) was added in one portion at RT and the reaction mixture was stirred overnight. The reaction mixture was diluted with EtOAc (20 mL) and 1M HCI (10 mL) was added. The organic layer was washed with water and saturated NaHCO3, then dried over sodium sulphate. The solvent was removed in vacuo. The crude product was purified by column chromatography to give 5-(5- bromo-1,3,4-oxadiazol-2-yl)-2-[(1-methylethyl)oxy]benzonitrile (D87) (1.1 g). MS (ES): Ci2H10BrN3O2 requires 307; found 308.0 (M+H+).
Description for D88 ethyl 4-[3-(5-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,3,4-oxadiazol-2-yl)-2- ethylphenyl]butanoate (D88)
Figure imgf000073_0001
To a suspension of 5-(5-bromo-1,3,4-oxadiazol-2-yl)-2-[(1- methylethyl)oxy]benzonitrile (D87) (64.1 mg), tripotassium phosphate (92 mg) and ethyl 4-[2-ethyl-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)phenyl]butanoate (60 mg) in Λ/,/V-dimethylformamide (DMF) (4.00 mL) and water (0.8 mL) under nitrogen at room temperature was added Pd(Ph3P)4 (20.02 mg) in one charge. The reaction vessel was sealed and heated under microwave at 110 °C for 20 min. After cooling the reaction, the reaction mixture was partitioned between ethyl acetate and water. The organic layers were combined, dried over sodium sulphate and evaporated in vacuo. The residue was purified by column chromatography to give ethyl 4-[3-(5-{3- cyano-4-[(1-methylethyl)oxy]phenyl}-1,3,4-oxadiazol-2-yl)-2-ethylphenyl]butanoate (D88) (40 mg). MS (ES): C26H29N3O4 requires 447; found 448.2 (M+H+).
Description for D89 3-chlorophenyl diethylcarbamate (D89)
Figure imgf000073_0002
To a solution of 3-chlorophenol (10 g) in tetrahydrofuran (THF) (100 mL) was added NaH (6.22 g) at room temperature. The result suspension was stirred for 2 h. Diethylcarbamic chloride (21.09 g) was added and the reaction mixture was stirred for another 3 h. The reaction was quenched with water(10 mL), washed with brine (20 mL) for 3 times. The organic phase was concentrated and the residue was purified by column chromatography to give 3-chlorophenyl diethylcarbamate (D89) (14.2 g) as a light oil. δH (CDCI3, 400MHz): 1.24 (6H, m), 3.41 (4H, m), 7.05 (1H, m), 7.19 (2H, m), 7.27 (1H, m). MS (ES): CnH14CINO2 requires 227; found 228.1 (M+H+).
Description for D90
3-chloro-2-ethylphenyl diethylcarbamate (D90)
Figure imgf000074_0001
To a solution of TMEDA (16.94 ml.) and 3-chlorophenyl diethylcarbamate (D89) (14.2 g) in dry tetrahydrofuran (THF) (25 ml_) at -70 0C was added sec-butyllithium (86 ml_). The reaction mixture was stirred at this temperature for 2 h. Ethyl iodide (15.12 ml_) was added and the reaction mixture was stirred at -700C for 1 hour. Then the reaction mixture was warmed to room temperature and stirred overnight. The reaction was quenched with saturated aqueous NH4CI (10 ml_) and partitioned between brine (10 ml_) and ethyl acetate (50 mL). The organic phase was concentrated and the residue was purified by column chromatography to give 3- chloro-2-ethylphenyl diethylcarbamate (D90) (11.7 g) as a light yellow oil. MS (ES): C13H18CINO2 requires 255; found 256.1 (M+H+).
Description for D91 3-chloro-2-ethylphenol (D91)
Figure imgf000074_0002
To a solution of 3-chloro-2-ethylphenyl diethylcarbamate (D90) (2.5 g) in ethanol (8 mL) was added NaOH (2.5 g) at room temperature. The reaction vessel was sealed and heated under microwave at 1200C for 90 min. The mixture was concentrated to remove the solvent and the pH value was adjusted to about 6 with cone. HCI and 2M HCI under ice bath. The mixture was partitioned between ethyl acetate and brine. The organic phase was concentrated to give 3-chloro-2-ethylphenol (D91) (990 mg) as a light brown oil. δH (DMSO-Cf6, 400MHz): 1.09 (3H, t), 2.71 (2H, m), 6.80 (1H, d), 6.85 (1H, d), 7,03 (1H, t), 9.80 (1H, s).
Description for D92
3-chloro-2-ethylphenyl trifluoromethanesulfonate (D92)
Figure imgf000075_0001
To the mixture of 3-chloro-2-ethylphenol (D91) (12.4 g) and DMAP (13.54 g) in dichloromethane (DCM) (50 mL) was added 1,1,1-trifluoro-N-phenyl-N-
[(trifluoromethyl)sulfonyl]methanesulfonamide (28.3 g). The reaction mixture was stirred at room temperature overnight. Water (1mL) was added and the mixture was stirred for 2 min. The resulting mixture was concentrated to remove the solvent.
Petroleum ether (50 mL) was added and most of suspenstion emerged. The mixture was filtered, the filtrate was concentrated and the residue was purified by column chromatography to give 3-chloro-2-ethylphenyl trifluoromethanesulfonate (D92) (10.0 g). δH (CDCI3, 400MHz): 1.15 (3H, t), 2.80 (2H, m), 7.14 (2H, m), 7.33 (1H, m).
Description for D93 ethyl 4-(3-chloro-2-ethylphenyl)butanoate (D93)
Figure imgf000075_0002
To the mixture of Pd2(dba)3 (0.095 g) and 1,1'-bis(diphenylphosphino)ferrocene (0.058 g) in tetrahydrofuran (THF) (8 mL) was added 3-chloro-2-ethylphenyl trifluoromethanesulfonate (D92) (1.5 g) and bromo[4-(ethyloxy)-4-oxobutyl]zinc (18.71 mL) under nitrogen at room temperature. The reaction vessel was sealed and heated under microwave at 120 0C for 45 min. The reaction was quenched with water, the mixture was concentrated in vacuo and the residue was purified by column chromatography to give ethyl 4-(3-chloro-2-ethylphenyl)butanoate (D93) (0.66 g) as a brown oil. MS (ES): Ci4H19CIO2 requires 254; found 255.1 (M+H+).
Description for D94 ethyl 4-[2-ethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]butanoate (D94)
Figure imgf000076_0001
Tricyclohexylphosphine (0.550 g) and Pd2(dba)3 (0.144 g) in Λ/,Λ/-dimethylformamide (DMF) (12 mL) were stirred under nitrogen for 30 min. Ethyl 4-(3-chloro-2- ethylphenyl)butanoate (D93) (1 g), 4I4,4\4',5,5,5'l5'-octamethyl-2,2'-bi-1l3,2- dioxaborolane (1.794 g) and potassium acetate (0.770 g) were added to the reacion mixture under nitrogen at room temperature. The reaction vessel was sealed and heated under microwave at 1800C for 90 min. After cooling the reaction, the reaction was filtered, the filtrate was concentrated in vacuo and the residue was purified by column chromatography to give ethyl 4-[2-ethyl-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl]butanoate (D94) (0.617 g) as a brown oil. δH (CDCI3, 400MHz): 1.15 (3H, t), 1.28 (3H, t), 1.36 (12H, s), 1.92 (2H, m), 2.38 (2H, t), 2.68 (2H, t), 2.96 (2H, m), 4.15 (2H1 m), 7.13 (1 H, m), 7.21 (1H, d), 7.63 (1 H, d). MS (ES): C20H31BO4 requires 346; found 347.3 (M+H+).
Description for D95 5-(5-amino-1,3,4-thiadia2ol-2-yl)-2-[(1-methylethyl)oxy]benzonitrile (D95)
Figure imgf000076_0002
To a mixture of 3-cyano-4-[(1-methylethyl)oxy]benzoic acid (2 g) and hydrazinecarbothioamide (1.332 g) was added POCI3 (20 mL). The reaction mixture was stirred at 90 0C for 3 h. After cooling the reaction, the mixture was concentrated to remove POCI3. The residue was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic phase was washed with water (50 mL), 2M sodium hydroxide solution (50 mL) and saturated brine (50 mL), dried over sodium sulphate and evaporated to give the crude product 5-(5-amino-1 ,3,4-thiadiazol-2-yl)-2-[(1- methylethyl)oxy]benzonitrile (D95) (2g). MS (ES): Ci2H12N4OS requires 260; found 261.1 (M+H+).
Description for D96 5-(5-bromo-1 ,3,4-thiadiazol-2-yl)-2-[(1 -methylethyl)oxy]benzonitrile (D96)
Figure imgf000077_0001
To a suspension of 5-(5-amino-1,3,4-thiadiazol-2-yl)-2-[(1- methylethyl)oxy]benzonitrile (D95) (800 mg), copper(ll) bromide (1373 mg) in acetonitrile (10 ml_) was added 1,1-dimethylethyl nitrite (0.737 mL). The reaction mixture was stirred at 20 0C for 1.5 h. The reaction was quenched with aqueous HCI(2M), the mixture was partitioned between ethyl acetate (50 mL) and water (25 mL). The organic phase was washed with water (25 mL) and saturated brine (25 mL), dried over sodium sulphate and evaporated in vacuo, the residue was purified by column chromatography to give 5-(5-bromo-1,3,4-thiadiazol-2-yl)-2-[(1- methylethyl)oxy]benzonitrile (D96) (800 mg). MS (ES): C12Hi0BrN3OS requires 323; found 324.0 (M+H+).
Description for D97 ethyl 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-2- ethylphenyl]butanoate (D97)
Figure imgf000077_0002
To a solution of 5-(5-bromo-1,3,4-thiadiazol-2-yl)-2-[(1-methylethyl)oxy]benzonitrile (D96) (57.1 mg), ethyl 4-[2-ethyl-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)phenyl]butanoate (D94) (61 mg) and tripotassium phosphate (93 mg) in N1N- dimethylformamide (DMF) (6 mL) and water (1.5 mL) stirred under nitrogen at room temperature was added Pd(Ph3P)4 (20.36 mg). The reaction vessel was sealed and heated under microwave at 130 0C for 8 min. After cooling the reaction, the reaction was quenched with water. After filtration, the filtrate was partitioned between ethyl acetate and aqueous layer. The aqueous layer was extracted with EA for 3 times. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated, the residue was purified by column chromatography to afford ethyl 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3,4-thiadiazol-2-yl)-2- ethylphenyljbutanoate (D97) (59 mg) as a yellow oil. MS (ES): C26H29N3O3S requires 463; found 464.2 (M+H+).
Description for D98 2-ethy|-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ben2aldehyde (D98)
Figure imgf000078_0001
To a solution of 3-bromo-2-ethylbenzaldehyde (2 g) in Λ/,Λ/-dimethylformamide (DMF) (20 mL) was added 4,4,4l,4l,5,5,5',5l-octamethyl-2,2l-bi-1,3,2-dioxaborolane (3.10 g), potassium acetate (2.76 g) and PdCI2(dppf)-CH2Cl2 adduct (1.150 g). The reaction mixture was heated to 80 0C overnight. The solvent was removed in vacuo and the residue was purified by column chromatography to afford 2-ethyl-3-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzaldehyde (D98) (1.27 g). MS (ES): C15H21BO3 requires 260; found 261.2 (M+H+).
Description for D99
5-{3-chloro-4-[(1 -methylethyl)oxy]phenyl}-1 ,3,4-thiadiazol-2-amine (D99)
Figure imgf000078_0002
The mixture of 3-chloro-4-[(1-methyjethyl)oxy]benzoic acid (5 g), hydrazinecarbothioamide (2.229 g) in phosphoric trichloride (21.43 g) was stirred at 75 0C for 3 h. Concentrated the mixture in vacuum to remove POCI3, the residue was poured into crush ice. Basified the mixture with aqueous NaOH. Extracted it with EA twice.The EA layer was concentrated in vacuum to give crude product 5-{3-chloro-4- [(1-methylethyl)oxy]phenyl}-1 ,3,4-thiadiazol-2-amine (D99) (7.5 g), which was used in the next step without further purification. MS (ES): CnH12CIN3OS requires 269; found 270.1 (M+H+).
Description for D100 2-bromo-5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazole (D100)
Figure imgf000079_0001
The mixture of 5-{3-chloro-4-[(1-methylethyl)oxy]phenylH ^4-thiadiazol-2-amine (D99) (6.25 g), copper(ll) bromide (10.35 g) in acetonitrile (60 ml_) was stirred at room temperature, then 1,1-dimethylethyl nitrite (5.51 mL) was added. The mixture was stirred at room temperature for 3 h. It was treated with EA and aqueous HCI, the EA layer was combined and purified by column chromatography to give 2-bromo-5- {3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3,4-thiadiazole (D100) (4.76 g). MS (ES): Cu Hi0BrCIN2OS requires 333; found 334.0 (IvHH+).
Description for D101 a-tδ-ia-chloro^-KI-methylethyOoxylpheny^-I.S.Φthiacliazol-Z-yO-a- ethylbenzaldehyde (D101)
Figure imgf000079_0002
To a suspension of 2-bromo-5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3,4- thiadiazole (D100) (0.5 g), 2-ethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzaldehyde (D98) (0.468 g) and tripotassium phosphate (0.795 g) in N1N- dimethylformamide (DMF) (10 mL) and water (1.5 mL) stirred under nitrogen at room temperature was added Pd(Ph3P)4 (0.173 g). The reaction vessel was sealed and heated under microwave at 130 0C for 10 min. After cooling the reaction, water was added to the reaction mixture. The mixture was extracted with EA. The combined organic solution was dried over anhydrous sodium sulphate. After filtration and concentration, the residue was purified by column chromatography to give 3-(5-{3- chloro-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-2-ethylbenzaldehyde (D101) (164 mg). MS (ES): C20H19CIN2O2S requires 386; found 387.1 (M+H+).
Description for D102
5-bromo-2-[(1 -methylethyl)oxy]benzonitrile (D102)
Figure imgf000080_0001
To a solution of 5-bromo-2-hydroxybenzonitrile (25 g) in acetonitrile (150 ml_) was added 2-iodopropane (15.14 mL) and potassium carbonate (34.9 g). The reaction mixture was stirred at room temperature for two days. The solvent was removed in vacuo, the residue was dissolved in ethyl acetate (150 mL), washed with water (2*30 mL), the organic phase was dried over sodium sulphate and concentrated to afford 5- bromo-2-[(1-methylethyl)oxy]benzonitrile (D102) (29.8 g) as a white solid without further purification. δH (CDCI3, 400MHz): 1.39 (6H, d), 4.61 (1 H1 m), 6.85 (1H, d), 7.58 (1H, dd), 7.64 (1H, d). MS (ES): C10Hi0BrNO requires 239; found 240.0 (M+H+).
Description for D103
2-[(1-methylethyl)oxy]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzonitrile
(D103)
Figure imgf000080_0002
To a suspension of 5-bromo-2-[(1-methylethyl)oxy]benzonitrile (D102) (123 mg), 4,4,4\4\5,5,5\5l-otfamethyl-2,2'-bi-1 ,3,2-dioxaborolane (156 mg) and potassium acetate (101 mg) in N,N-dimethylformamide (DMF) (150 mL) stirred under nitrogen at room temperature was added PdCI2(dppf)-CH2Cl2 adduct (25.1 mg). The reaction vessel was sealed and heated under microwave at 120 0C for 1 h. After cooling the reaction, the reaction mixture was concentrated in vacuo and the residue was purified by column chromatography to give 2-[(1-methylethyl)oxy]-5-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzonitrile (D103) (54 mg). MS (ES): Ci6H22BNO3 requires 287; found 288.2 (M+H+).
Description for D104 ethyl 4-[3-(3-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-5-yl)-2- ethylphenyl]butanoate (D104)
Figure imgf000081_0001
To a suspension of 2-[(1-methylethyl)oxy]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)benzonitrile (D103) (74.9 mg), ethyl 4-[3-(3-bromo-1,2,4-thiadiazol-5-yl)-2- ethylphenyl]butanoate (D35) (100 mg) and tripotassium phosphate (138 mg) in 1 ,2- dimethoxyethane (DME) (4 ml_) and water (1 ml_) under nitrogen was added Pd(Ph3P)4 (30.1 mg). The reaction vessel was sealed and heated under microwave at 120 0C for 10 min. The reaction mixture was concentrated to give the crude product ethyl 4-[3-(3-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-5-yl)-2- ethylphenyl]butanoate (D104) (61 mg), which was directly used for the next step without further purification. MS (ES): C2SH29N3O3S requires 463; found 464.2 (M+H+).
Description for D105
3-bromo-5-{3-chloro-4-[(1 -methy lethyl)oxy]phenyl}-1 ,2,4-thiadiazole (D105)
Figure imgf000081_0002
To a solution of 3-bromo-5-chloro-1,2,4-thiadiazole (558 mg), {3-chloro-4-[(1- methylethyl)oxy]phenyl}boronic acid (300 mg) and tripotassium phosphate (148 mg) in Λ/,Λ/-dimethylformamide (DMF) (3 ml_) and water (0.600 mL) under nitrogen was added PdCI2(dppf)-CH2CI2 adduct (3.43 g). The reaction vessel was sealed and heated under microwave at 80 0C for 1 h. After cooling the reaction, the mixture was filtered and the filtrate was diluted with ethyl acetate (50 mL), washed with brine (2*10 mL), dried over sodium sulphate, concentrated and purified by column chromatography to afford 3-bromo-5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4- thiadiazole (D105) (450 mg) as a clear oil.. MS (ES): C11Hi0BrCIN2OS requires 332; found 333.0 (M+H+).
Description for D106 ethyl 4-[3-(5-{3-chloro-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2- ethylphenyl]butanoate (D106)
Figure imgf000082_0001
To a mixture of ethyl 4-[2-ethyl-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)phenyl]butanoate (D94) (50 mg), 3-bromo-5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-thiadiazole (D105) (53 mg) and potassium phosphate (61.3 mg) in Λ/,Λ/-dimethylformamide (DMF) (4 mL) and water (1 mL) under nitrogen was added Pd(Ph3P)4 (30 mg). The reaction vessel was sealed and heated under microwave at 130 0C for 8 min. The organic layer was concentrated and purified by column chromatography to give ethyl 4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}- 1,2,4-thiadiazol-3-yl)-2-ethylphenyl]butanoate (D106) (51 mg,) as a brown solid. MS (ES): C25H29CIN2O3S requires 472; found 473.2 (M+H+).
Description for D107
5-(3-bromo-1 ,2,4-thiadiazol-5-yl)-2-[(1 -methylethyl)oxy]benzonitrile (D107)
Figure imgf000082_0002
To a solution of 2-[(1-methylethyl)oxy]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzonitrile (D103) (280 mg), 3-bromo-5-chloro-1,2,4-thiadiazole (194 mg) and tripotassium phosphate (517 mg) in 1 ,2-dimethoxyethane (DME) (4 mL) and water (1 mL) under nitrogen was added Pd(Ph3P)4 (113 mg). The reaction vessel was sealed and heated under microwave at 120 0C for 10 min. Water was added, the reaction mixture was filtered through the celite. The aqueous layer was extracted with EA for 3 times, the combined organic layers were washed with brine, dried over anhydrous sodium sulfate. The dried solution was concentrated and purified by column chromatography to give 5-(3-bromo-1 ,2,4-thiadiazol-5-yl)-2-[(1- methylethyl)oxy]benzonitrile (D107) (152 mg) as a white solid. MS (ES): Ci2Hi0BrN3OS requires 323; found 324.0 (M+H+).
Description for D108 ethyl 4-[3-(5-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2- ethylphenyl]butanoate (D108)
Figure imgf000083_0001
To a suspension of 5-(3-bromo-1 ,2,4-thiadiazol-5-yl)-2-[(1- methylethyl)oxy]benzonitrile (D107) (69 mg), ethyl 4-[2-ethyl-3-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)phenyl]butanoate (D94) (73 mg) and tripotassium phosphate (112 mg) in Λ/,Λ/-dimethylformamide (DMF) (4 ml_) and water (1 ml_) under nitrogen was added Pd(Ph3P)4 (24.36 mg). The reaction vessel was sealed and heated under microwave at 120 0C for 10 min. Water was added, the reaction mixture was filtered through the celite. The aqueous layer was extracted with EA for 3 times, the combined organic layers were washed with brine, dried over anhydrous sodium sulfate. The dried solution was concentrated to afford the crude product ethyl 4-[3-(5- {3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2-ethylphenyl]butanoate (D108) (98 mg). MS (ES): C26H29N3O3S requires 463; found 464.3 (M+H+).
Description for D109
5-[3-(2-ethyl-3-formylphenyl)-1,2,4-thiadiazol-5-yl]-2-[(1-methylethyl)oxy] benzonitrile (D109)
Figure imgf000083_0002
To a solution of 5-(3-bromo-1 ,2,4-thiadiazol-5-yl)-2-[(1-methylethyl)oxy]benzonithle (D107) (550 mg), 2-ethyl-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)benzaldehyde (463 mg) and tripotassium phosphate (1080 mg) in N1N- dimethylformamide (DMF) (4 mL) and water (1.000 mL) stirred under nitrogen was added Pd(Ph3P)4 (196 mg). The reaction was sealed and heated under microwave at 120 0C for 15 min. After cooling, the reaction mixture was diluted with ethyl acetate (20 mL), washed with water (2*8 mL), dried over sodium sulphate, concentrated and purified by column chromatography to afford 5-[3-(2-ethyl-3-formylphenyl)-1,2,4- thiadiazol-5-yl]-2-[(1-methylethyl)oxy]benzonitrile (D 109) (420 mg) as a solid. MS (ES): C2IH19N3O2S requires 377; found 378.0 (M+H+). Description for D110
5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-3-{2-ethyl-3-[(E)-2-(methyloxy)ethenyl] phenyl}-1,2,4-thiadiazole (D110)
Figure imgf000084_0001
To a solution of 3-bromo-5-{3-chloro-4-t(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazole (D105) (388 mg), 2-{2-ethyl-3-[(E)-2-(methyloxy)ethenyl]phenyl}-4.4,5,5-tetramethyl- 1,3,2-dioxaborolane (335 mg) and tripotassium phosphate (741 mg) in N1N- dimethylformamide (DMF) (10 ml_) and water (1.000 ml_) stirred under nitrogen was added Pd(Ph3P)4 (134 mg). The mixture was sealed and heated under microwave at 120 0C for 10 min. After cooling the reaction, the mixture was concentrated and purified by column chromatography to give 5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}- 3-{2-ethyl-3-[(£)-2-(methyloxy)ethenyl]pheny^1,2,4-thiadiazole (D110) (313 mg) as a colorless oil. MS (ES): C22H23CIN2O2S requires 414; found 415.1 (M+H+).
Description for D111
[3-(5-{3-chloro.4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiacliazol-3-yl)-2- ethylphenyl] acetaldehyde (D111)
Figure imgf000084_0002
To a solution of 5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-3-{2-ethyl-3-[(E)-2- (methyloxy)ethenyl]phenyl}-1,2,4-thiadiazole (D110) (313 mg) in tetrahydrofuran (THF) (20 ml_) stirred under nitrogen at room temperature was added 14 drops 2M hydrochloric acid. The reaction mixture was stirred at 70 0C for 4 h. After cooling the reaction, the solution was condensed under reduced pressure to give [3-(5-{3-chloro- 4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2-ethylphenyl]acetaldehyde (D111) (300 mg), which was used directly in the next step without further purification. MS (ES): C21H2ICIN2O2S requires 400; found 401.1 (M+H+).
Description for D112 1 -bromo-5-fluoro-2-(methyloxy)-3-nitrobenzene (D112)
Figure imgf000085_0001
To a stirred solution of 2-bromo-4-fluoro-1-(methyloxy)benzene (8 g) in sulfuric acid (31.2 ml) at -10 0C was added nitric acid (2.79 ml) dropwise. After stirring for 30 min, the mixture was poured into ice, extracted with EtOAc (4*50 ml_). The combined organic phases were washed with brine, dried over Na2SO4 and concentrated, the residue was purified by column chromatography to afford 1-bromo-5-fluoro-2- (methyloxy)-3-nitrobenzene (D112) (4.09 g). δH (CDCI3, 400MHz): 4.00 (3H, t), 7.55 (2H, m).
Description for D113 ethyl 4-[5-fluoro-2-(methyloxy)-3-nitrophenyl]butanoate (D113)
Figure imgf000085_0002
To a suspension of 1-bromo-5-fluoro-2-(methyloxy)-3-nitrobenzene (D112) (4.09 g), cesium carbonate (2.132 g) and tri-t-butylphosphine (1.898 g) in tetrahydrofuran (THF) (30 ml_) under nitrogen was added bromo[4-(ethyloxy)-4-oxobutyl]zinc (65.4 mL) followed by Pd2(dba)3 (1.498 g). The reaction mixture was stirred at room temperature overnight. Saturated aqueous ammonium chloride solution was added to quench the reaction. The aqueous phase was extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulphate and concentrated, the residue was purified by column chromatography to give ethyl 4-[5- fluoro-2-(methyloxy)-3-nitrophenyl]butanoate (D113) (3.64 g). MS (ES): Ci3H16FNO5 requires 285; found 286.1 (M+H+).
Description for D114 ethyl 4-[3-amino-5-fluoro-2-(methyloxy)phenyl]butanoate (D114)
Figure imgf000086_0001
A mixture of ethyl 4-[5-fluoro-2-(methyloxy)-3-nitrophenyl]butanoate (D113) (4.19 g), iron (8.20 g) and saturated aqueous ammonium chloride solution (20 mL) was stirred at 90 0C overnight. After cooling the reaction, the reaction mixture was filtered and the filtrate was evaporated to remove organic solvent, the residue was extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulphate and concentrated, the residue was purified by column chromatography to give ethyl 4-[3-amino-5-fluoro-2-(methyloxy)phenyl]butanoate (D114) (2.27 g). MS (ES): C13H18FNO3 requires 255; found 256.2 (M+H+).
Description for D115 ethyl 4-[3-bromo-5-fluoro-2-(methyloxy)phenyl]butanoate (D115)
Figure imgf000086_0002
To a solution of ethyl 4-[3-amino-5-fluoro-2-(methyloxy)phenyl]butanoate (D114) (1.7 g) in acetonitrile (50 mL) was added HBr (7.23 mL) at 0 0C. Then a solution of sodium nitrite (0.919 g) in water (5 mL) was added to the reaction mixture. After stirring for 10 min, copper(ll) bromide (2.97 g) and copper(l) bromide (0.191 g) were added, The reaction mixture was stirred at 50 0C for 1 h. After cooling the reaction, aqueous NH4CI solution was added, the resulting suspension was extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulphate and concentrated. The residue was purified by column chromatography to give ethyl 4-[3-bromo-5-fluoro-2-(methyloxy)phenyl]butanoate (D115) (1.84 g). MS (ES): C13H16BrFO3 requires 318; found 319.1 (M+H+).
Description for D116 ethyl 4-[5-fluoro-2-(methyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl]butanoate (D116)
Figure imgf000087_0001
To a solution of ethyl 4-[3-bromo-5-fluoro-2-(methyloxy)phenyl]butanoate (D115) (234 mg), 4,4,4',4',5,5,5l,5l-octamethyl-2,2l-bi-1,3,2-clioxaborolane (335 mg), tricyclohexylphosphine (103 mg) and potassium acetate (144 mg) in N1N- dimethylformamide (DMF) (2 ml.) was added Pd2dba3 (26.9 mg) under nitrogen. The reaction vessel was sealed and heated under microwave at 150 0C for 45 min. After cooling the reaction, the mixture was diluted with brine, extracted with ethyl acetate, the combined organic phases were dried over anhydrous sodium sulphate and concentrated, the residue was purified by column chromatography to give ethyl 4-[5- fluoro-2-(methyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]butanoate (D116) (113 mg). MS (ES): Ci9H28BFO5 requires 366; found 367.3 (M+H+).
Description for D117 4-bromo-2-chloro-1-[(1-methylethyl)oxy]benzene (D117)
Figure imgf000087_0002
To a solution of 4-bromo-2-chlorophenol (50 g) in Λ/,Λ/-dimethylformamide (DMF) (250 ml_) stirred under nitrogen at room temperature was added K2CCb (100 g) and 2-bromopropane (136 mL) in one charge. The reaction mixture was stirred at 85 0C for 16 h. After cooling the reaction, the reaction mixture was filtered, the solvent of the filtrate was removed in vacuo. The residue was dissolved in diethyl ether (300 mL), washed with water (6* 100 mL), the organic phase was dried over MgSO4 and concentrated to give 4-bromo-2-chlorophenyl 1-methylethyl ether (D117) (56 g) as a yellow oil. δH (CDCI3, 400MHz): 1.37 (6H, d), 4.52 (1 H, m), 6.82 (1H, d), 7.29 (1H, m), 7.50 (1H, d).
Description for D118
2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-4,4,5,5-tetrametrιyM,3,2- dioxaborolane (D118)
Figure imgf000088_0001
To a suspension of 4-bromo-2-chloro-1-[(1-methylethyl)oxy]benzene (D117) (1Og), 4,4,4',4l,5,5,5',5'-octamethyl-2,2I-bi-1,3,2-dioxaborolane (15.26 g) and potassium acetate (15.73 g) in N,N-dimethylformamide (DMF) (150 ml_) stirred under nitrogen at room temperature was added PdCI2(dppf)-CH2Cl2 adduct (1.964 g). The reaction mixture was stirred at 80 0C overnight. After cooling the reaction, the reaction mixture was concentrated in vacuo, the residue was diluted with ethyl acetate and filtered through celite, the filtrate was washed with water and brine, the organic phase was dried over anhydrous Na2SO4 After removing the solvent, the residue was purified by column chromatography to give 2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-4,4,5,5- tetramethyl-1 ,3,2-dioxaborolane (D118) (11.8 g). MS (ES): C15H22BCIO3 requires 296; found 297.1 (M+H+).
Description for D119 2-[(1 -methylethy l)oxy]-5-(1 ,3-thiazol-2-yl)benzonitrile (D119)
Figure imgf000088_0002
To a suspension of 2-[(1-methylethyl)oxy]-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan- 2-yl)benzonitrile (D103) (109 mg), 2-bromo-1,3-thiazole (93 mg) and cesium carbonate (148 mg) in acetonitrile (3 mL) / water (0.750 mL) stirred under nitrogen was added PdCI2(dppf)-CH2CI2 adduct (31.0 mg). The reaction vessel was sealed and heated under microwave at 120 0C for 1 h. After cooling the reaction, the reaction mixture was diluted with ethyl acetate, filtered through celite. The filtrate was partitioned between ethyl acetate and water. The organic phase was dried over sodium sulphate and evaporated in vacuo to give the crude product, which was purified by column chromatography to afford 2-[(1-methylethyl)oxy]-5-(1,3-thiazol-2- yl)benzonitrile (D119) (50 mg). MS (ES): C13H12N2OS requires 244; found 245.1 (M+H+).
Description for D120 5-(5-bromo-1,3-thiazol-2-yl)-2-[(1-methylethyl)oxy]benzonitrile (D120)
Figure imgf000089_0001
To a solution of 2-[(1-methylethyl)oxy]-5-(1 ,3-thiazol-2-yl)benzonitrile (D119) (215 mg) and sodium acetate (144 mg) in acetic acid (8 mL) stirred at room temperature was added a solution of Br2 (0.045 mL) in acetic acid (1mL) dropwise. The reaction mixture was stirred at 20 0C until start material was consumed completely. The reaction mixture was basified with 2M NaOH, then diluted with ethyl acetate. The mixture was washed with water and brine. The organic phase was dried over anhydrous sodium sulphate. After concentration, the crude product 5-(5-bromo-1,3- thiazol-2-yl)-2-[(1-methylethyl)oxy]benzonitrile (D120) (320 mg) was used for next step without further purification. δH (CDCI3, 600MHz): 1.36 (6H, d), 4.65 (1 H, m), 6.95 (1H, d), 7.64 (1H, s), 7.92 (1H1 d), 7.97 (1H, dd).
Description for D121 ethyl 4-[3-(2-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2- ethylphenyl]butanoate (D121)
Figure imgf000089_0002
To a suspension of 5-(5-bromo-1,3-thiazol-2-yl)-2-[(1-methylethyl)oxy]benzonitrile (D120) (110 mg), ethyl 4-[2-ethyl-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)phenyl]butanoate (D94) (98 mg) and tripotassium phosphate (150 mg) in N1N- dimethylformamide (DMF) (4 mL) / water (1.000 mL) stirred under nitrogen was added Pd(Ph3P)4 (32.7 mg). The reaction vessel was sealed and heated under microwave at 120 0C for 20 min. After cooling the reaction, The reaction mixture was diluted with ethyl acetate, filtered through celite. The filtrate was partitioned between ethyl acetate and water. The organic phase was dried over sodium sulphate and evaporated in vacuo to afford the crude product ethyl 4-[3-(2-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]butanoate (D121) (320 mg). The crude product was used for next step without further purification. MS (ES): C27H30N2O3S requires 462; found 463.3 (M+H+).
Description for D122 ethyl 4-[3-(2-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-5-fluoro-2- (methyloxy)phenyl]butanoate (D122)
Figure imgf000090_0001
To a suspension of 5-(5-bromo-1 ,3-thiazol-2-yl)-2-[(1-methylethyl)oxy]benzonitrile (D120) (110 mg), ethyl 4-[5-fluoro-2-(methyloxy)-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl]butanoate (D116) (74.8 mg) and tripotassium phosphate (99 mg) in 1 ,2-Dimethoxyethane (DME) (2 ml.) / water (0.4.000 ml_) stirred under nitrogen was added Pd(Ph3P)4 (21.45 mg). The reaction vessel was sealed and heated under microwave at 130 0C for 15 min. After cooling the reaction, The reaction mixture was diluted with ethyl acetate, filtered through celite. The filtrate was partitioned between ethyl acetate and water. The organic phase was dried over sodium sulphate and evaporated in vacuo to afford the crude product ethyl 4-[3-(2-{3- cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-5-fluoro-2- (methyloxy)phenyl]butanoate (D122) (280 mg). The crude product was used for next step without further purification. MS (ES): C26H27FN2O4S requires 482; found 483.2 (M+H+).
Description for D123
2-{3-chloro-4-[(1 -methylethyl)oxy]phenyl}-1 ,3-thiazole (D123)
Figure imgf000090_0002
To a suspension of 2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolane (D118) (3 g), 2-bromo-1 ,3-thiazole (1.659 g) and Cs2CO3 (3.95 g) in 1,2-dimethoxyethane (DME) (40 ml_)/water (10 mL) stirred under nitrogen at room temperature was added PdCl2(dppf)-CH2CI2 adduct (661 mg) in one charge. The reaction vessel was sealed and heated under microwave at 120 0C for 2h. After cooling the reaction, the reaction mixture was filtered and the filtrate was partitioned between ethyl acetate (150 mL) and saturated brine (50 mL). The organic phase was dried over sodium sulphate and evaporated in vacuo. The crude product was purified by column chromatography to give 2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}- 1 ,3-thiazole (D123) (1.5 g). MS (ES): CI2HI2CINOS requires 253; found 254.1 (M+H+).
Description for D124 5-bromo-2-{3-chloro-4-[(1 -methylethyl)oxy]phenyl}-1 ,3-thiazole (D124)
Figure imgf000091_0001
To a solution of 2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazole (D123) (1.5 g) and sodium acetate (0.970 g) in acetic acid (10 ml_) stirred at room temperature was added a solution of Br2 (0.31 ml) in acetic acid (1 ml_) dropwise during 30 min. The reaction mixture was stirred at 20 0C until start material was consumed completely. The reaction mixture was basified with 2M NaOH. The resulting solution was diluted with ethyl acetate. The mixture was washed with brine. The organic phase was dried over anhydrous sodium sulphate and evaporated in vacuo. The crude product was purified by column chromatography to give 5-bromo-2-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,3-thiazole (D124) (1.2 g). MS (ES): C12H11BrCINOS requires 332; found 333.0 (M+H+).
Description for D125 ethyl 4-[3-(2-{3-chloro-4-[(1 -methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2- ethylphenyl]butanoate (D125)
Figure imgf000091_0002
To a suspension of 5-bromo-2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazole (D124) (92 mg), ethyl 4-[2-ethyl-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)phenyl]butanoate (D94) (115 mg) and tripotassium phosphate (106 mg) in acetonitrile (6 ml_) and water (2 ml_) stirred under nitrogen was added Pd(Ph3P)4 (32.1 mg). The reaction vessel was sealed and heated under microwave at 120 °C for 15 min. After cooling the reaction, The reaction mixture was diluted with ethyl acetate, filtered through celite. The filtrate was partitioned between ethyl acetate and water. The organic phase was dried over sodium sulphate. After concentration, the crude product was purified by column chromatography to afford ethyl 4-[3-(2-{3- chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2-ethylphenyl]butanoate (D125) (113 mg). MS (ES): C26H30CINO3S requires 471; found 472.2 (M+H+).
Description for D126
5-[5-(2-ethyl-3-formylphenyl)-1,3-thiazol-2-yl]-2-[(1-methylethyl)oxy]benzonitrile (D126)
Figure imgf000092_0001
To a solution of 5-(5-bromo-1 ,3-thiazol-2-yl)-2-[(1-methylethyl)oxy]benzonitrile (D120) (500 mg), 2-ethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzalclehyde (443 mg) and tripotassium phosphate (657 mg) in Λ/,Λ/-dimethylformamide (DMF) (12 ml_) and water (2 mL) stirred under nitrogen at room temperature was added Pd(Ph3P)4 (179 mg) in one charge. The reaction vessel was sealed and heated under microwave at 120 "C for 15 min. After cooling the reaction, the reaction mixture was filtered and the filtrate was partitioned between ethyl acetate (250 mL) and saturated brine (50 mL). The organic phase was dried over sodium sulphate and evaporated in vacuo. The crude product was purified by column chromatography to give 5-[5-(2- ethyl-3-formylphenyl)-1 ,3-thiazol-2-yl]-2-[(1-methylethyl)oxy]benzonitrile (D126) (500 mg) as a brown oil. MS (ES): C22H2ON2O2S requires 376; found 377.1 (M+H+).
Description for D127
3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2- ethylbenzaldehyde (D127)
Figure imgf000092_0002
To a solution of 5-bromo-2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazole (D124) (500 mg), 2-ethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzaldehyde (430 mg) and tripotassium phosphate (638 mg) in N, N- dimethylformamide (DMF) (12 mL) and water (2 mL) stirred under nitrogen at room temperature was added Pd(Ph3P)4 (174 mg) in one charge. The reaction vessel was sealed and heated under microwave at 120 0C for 15 min. After cooling the reaction, the reaction mixture was filtered and the filtrate was partitioned between ethyl acetate (250 mL) and saturated brine (50 mL). The organic phase was dried over sodium sulphate and evaporated in vacuo. The crude product was purified by column chromatography to give 3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-
2-ethylbenzaldehyde (D127) (500 mg) as a brown oil. MS (ES): C2IH20CINO2S requires 385; found 386.0 (M+H+). Description for D128
5-(5-{2-ethyl-3-[(£)-2-(methyloxy)ethenyl]phenyl}-1,3-thia2ol-2-yl)-2-[(1- methylethyl) oxy]benzonitrile (D128)
Figure imgf000093_0001
To a solution of 5-(5-bromo-1,3-thiazol-2-yl)-2-[(1-methylethyl)oxy]benzonitrile (D120) (500 mg), 2-{2-ethyl-3-[(E)-2-(methyloxy)ethenyl]phenyl}-4,4,5,5-tetramethyl-1 ,3,2- dioxaborolane (401 mg) and tripotassium phosphate (591 mg) in N1N- dimethylformamide (DMF) (12 mL) and water (2 mL) stirred under nitrogen at room temperature was added Pd(Ph3P)4 (161 mg) in one charge. The reaction vessel was sealed and heated under microwave at 120 0C for 15 min. After cooling the reaction, the reaction mixture was filtered and the filtrate was partitioned between ethyl acetate (250 mL) and saturated brine (50 mL). The organic phase was dried over sodium sulphate and evaporated in vacuo. The crude product was purified by column chromatography to give 5-(5-{2-ethyl-3-[(E)-2-(methyloxy)ethenyl]phenyl}-1,3-thiazol- 2-yl)-2-[(1-methylethyl)oxy]benzonitrile (D128) (548 mg) as a brown oil. MS (ES): C24H24N2O2S requires 404; found 405.2 (M+H+).
Description for D129
5-{5-[2-ethyl-3-(2-oxoethyl)phenyl]-1,3-thiazol-2-yl}-2-[(1-methylethyl)oxy] benzonitrile (D129)
Figure imgf000093_0002
To a mixture of 5-(5-{2-ethyl-3-[(E)-2-(methyloxy)ethenyl]phenyl}-1,3-thiazol-2-yl)-2- [(1-methylethyl)oxy]benzonitrile (D128) (550 mg) in tetrahydrofuran (THF) (20 mL) under nitrogen was added HCI (1.360 mL). The reaction was heated to 75 0C for 6 h. The mixture was concentrated to give the crude product 5-{5-[2-ethyl-3-(2- oxoethyl)phenyl]-1,3-thiazol-2-yl}-2-[(1-methylethyl)oxy]benzonitrile (D129) (531 mg) as a brown oil. MS (ES): C23H22N2O2S requires 390; found 391.0 (M+H+).
Description for D130 Z^S-chloro^-KI-methylethyOoxylpheny^-S^-ethyl-S-KEJ^-CmethyloxyJethenyl] phenyl}-1,3-thiazole (D130)
Figure imgf000094_0001
To a solution of 5-bromo-2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazole (D124) (500 mg), 2-{2-ethyl-3-[(E)-2-(methyloxy)ethenyl]phenyl}-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane (530 mg) and tripotassium phosphate (651 mg) in N1N- dimethylformamide (DMF) (12 ml.) and water (2 mL) stirred under nitrogen at room temperature was added Pd(Ph3P)4 (177 mg) in one charge. The reaction vessel was sealed and heated under microwave at 120 0C for 15 min. After cooling the reaction, the reaction mixture was filtered and the filtrate was partitioned between ethyl acetate (250 mL) and saturated brine (50 mL). The organic phase was dried over sodium sulphate and evaporated in vacuo. The crude product was purified by column chromatography to give 2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-{2-ethyl-3-[(E)-2- (methyloxy)ethenyl]phenyl}-1 ,3-thiazole (D130) (500 mg) as a brown oil. MS (ES): C23H24CINO2S requires 413; found 414.2 (M+H+).
Description for D131
[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl] acetaldehyde (D131)
Figure imgf000094_0002
To a mixture of 2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-{2-ethyl-3-[(E)-2-
(methyloxy)ethenyl]phenyl}-1 ,3-thiazole (D130) (500 mg) in tetrahydrofuran (THF) (100 mL) under nitrogen was added HCI (0.805 mL). The reaction was heated to 75 0C for 3 h. The mixture was concentrated to give the crude product [3-(2-{3-chloro-4- [(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2-ethylphenyl]acetaldehyde (D131) (483 mg) as a brown oil. MS (ES): C22H22CINO2S requires 399; found 400.1 (M+H+).
Description for D132 methyl Λ/-{2-[3-(2-{3-cyano-4-[(1 -methylethyl)oxy]phenylj-1 ,3-thiazol-5-yl)-2- ethylphenyl]ethyl}-W-methylglycinate (D132)
Figure imgf000095_0001
To a. solution of 5-{5-[2-ethyl-3-(2-oxoethyl)phenyl]-1,3-thiazol-2-yl}-2-[(1- methylethyl)oxy]benzonitrile (D129) (150 mg), acetic acid (0.044 mL) and sodium acetate (63 mg) in ethanol (20.00 mL) stirred under nitrogen at room temperature was added methyl Λ/-methylglycinate hydrochloride (161 mg) in one charge. The reaction mixture was stirred at room temperature for 30 min, then the solvent was evaporated in vacuo. The residue was dissolved in dichloromethane (DCM) (20 mL), sodium triacetoxyborohydride (204 mg) was added to the mixture. The reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate (100 mL) and saturated brine (30 mL). The organic phase was dried over sodium sulphate and evaporated in vacuo to give the crude product methyl /V-{2-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2- ethylphenyl]ethyl}-Λ/-methylglycinate (D132) (183 mg). The crude product was used for next step without further purification. MS (ES): C27H31N3O3S requires 477; found 478.2 (M+H+).
Description for D133 methyl /V-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2- ethylphenyl]methyl}-Λ/-methylglycinate (D133)
Figure imgf000095_0002
To a solution of 3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2- ethylbenzaldehyde (D127) (120 mg), acetic acid (0.036 mL) and sodium acetate (51.0 mg) in ethanol (20.00 mL) stirred under nitrogen at room temperature was added methyl Λ/-methylglycinate hydrochloride (174 mg) in one charge. The reaction mixture was stirred at room temperature for 30 min, then the solvent was evaporated in vacuo. The residue was dissolved in dichloromethane (DCM) (20 mL), sodium triacetoxyborohydride (165 mg) was added to the mixture. The reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate (100 mL) and saturated brine (30 mL). The organic phase was dried over sodium sulphate and evaporated in vacuo to give the crude product methyl N- {[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazo|-5-yl)-2-ethylphenyl]methyl}- Λ/-methylglycinate (D133) (100 mg) as a brown oil. The crude product was used for next step without further purification. MS (ES): C25H29CIN2O3S requires 472; found 473.2 (M+H+).
Description for D134 methyl /V-{[3-(2-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2- ethylphenyl]methyl}-W-methylglycinate (D134)
Figure imgf000096_0001
To a solution of 5-[5-(2-ethyl-3-formylphenyl)-1,3-thiazol-2-yl]-2-[(1- methylethyl)oxy]benzonitrile (D126) (120 mg), acetic acid (0.036 m!_) and sodium acetate (52.3 mg) in ethanol (20.00 ml_) stirred under nitrogen at room temperature was added methyl Λ/-methylglycinate hydrochloride (178 mg) in one charge. The reaction mixture was stirred at room temperature for 30 min, then the solvent was evaporated in vacuo. The residue was dissolved in dichloromethane (DCM) (20 ml_), sodium triacetoxyborohydride (169 mg) was added to the mixture. The reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate (100 mL) and saturated brine (30 ml_). The organic phase was dried over sodium sulphate and evaporated in vacuo to give the crude product methyl /V-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2- ethylphenyl]methyl}-Λ/-methylglycinate (D134) (148 mg) as a brown oil. The crude product was used for next step without further purification. MS (ES): C2BH29N3OaS requires 463; found 464.1 (M+ H+).
Description for D135 methyl Λ/-<2-[3-(2^3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2- ethylphenyl]ethyl}-Λ/-methylglycinate (D135)
Figure imgf000096_0002
To a solution of [3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2- ethylphenyl]acetaldehyde (D131) (160 mg), acetic acid (0.046 mL) and sodium acetate (65.6 mg) in ethanol (20.00 ml_) stirred under nitrogen at room temperature was added methyl Λ/-methylglycinate hydrochloride (168 mg) in one charge. The reaction mixture was stirred at room temperature for 30 min, then the solvent was evaporated in vacuo. The residue was dissolved in dichloromethane (DCM) (20 ml_), sodium triacetoxyborohydride (165 mg) was added to the mixture. The reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate (100 ml_) and saturated brine (30 mL). The organic phase was dried over sodium sulphate and evaporated in vacuo to give the crude product methyl Λ/-{2-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2- ethylphenyl]ethyl}-Λ/-methylglycinate (D135) (195 mg) as a brown oil. The crude product was used for next step without further purification. MS (ES): 026Ha1CIN2O3S requires 486; found 487.2 (M+H+).
Description for D136 5-[5-(2-chloro-3-ethyl-4-pyridinyl)-1,3-thiazol-2-yl]-2-[(1-methylethyl)oxy] benzonitrile (D136)
Figure imgf000097_0001
To a suspension of 5-(5-bromo-1 ,3-thiazol-2-yl)-2-[(1-methylethyl)oxy]benzonitrile (D120) (150 mg), (2-chloro-3-ethyl-4-pyridinyl)boronic acid (126 mg) and Cs2CO3 (403 mg) in 1 ,2-dimethoxyethane (DME) (2 ml_)/water (0.5 mL) stirred under nitrogen at room temperature was added PdCI2(dppf)-CH2CI2 adduct (50.5 mg). The reaction mixture was sealed and heated under microwave at 120 0C for 30 min. After cooling the reaction, the mixture was diluted with ethyl acetate and filtered through silica! gel. The filtrate was washed with aqueous saturated ammonium chloride and saturated brine. The organic phase was collected and dried over anhydrous sodium sulphate. The solvent was removed in vacuo to give the crude product, which was purified by column chromatography to afford 5-[5-(2-chloro-3-ethyl-4-pyridinyl)-1 ,3-thiazol-2-yl]- 2-[(1-methylethyl)oxy]benzonitrile (D136) (250 mg). MS (ES): C20H18CIN3OS requires 383; found 384.1 (M+H+).
Description 137
1,1-dimethylethyl (2£)-3-(3-cyanophenyl)-2-propenoate (D137)
Figure imgf000098_0001
A mixture of 3-bromobenzonitrile (5 g, 27.5 mmol) 1,1-dimethylethyl 2-propenoate (4.39 ml, 30.2 mmol), bis (tri-t-butylphosphine)palladium(O) (0.702 g, 1.373 mmol), and dicyclohexyl(methyl)amine (1.165 ml, 5.49 mmol) in 1 ,4-dioxane (60 ml) were heated at 7O0C for 17hrs. The cooled reaction mixture was diluted with ethyl acetate, filtered through celite and the filtrate evaporated to give a browncoloured oil (6.2g) which was loaded on top of Silica Biotage SP4; 40+M (40x150mm) cartridge and was purified by eluting with a gradient of 6-20% of Ethyl Acetate over 10 column volumes. The UV active fraction were analysed by TLC and pure fractions were combined to yield an orange solid which was analysed by LCMS (2.13g) 1H NMR (400 MHz, CDCI3) δ ppm 7.78 (t, J=1.5 Hz, 1 H), 7.72 (dt, J=7.5, 1.5 Hz, 1 H), 7.64 (dt,
Figure imgf000098_0002
Hz, 1 H), 6.42 (d, J=16.0 Hz, 1 H), 1.54 (s, 9 H)
Description 138
1,1 -dimethylethyl 3-(3-cyanophenyl)propanoate (D138)
Figure imgf000098_0003
A solution of 1 ,1-dimethylethyl (2E)-3-(3-cyanophenyl)-2-propenoate (D137; 2.12 g, 9.25 mmol) in ethanol (40ml) was hydrogenated over palladium on carbon (0.08g,0.752mmol) over 5hr. A further portion of palladium on carbon (0.08g, 0.254mmol) was added and the reaction mixture was stirred under hydrogen for a further 7 hours. A further portion of palladium on carbon (O.Oδg, 0.254mmol) was added and the reaction mixture was stirred under hydrogen for a further 7 hours. Palladium on Carbon(0.08g,0.752mmol) was added and the reaction mixture was stirred under continuous supply of hydrogen for 7hrs. The reaction mixture was filtered through celite and the filtrate evaporated to give the title compound as a colourless oil (1.97g)
1H NMR (400 MHz, CDCI3) δ ppm 6.97 - 7.53 (m, 4 H), 2.94 (t, J=7.5 Hz, 2 H), 2.55 (t, J=7.5 Hz, 2 H), 1.41 (s, 9 H)
Description 139
1,1-dimethylethyl 3-{3-[(hydroxyamino)(imino)methyl]phenyl}propanoate
(D139)
Figure imgf000099_0001
A mixture of 1 ,1-dimethylethyl 3-(3-cyanophenyl)propanoate (D138); 1.96 g, 8.47 mmol), hydroxylamine hydrochloride (1.178 g, 16.95 mmol), and sodium bicarbonate (2.85 g, 33.9 mmol) in ethanol (30 ml) were heated at 600C for 20 hr. The reaction mixture was filtered and the filtrate evaporated to yield a colourless oil which was dissolved in ethyl acetate (25ml) and washed with water (3x1 OmI). The organic layer was dried over anhydrous sodium sulphate and evaporated to give the title compound as an oil (2.18 g)
MS: (+ve ion electrospray) m/z 265 [MH+];
Description 140
1,1-dimethylethyl S-p^S^-chloro^-KI-methylethyOoxylphenyO-I.Z^- oxadiazol-3-yl)phenyl]propanoate (D140)
Figure imgf000100_0001
1 , 1 -dimethylethyl 3-{3-[(hydroxyamino)(imino)methyl]phenyl}propanoate
(D139; 2.18 g, 8.25 mmol) in dry DMF(15ml) was cooled in ice bath and was treated with triethylamine (1.61 ml, 11.55 mmol) followed by the dropwise addition of a solution of 3-chloro-4-[(1-methylethyl)oxy]benzoyl chloride (2.31 g, 9.90 mmol) in dry
DMF (10ml). The yellow coloured reaction mixture was stirred at room temperature for 1hr then heated at 12O0C for 2hrs. The reaction mixture was partitioned between ethyl acetate (3x150ml) and water (200ml). The combined organic layers were washed with water (3x200ml), dried over anhydrous sodium sulphate and evaporated to yield a brown oil which was purified by chromatography on silica. Eluting with a gradient of 10-30% ethyl acetate in cyclohexane gave the title compound as a white solid (1.94g)
MS: (+ve ion electrospray) m/z 443 [MH+];
Example-1
3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- methylphenyl]propanoic acid (E1)
Figure imgf000100_0002
Sodium hydroxide (59 mg) was added to a solution of ethyl 3-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl]propanoate (D3) (126 mg) in 1PrOH (4 ml) and water (4 ml). The resulting mixture was stirred at 65 0C for 2 hours. Then 2 M HCI solution was added until pH was about 6. The organic phase was washed with water (1OmL), dried over sodium sulphate and evaporated in vacuo. The precipitate was purified by Mass Directed Auto Prep to afford 3-[3-(5-{3-chloro-4- [(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl]propanoic acid (E1) (13 mg) as a white solid. δH (CDCI3, 400 MHz): 1.46 (6H, d), 2.41 (3H, s), 2.74 (2H, t), 3.06 (2H, t),4.71-4.73 (1 H, m), 7.06 (1 H, d), 7.27 (1 H, d), 7.95 (2H, d), 8.06-8.08 (1H, dd), 8.25 (1H, d). MS (ES): C2IH21CIN4O4 requires 400; found 401.2 (M+H+).
Example-2
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- methylphenyl] butanoic acid (E2)
Figure imgf000101_0001
Sodium hydroxide (38 mg) was added to a solution of ethyl 4-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl]butanoate (D4) (141 mg) in 1PrOH (4 ml) and water (4 ml). The resulting mixture was stirred at 600C for 1.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl]butanoic acid (E2) (41 mg) as a white solid. δH (CDCI3, 400 MHz): 1.46 (6H, d), 2.01-2.04 (2H, m),2.40 (3H, s), 2.49 (2H, t), 2.77 (2H, t), 4.71-4.73 (1H, m), 7.06 (1H, d), 7.27 (1H, d), 7.91 (2H, d), 8.06 (1H, dd), 8.25 (1H, d). MS (ES): C22H23CIN2O4 requires 414; found 415.2 (M+H+).
Example-3
(2/?)-3-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1I2,4-oxadiazol-3-yl)-2- methylphenyl]-2-methylpropanoic acid (E3)
Figure imgf000101_0002
Sodium hydroxide (39 mg) was added to a solution of methyl (2R)-3-[3-(5-{5-chloro-
6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl]-2- methylpropanoate (146 mg) in 1PrOH (4 ml) and water (4 ml). The resulting mixture was stirred at 60 0C for 1.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml,three times). The precipitate was purified by Mass Directed Auto Prep to afford (2R)-3-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)- 2-methylphenyl]-2-methylpropanoic acid (14 mg) as a white solid. δH (CDCI3, 400 MHz): 1.27(3H1 d), 1.46 (6H, d), 2.42 (3H, s), 2.69-2.88 (2H, m), 3.17-3.21 (1H, m),5.50 (1H, m), 7.29 (1 H, d), 7.92 (2H, dd), 8.40 (1 H, d), 8.88 (1H, dd). MS (ES): C21H22N3O4 requires 415; found 416.2 (M+H+).
Example-4 4-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-2- methylphenyl]butanoic acid (E4)
Figure imgf000102_0001
Sodium hydroxide (96 mg) was added to a solution of ethyl 4-[3-(5-{5-chloro-6-[(1- methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl]butanoate (231 mg) in 1PrOH (4 ml) and water (4 ml). The resulting mixture was stirred at 6O0C for 1.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc (5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[3-(5-{5-chloro-6-[(1- methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl]butanoic acid (13 mg) as a white solid. δH (CDCI3, 400 MHz): 1.37 (6H, d), 2.01-2.04 (2H, t),2.40 (3H, s), 2.49 (2H, t), 2.77 (2H, t), 5.50-5.52 (1H, m), 7.38 (1H, d), 8.00 (1H, dd), 8.88 (1H, d), 8.40 (1H, d), 8.88 (1 H, d). MS (ES): C2IH22CIN3O4 requires 415; found 416.2 (M+H+).
Example-5
3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- methylphenyl]propanoic acid (E5)
Figure imgf000102_0002
Sodium hydroxide (69 mg) was added to a solution of ethyl 3-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl]propanoate (146 mg) in
1PrOH (3 ml_) and water (3 ml). The resulting mixture was stirred at 60 0C for 1.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc (5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 3-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-methylphenyl]propanoic acid (36 mg) as a white solid. δH (CDCI3, 400 MHz): 1.48 (6H, d), 2.42 (3H, s), 2.75 (2H, t), 3.06 (2H, t),4.79-4.82 (1H, m), 7.12 (1 H, d), 7.31 (1 H, d), 7.92 (1 H, d), 7.96 (1 H1 s), 8.33- 8.36 (1 H, dd), 8.44 (1 H, d). MS (ES): C22H2IN3O4 requires 391 ; found 392.2 (M+H+).
Example-6
4-[3-(5-{3-cyano-4-[( 1 -methylethy l)oxy]pheny I}- 1 , 2,4-oxadiazol-3-yl)-2- methylphenyl]butanoic acid (E6)
Figure imgf000103_0001
Sodium hydroxide (70 mg) was added to a solution of ethyl 4-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl]butanoate (153 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 600C for 1.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml,three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-methylphenyl]butanoic acid (41 mg) as a white solid. δH (CDCI3, 400 MHz): 1.49 (6H, d), 1.99-2.03 (2H, m),2.41 (3H, s), 2.49 (2H, t), 2.77 (2H, t), 4.78-4.82 (1H, m), 7.12 (1H, d), 7.29 (1H, d), 7.90 (1H, d), 7.93(1 H, s), 8.33-8.36 (1H, dd), 8.44 (1H, d). MS (ES): C23H23N3O4 requires 405; found 406.2 (M+H+)-
Example-7
4-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-3-methyl-2- pyridinyl]butanoic acid (E7)
Figure imgf000103_0002
Sodium hydroxide (60 mg) was added to a solution of ethyl 4-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-methylphenyl]butanoate (135 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 600C for 3 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml,three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[4-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-3-methyl-2-pyridinyl]butanoic acid (42 mg) as a white solid. δH (CDCI3, 400 MHz): 1.46 (6H, d), 2.14-2.17 (2H, m), 2.48 (2H, t), 2.69 (3H, s), 3.17 (2H, t),4.71-4.77 (1H, m), 7.08 (1 H, d), 7.87 (1 H, d), 8.07 (1 H, dd), 8.25 (1H, d), 8.55 (1H1 d). MS (ES): C21H22CIN3O4 requires 415; found 416.2 (M+H+).
Example-8
S-tZ-chloro-S-tSHiδ-chloro-θ-KI-methylethyOoxyl-S-pyridiny^-i^^-oxadiazol-S- yl)phenyl]propanoic acid (E8)
Figure imgf000104_0001
Sodium hydroxide (42 mg) was added to a solution of ethyl 3-[2-chloro-3-(5-{5- chloro-e-KI-methylethyOoxyl-S-pyridinyl^i ^^-oxadiazol-S-yOphenyljpropanoate (94 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 60 0C for 4 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 3-[2-chloro-3-(5-{5- chloro-e-KI-methylethyOoxyl-S-pyridinyl^i^^-oxadiazol-S-yOphenylJpropanoic acid (12 mg) as a white solid. δH (CDCI3, 400 MHz): 1.46 (6H, d), 2.80 (2H, t), 3.21 (2H, t), 5.49-5.52 (1H, m), 7.36-7.39 (1 H1 dd), 7.49 (2H, d), 7.80 (1H, d), 8.40 (1H, d), 8.88 (1H, d). MS (ES): Ci9Hi7CI2N3O4 requires 421; found 422.2 (M+H+).
Example-9
^[Z-chloro-S-tS^S-chloro-β-KI-methylethyOoxyl-a-pyridiny^-i^^-oxadiazol-S- yl)phenyl]butanoic acid (E9)
Figure imgf000105_0001
Sodium hydroxide (63 mg) was added to a solution of ethyl 4-[2-chloro-3-(5-{5- chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)phenyl]butanoate (147 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 600C for 1.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc (5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[2-chloro-3-(5-{5- chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)phenyl]butanoic acid (74 mg) as a white solid. δH (CDCI3, 400 MHz): 1.45 (6H, d), 2.04-2.07 (2H, m), 2.47 (2H, t), 2.94 (2H, t), 5.47-5.53 (1H, m), 7.35-7.39 (1H, dd), 7.42-7.45 (1 H, dd), 7.76- 7.78 (1H, dd), 8.40 (1H, d), 8.88 (1H, d). MS (ES): C20Hi9CI2N3O4 requires 435; found 436.2 (M+H+).
Example-10 3-[2-chloro-3-(5-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3- yl)phenyl]propanoic acid (E10)
Figure imgf000105_0002
Sodium hydroxide (72 mg) was added to a solution of ethyl 3-[2-chloro-3-(5-{3- cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)phenyl]propanoate (159 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 60 0C for 1.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc (5ml,three times). The precipitate was purified by Mass Directed Auto Prep to afford 3-[2-chloro-3-(5-{3- cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)phenyl]propanoic acid (64 mg) as a white solid. δH (CDCI3, 400 MHz): 1.49 (6H, d), 2.79 (2H, t), 3.21 (2H1 t),4.79-4.82 (1H1 m), 7.13 (1H1 d), 7.36-7.39 (1H, dd), 7.49 (1H, d), 7.80 (1H, d), 8.35 (1H, d), 8.44 (1H, s). MS (ES): C2IH18CIN3O4 requires 411; found 412.2 (M+H+).
Example-11 ^[a-chloro-a-fS-ia-cyano-^πi-methylethyOoxylphenyl^i^^-oxadiazol-a- yl)phenyl]butanoic acid (E11)
Figure imgf000106_0001
Sodium hydroxide (62 mg) was added to a solution of ethyl 4-[2-chloro-3-(5-{3- cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)phenyl]butanoate (142 mg) in 'PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 600C for 0.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml,three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[2-chloro-3-(5-{3- cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)phenyl]butanoic acid (54 mg) as a white solid. δH (CDCI3, 400 MHz): 1.48 (6H, d), 2.03-2.07 (2H, m), 2.47 (2H, t), 2.94 (2H, t), 4.78-4.84 (1H, m), 7.13 (1 H1 d), 7.34-7.38 (1H, dd), 7.42-7.44 (1 H, dd), 7.75-7.77(1 H, dd), 8.33-8.36 (1H, dd), 8.44 (1 H, d). MS (ES): C22H20CIN3O4 requires 425; found 426.2 (M+H+).
Example-12 β-P-chloro-a-tδ^a-cyano^-KI-methylethyOoxylpheny^-i^^-oxadiazol-a- yl)phenyl]hexanoic acid (E12)
Figure imgf000106_0002
Sodium hydroxide (69 mg) was added to a solution of ethyl 6-[2-chloro-3-(5-{3- cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)phenyl]hexanoate (167 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 5O0C for 3 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 6-[2-chloro-3-(5-{3- cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)phenyl]hexanoic acid (22 mg) as a white solid. δH (CDCI3, 400 MHz): 1.48 (6H, d), 1.98-1.99 (2H, m), 2.32 (2H, t), 2.78 (2H, t), 4.71-4.74 (1H, m), 7.05 (1H, d), 7.24-7.28 (1H, dd), 7.32 (1H, dd), 7.65 (1H, d), 8.27 (1H, d), 8.36 (1H, d). MS (ES): C24H24CIN3O4 requires 453; found 454.2 (M+H+). Example-13 a-p-tS^S-chloro-e-KI-methylethyOoxyl-a-pyridiny^-I^.Φoxacliazol-a-yl)^- ethylphenyljpropanoic acid (E13)
Figure imgf000107_0001
Sodium hydroxide (49 mg) was added to a solution of ethyl 3-[3-(5-{5-chloro-6-[(1- methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-2-ethylphenyl]propanoate (108 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 60 0C for 3 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 3-[2-chloro-3-(5-{5- chloro-e-KI-methylethyOoxyl-S-pyridinyl^i^^-oxadiazol-S-yOphenylJpropanoic acid (14 mg) as a white solid. δH (CDCI3, 400 MHz): 1.28(3H, t), 1.46 (6H, d), 2.73 (2H, t), 3.02(2H, t), 3.12 (2H, t), 5.48-5.52 (1 H, m), 7.28-7.32 (1 H1 dd), 7.37 (2H, d), 7.76- 7.78 (1 H, dd), 8.39 (1H, d), 8.88 (1H1 d). MS (ES): C2IH22CIN3O4 requires 415; found 416.2 (M+H+).
Example-14
4-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyl]butanoic acid (E14)
Figure imgf000107_0002
Sodium hydroxide (153 mg) was added to a solution of ethyl 4-[3-(5-{5-chloro-6-[(1- methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-2-ethylphenyl]butanoate (174 mg) in 'PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 600C for 3 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc (5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[3-(5-{5-chloro-6-[(1- methylethyOoxyJ-S-pyridinylJ-i^^-oxadiazol-S-yO^-ethylphenylJbutanoic acid (40 mg) as a white solid. δH (CDCI3, 400 MHz): 1.21(3H, t), 1.45 (6H, d), 1.98-2.06 (2H, m),2.50 (2H1 1), 2.81 (2H, t), 2.98-3.03 (2H, m), 5.49-5.52 (1H, m), 7.26-7.36 (2H1 m), 7.73-7.75 (1H, dd), 8.39 (1H, d), 8.88 (1H1 d). MS (ES): C22H24CIN3O4 requires 429; found 430.2 (M+H+).
Example-15
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyl]butanoic acid (E15)
Figure imgf000108_0001
Sodium hydroxide (46 mg) was added to a solution of ethyl 4-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-ethylphenyl]butanoate (152 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 600C for 1.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml,three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-ethylphenyl]butanoic acid (46 mg) as a white solid. δH (CDCI3, 400 MHz): 1.22(3H1 1), 1.49 (6H, d), 1.98-2.02 (2H, m),2.49 (2H, t), 2.81 (2H, t), 2.97-3.03 (2H, m), 4.76-4.84 (1H, m), 7.13 (1 H, d), 7.29 (1 H, d), 7.35 (1H, d), 7.72-7.74(1 H, dd), 8.33-8.36 (1H, dd), 8.44 (1H, d). MS (ES): C24H25N3O4 requires 419; found 420.2 (M+H+).
Example-16
3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- (methyloxy)phenyl]propanoic acid (E16)
Figure imgf000108_0002
Sodium hydroxide (69 mg) was added to a solution of ethyl 3-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-(methyloxy)phenyl]propanoate (126 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 60 0C for
2.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 3-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-(methyloxy)phenyl]propanoic acid
(58 mg) as a white solid. δH (CDCI3, 400 MHz): 1.46 (6H, d), 2.78 (2H, t), 3.10 (2H, t), 3.87 (3H, s),4.71-4.74 (1 H, m), 7.07 (1H, d), 7.20-7.24 (1 H1 dd), 7.41 (1 H, d), 7.95- 7.97 (1 H, dd), 8.07-8.09(1H, d), 8.26 (1H, d). MS (ES): C2iH21CIN2O5 requires 416; found 417.2 (M+H+).
Example-17
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- (methyloxy)phenyl]butanoic acid (E17)
Sodium hydroxide (70 mg) was added to a solution of ethyl 4-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-methylphenyl]butanoate (160 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 600C for 1.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenylH,2,4-oxadiazol-3-yl)-2-(methyloxy)phenyl]butanoic acid (55 mg) as a white solid. δH (CDCI3, 400 MHz): 1.46 (6H, d), 2.02-2.06 (2H, m), 2.45 (2H, t), 2.82 (2H, t), 3.84 (3H, s),4.71-4.73 (1H, m), 7.06 (1H, d), 7.19-7.23 (1H, dd), 7.37- 7.39 (1 H, dd), 7.92-7.95 (1H, dd), 8.06-8.08 (1H, dd), 8.25 (1 H, d). MS (ES): C22H23CIN2O5 requires 430; found 431.2 (M+H+).
Example-18
3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- (methyloxy)phenyl]propanoic acid (E18)
Figure imgf000109_0002
Sodium hydroxide (67 mg) was added to a solution of ethyl ethyl 3~[3-(5-{3-cyano-4- [(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-(methyloxy)phenyl]propanoate (147 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 60 0C for 1.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc (5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 3-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-(methyloxy)phenyl]propanoic acid (62 mg) as a white solid. δH (CDCI3, 400 MHz): 1.48 (6H, d), 2.78 (2H, t), 3.10 (2H1 1), 3.87 (3H, s), 4.79-4.82 (1H, m), 7.12 (1H, d), 7.21-7.25 (1H, dd), 7.42 (1H, d), 7.95- 7.98 (1 H, dd), 8.35-8.37 (1 H, dd), 8.45 (1 H, d). MS (ES): C22H21N3O5 requires 407; found 408.2 (M+H+).
Example-19
4-[3-(5^3-cyano^-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- (methyloxy)phenyl]butanoic acid (E19)
Figure imgf000110_0001
Sodium hydroxide (62 mg) was added to a solution of ethyl 4-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-(methyloxy)phenyl]butanoate (139 mg) in 'PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 600C for 1.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml,three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-(methyloxy)phenyl]butanoic acid (61 mg) as a white solid. δH (CDCI3, 400 MHz): 1.49 (6H, d), 2.02-2.06 (2H, m), 2.46 (2H1 t), 2.83 (2H, t), 3.85 (3H, s), 4.77-4.84 (1H, m), 7.13 (1H, d), 7.23 (1H, d), 7.39-7.41 (1H, dd), 7.93-7.95(1 H, dd), 8.33-8.36 (1H, dd), 8.44 (1H, d). MS (ES): C23H23N3O5 requires 421; found 422.2 (M+H+).
Example-20
3-[4-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- pyridinyl]propanoic acid (E20)
Figure imgf000110_0002
Sodium hydroxide (72 mg) was added to a solution of ethyl 3-[4-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-pyridinyl]propanoate (158 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 60 0C for 1.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc (5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 3-[4-(5-{3-cyano-4-[(1- methylethyl)oxy)phenyl}-1 ,2,4-oxadiazol-3-yl)-2-ρyridinyl]propanoic acid (11 mg) as a white solid. δH (CDCI3, 400 MHz): 1.49 (6H1 d), 2.48 (2H1 1), 3.08 (2H1 1), 4.80-4.84 (1 H, m), 7.15 (1 H, d), 7.95 (1H, d), 7.99 (1 H1 s), 8.34-8.37 (1H, dd), 8.45 (1 H, d). 8.76 (1H, d). MS (ES): C20H18N4O4 requires 378; found 379.2 (M+H+).
Example-21
4-[4-(5^3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- pyridinyl]butanoic acid (E21)
Figure imgf000111_0001
Sodium hydroxide (66 mg) was added to a solution of ethyl 4-[4-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-pyridinyl]butanoate (139 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 6O0C for 2 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[4-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-pyridinyl]butanoic acid (31 mg) as a white solid. δH (CDCI3, 400 MHz): 1.49 (6H, d), 2.16-2.19 (2H1 m), 2.48 (2H, t), 3.08 (2H1 1), 4.80-4.84 (1H1 m). 7.15 (1H, d), 7.95 (1H, d), 7.99 (1H, s), 8.34-8.37 (1H, dd), 8.45 (1H, d), 8.76 (1H1 d). MS (ES): C21H20N4O4 requires 392; found 393.2 (M+H+).
Example-22
3-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- fluorophenyl]propanoic acid (E22)
Figure imgf000111_0002
Sodium hydroxide (79 mg) was added to a solution of ethyl 3-[5-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-fluorophenyϊ]propanoate (168 mg) in 'PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 50 0C for 1 hour. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc (5ml,three times). The precipitate was purified by Mass Directed Auto Prep to afford 3-[5-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-fluorophenyl]propanoic acid (31 mg) as a white solid. δH (CDCI3, 400 MHz): 1.41 (6H, d), 2.70 (2H, t), 3.01 (2H, t), 4.71- 4.74 (1H, m), 7.04-7.12 (2H, m), 7.94-8.00 (1H, m), 8.26 (1 H, d), 8.35 (1 H, s). MS (ES): C20H18FN3O4 requires 395; found 396.2 (M+H+).
Example-23
4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- fluorophenyljbutanoic acid (E23)
Figure imgf000112_0001
Sodium hydroxide (77 mg) was added to a solution of ethyl 4-[5-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-fluorophenyl]butanoate (168 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 600C for 2.5 hours. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[5-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-fluorophenyl]butanoic acid (31 mg) as a white solid. δH (CDCI3, 400 MHz): 1.44 (6H, d), 2.22-2.24(2H, m), 2.70 (2H, t), 3.01 (2H, t), 4.71-4.74 (1H, m), 7.04-7.12 (2H, m), 7.94-8.00 (1H, m), 8.26 (1H, d), 8.35 (1H, s). MS (ES): C22H20FN3O4 requires 409; found 410.2 (M+H+).
Example-24
3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- (trifluoromethyl)phenyljpropanoic acid (E24)
Figure imgf000112_0002
Sodium hydroxide (42 mg) was added to a solution of ethyl 3-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-(trifluoromethyl)phenyl]propanoate (121 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 50 0C for 1 hour. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc (5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 3-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-(trifluoromethyl)phenyl]propanoic acid (50 mg) as a white solid. δH (CDCI3, 400 MHz): 1.40 (6H, d), 2.69 (2H, t), 3.19 (2H1 t), 4.71-4.74 (1 H, m), 7.05 (1 H, d), 7.39-7.41 (1 H1 m), 7.52-7.54 (2H1 m), 8.23- 8.26 (1H, dd), 8.33 (1 H1 d). MS (ES): C22H18F3N3O4 requires 445; found 446.2 (M+H+).
Example-25
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- (trifluoromethyl)phenyl]butanoic acid (E25)
Figure imgf000113_0001
Sodium hydroxide (44 mg) was added to a solution of ethyl 4-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-(trifluoromethyl)phenyl]butanoate (108 mg) in 1PrOH (3 ml) and water (3 ml). The resulting mixture was stirred at 500C for 1 hour. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford 4-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-(trifluoromethyl)phenyl]butanoic acid (31 mg) as a white solid. δH (CDCI3, 400 MHz): δH (CDCI3, 400 MHz): 1.40 (6H, d), 2.24-2.26 (2H, m), 2.69 (2H, t), 3.19 (2H, t), 4.71-4.74 (1H, m), 7.05 (1H, d), 7.39- 7.41 (1H, m), 7.52-7.54 (2H, m), 8.23-8.26 (1H, dd), 8.33 (1H, d). MS (ES): C23H20F3N3O4 requires 459; found 460.2 (M+H+).
Example-26
3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- methylbenzoic acid (E26)
Figure imgf000113_0002
5-[3-(3-formyl-2-methylphenyl)-1 ,2,4-oxadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (64 mg) were well dissolved in THF (3 ml). In the resulting solution was added m-CPBA (95 mg), stirred at room temperature for 5.5 hours, LCMS show complete conversion, evaporate off the solvent ,EtOAc(IO ml) added, the organic layer was washed water(5 ml) 3 times,evaporate off the solvent, The precipitate was purified by Mass Directed Auto Prep to afford the desired compound 3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- methylbenzoic acid (29 mg). δH (CDCI3, 400 MHz): δH (CDCI3, 400 MHz): 1.48 (6H, d), 2.86 (3H, s), 4.77-4.84 (1H, m), 7.14 (1H, d), 7.45 (1H, dd), 8.07-8.15 (1H, dd), 8.34-8.37(1 H, dd), 8.44 (1 H, d). MS (ES): C20H17N3O3 requires 363; found 364.2 (M+H+).
Example-27 {^-(S^S-chloro-e-KI-methylethyOoxyl-a-pyridinyO-i^^-oxacliazol-a-yl)^- methylphenyl]oxy}acetic acid (E27)
Figure imgf000114_0001
Sodium hydroxide (17 mg) was added to a solution of ethyl {[3-(5-{5-chloro-6-[(1- methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-2-methylphenyl]oxy}acetate (47 mg) in 'PrOH (4 ml) and water (4 ml). The resulting mixture was stirred at 500C for 1 hour. Then 2 M HCI solution was added until pH was about 6. The solvent was evaporated, and the residue was extracted by EtOAc(5ml, three times). The precipitate was purified by Mass Directed Auto Prep to afford {[3-(5-{5-chloro-6-[(1- methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-2-methylphenyl]oxy}acetic acid (12 mg) as a white solid. δH (CDCI3, 400 MHz): δH (CDCI3, 400 MHz): 1.43 (6H, d), 2.54 (3H, s), 4.71 (2H, s), 5.51-5.54 (1H, m), 7.05 (1 H, d), 7.28-7.32(1 H, dd), 7.55 (1H, d), 8.48 (1H, d), 8.90 (1H, d). MS (ES): Ci9H18CIN3O5 requires 403; found 404.2 (M+H+).
Example-28 4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyl]butanoic acid (E28)
Figure imgf000114_0002
Sodium hydroxide (50 mg) was added to a solution of ethyl 4-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-ethylphenyl]butanoate (D54) (170 mg) in tetrahydrofuran (THF) (3 mL) and water (3 ml_). The resulting mixture was stirred and heated at 90 0C for 6 h. After cooling the reaction, the mixture was neutralized with 0.5 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was extracted with EtOAc (5 mL) for three times. The organic phases were evaporated in vacuo and the residue was purified by Mass Directed Auto Prep to afford 4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyl]butanoic acid (E28) (84 mg) as a white solid. δH (DMSO-d6, 400MHz): 1.12 (3H, t), 1.36 (6H, d), 1.80 (2H, m), 2.33 (2H, t), 2.72 (2H, m), 2.93 (2H, m), 4.89 (1H, s), 7.33 (1H, t), 7.42 (2H, m), 7.66 (1 H, dd), 8.10 (1 H, dd), 8.17 (1H, d), 12.12 (1H, br s). MS (ES): C23H25CIN2O4 requires 428; found 429.2 (M+H+).
Example-29
3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxacliazol-3-yl)-2- ethylphenyl]propanoic acid (E29)
Figure imgf000115_0001
Sodium hydroxide (50 mg) was added to a solution of ethyl 3-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-ethylphenyl]propanoate (D55) (164 mg) in tetrahydrofuran (THF) (3 mL) and water (3 mL). The resulting mixture was stirred and heated at 90 0C for 4 h. After cooling the reaction, the mixture was neutralized with 0.5 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was extracted with EtOAc (5 mL) for three times. The organic phases were evaporated in vacuo and the residue was purified by Mass Directed Auto Prep to afford 3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4- oxadiazol-3-yl)-2-ethylphenyl]propanoic acid (E29) (83 mg) as a white solid. δH (DMSO-Cf6, 400MHz): 1.14 (3H, t), 1.36 (6H, d), 2.57 (2H, t), 2.94 (4H, m), 4.89 (1H, m), 7.32 (1H, t), 7.44 (2H, m), 7.67 (1 H, dd), 8.10 (1H, dd), 8.17 (1H, d), 12.23 (1H, s). MS (ES): C22H23CIN2O4 requires 414; found 415.2 (M+H+).
Example-30 S-P-lSKS-cyano^-KI-methylethyOoxylpheny^-i^^-oxadiazol-a-yO-S-fluoro^- (methyloxy)phenyljpropanoic acid (E30)
Figure imgf000116_0001
Sodium hydroxide (50 mg) was added to a solution of ethyl 3-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-5-fluoro-2-
(methyloxy)phenyl]propanoate (D59) (128 mg) in tetrahydrofuran (THF) (2 ml_) and water (2 ml_). The resulting mixture was stirred and heated at 90 0C for 2 h. After cooling the reaction, the mixture was neutralized with 1 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was extracted with EtOAc (5 ml_) for three times. The organic phases were evaporated in vacuo and the residue was purified by Mass Directed Auto Prep to afford 3-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5-fluoro-2-(methyloxy)phenyl]propanoic acid (E30) (74 mg) as a yellow solid. δH (DMSO-de, 400MHz): 1.38 (6H, d), 2.62 (2H, t), 2.94 (2H, t), 3.76 (3H, s), 4.99 (1 H, m), 7.42 (1H, dd), 7.56 (1 H, d), 7.64 (1H, dd), 8.42 (1 H, dd), 8.54 (1H, d), 12.25 (1H, br s). δF (DMSO-d6, 376MHz): -117.8. MS (ES): C22H20FN3O5 requires 425; found 426.2 (M+H+).
Example-31
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5-fluoro-2- (methyloxy)phenyl]butanoic acid (E31)
Figure imgf000116_0002
Sodium hydroxide (50 mg) was added to a solution of ethyl 4-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-5-fluoro-2-(methyloxy)phenyl]butanoate (D60) (100 mg) in tetrahydrofuran (THF) (3 ml_) and water (3 mL). The resulting mixture was stirred and heated at 90 0C for 2 h. After cooling the reaction, the mixture was neutralized with 1 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was extracted with EtOAc (5 mL) for three times. The organic phases were evaporated in vacuo and the residue was purified by Mass Directed Auto Prep to afford 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4- oxadiazol-3-yl)-5-fluoro-2-(methyloxy)phenyl]butanoic acid (E31) (65 mg) as a white solid. δH (DMSO-Cf6, 400MHz): 1.38 (6H, d), 1.85 (2H, m), 2.29 (2H, t), 2.72 (2H, m), 3.75 (3H, s), 4.99 (1 H, m), 7.39 (1H, dd), 7.56 (1H, d), 7.64 (1 H, dd), 8.42 (1H, dd), 8.54 (1 H, d), 12.10 (1 H, s). δF (DMSO-Cf6, 376MHz): -117.8. MS (ES): C23H22FN3O5 requires 439; found 440.2 (M+H+).
Example-32
4-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-5- fluoro-2-(methyloxy)phenyl]butanoic acid (E32)
Figure imgf000117_0001
Sodium hydroxide (50 mg) was added to a solution of ethyl 4-[3-(5-{5-chloro-6-[(1- methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-5-fluoro-2-(methyloxy)phenyl] butanoate (D62) (120 mg) in tetrahydrofuran (THF) (3 ml.) and water (3 ml_). The resulting mixture was stirred and heated at 90 0C for 2 h. After cooling the reaction, the mixture was neutralized with 1 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was extracted with EtOAc (5 ml_) for three times. The organic phases were evaporated in vacuo and the residue was purified by Mass Directed Auto Prep to afford 4-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}- 1,2,4-oxadiazol-3-yl)-5-fluoro-2-(methyloxy)phenyl]butanoic acid (E32) (60 mg) as a white solid. δH (DMSO-Cf6, 400MHz): 1.39 (6H, d), 1.85 (2H, m), 2.29 (2H, t), 2.71 (2H, t), 3.75 (3H, s), 5.46 (1 H1 m), 7.39 (1H, dd), 7.64 (1H, dd), 8.58 (1 H, d), 8.95 (1 H, d), 12.11 (1 H, s). δF (DMSO-Cf6, 376MHz): -117.8. MS (ES): C2iH21CIFN3O5 requires 449; found 450.1 (M+H+).
Example-33
3-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-5- fluoro-2-(methyloxy)phenyl]propanoic acid (E33)
Figure imgf000118_0001
Sodium hydroxide (50 mg) was added to a solution of ethyl 3-[3-(5-{5-chloro-6-[(1- methylethyl)oxy]-3-pyridinyl}-1 l2,4-oxadiazol-3-yl)-5-fluoro-2-(methyloxy)phenyl] propanoate (D63) (140 mg) in tetrahydrofuran (THF) (3 mL) and water (3 ml_). The resulting mixture was stirred and heated at 90 0C for 2 h. After cooling the reaction, the mixture was neutralized with 1 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was extracted with EtOAc (5 mL) for three times. The organic phases were evaporated in vacuo and the residue was purified by Mass Directed Auto Prep to afford 3-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}- 1 ,2,4-oxadiazol-3-yl)-5-fluoro-2-(methyloxy)phenyf]propanoic acid (E33) (84 mg) as a white solid. δH (DMSO-Cf6, 400MHz): 1.39 (6H, d), 2.62 (2H, t), 2.94 (2H, t), 3.76 (3H, s), 5.46 (1 H, m), 7.42 (1H, dd), 7.65 (1 H, dd), 8.58 (1 H, d), 8.95 (1 H, d), 12.25 (1H, s). δF (DMSO-Cl6, 376MHz): -117.8. MS (ES): C20Hi9CIFN3O5 requires 435; found 436.1 (M+H+).
Example-34
3-[3-(5-{3-chloro-4-[(1-mβthylβthyl)oxy]phβnyl}-1,2,4-oxadiazol-3-yl)-5-fluoro-2- (methyloxy)phenyl]propanoic acid (E34)
Figure imgf000118_0002
Sodium hydroxide (50 mg) was added to a solution of ethyl 3-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-5-fluoro-2-
(methyloxy)phenyljpropanoate (D65) (109 mg) in tetrahydrofuran (THF) (3 mL) and water (3 mL). The resulting mixture was stirred and heated at 90 0C for 2 h. After cooling the reaction, the mixture was neutralized with 1 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was extracted with EtOAc (5 mL) for three times. The organic phases were evaporated in vacuo and the residue was purified by Mass Directed Auto Prep to afford 3-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}- 1,2, 4-oxadiazol-3-y l)-5-f luoro-2-(methy loxy)phenyl]propanoic acid (E34) (58 mg) as a white solid. δH (DMSO-d6, 400MHz): 1.36 (6H1 d), 2.62 (2H, t), 2.93 (2H, t), 3.75 (3H, s), 4.89 (1H, m), 7.42 (2H, m), 7.64 (1H, dd), 8.12 (1H, dd), 8.20 (1H1 d), 12.25 (1H, s). δF (DMSO-Cf6, 376MHz): -117.8. MS (ES): C2IH20CIFN2O5 requires 434; found 435.1 (M+H+).
Example-35
^p-tS^a-chloro^-KI-methylethyOoxylpheny^-I.Z^-oxacliazol-S-yO-S-fluoro^- (methyloxy)phenyl]butanoic acid (E35)
Figure imgf000119_0001
Sodium hydroxide (50 mg) was added to a solution of ethyl 4-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5-fluoro-2-(methyloxy)phenyl]butanoate (D66) (95 mg) in tetrahydrofuran (THF) (3 mL) and water (3 mL). The resulting mixture was stirred and heated at 90 0C for 2 h. After cooling the reaction, the mixture was neutralized with 1 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was extracted with EtOAc (5 mL) for three times. The organic phases were evaporated in vacuo and the residue was purified by Mass Directed Auto Prep to afford 4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4- oxadiazol-3-yl)-5-fluoro-2-(methyloxy)phenyl]butanoic acid (E35) (20 mg) as a white solid. δH (DMSO-C6, 400MHz): 1.29 (6H, d), 1.78 (2H, m), 2.22 (2H, t), 2.65 (2H, t), 3.67 (3H, s), 4.82 (1H, m), 7.30 (1H, dd), 7.37 (1H, d), 7.55 (1H, dd), 8.06 (1H, dd), 8.13 (1 H, d), 12.03 (1 H, s). δF (DMSO-d6, 376MHz): -117.8. MS (ES): C22H22CIFN2O5 requires 448; found 449.2 (M+H+).
Example-36 4-[3-(5-{3-chloro-4-t(1 -methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- propylphenyl]butanoic acid (E36)
Figure imgf000119_0002
Sodium hydroxide (50 mg) was added to a solution of ethyl 4-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-propylphenyl]butanoate (D69) (85 mg) in tetrahydrofuran (THF) (3 mL) and water (3 mL). The resulting mixture was stirred at room temperature for 2 h. The mixture was neutralized with 1 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed Auto Prep to afford 4-[3-(5-{3- chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-propylphenyl]butanoic acid (E36)
(36 mg) as a white solid. δH (DMSO-Cf6, 400MHz): 0.93 (3H, t), 1.36 (6H, d), 1.50 (2H, m), 1.79 (2H, m), 2.33 (2H, t), 2.71 (2H, t), 2.88 (2H, t), 4.89 (1H, m), 7.32 (1H, t), 7.40 (1H, d), 7.45 (1H, d), 7.68 (1H, dd), 8.10 (1 H, dd), 8.18 (1H, d), 12.13 (1 H, s). MS (ES): C24H27CIN2O4 requires 442; found 443.2 (M+H+).
Example-37 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxacliazol-3-yl)-2- propylphenyl]butanoic acid (E37)
Figure imgf000120_0001
Sodium hydroxide (50 mg) was added to a solution of ethyl 4-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-propylphenyl]butanoate (D70) (136 mg) in tetrahydrofuran (THF) (3 mL) and water (3 mL). The resulting mixture was stirred at room temperature for 2 h. The mixture was neutralized with 1 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed Auto Prep to afford 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- propylphenyl]butanoic acid (E37) (32 mg) as a white solid. δH (DMSO-Cf6, 400MHz): 0.93 (3H, t), 1.38 (8H, m), 1.80 (2H, m), 2.33 (2H, t), 2.70 (2H, t), 2.88 (2H, m), 4.97 (1H, m), 7.31 (1H, t), 7.39 (1H, d), 7.54 (1H, d), 7.68 (1H, d), 8.38 (1H, d), 8.47 (1 H, s), 12.14 (1H, br s). MS (ES): C25H27N3O4 requires 433; found 434.3 (M+H+).
Example-38
4-{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyl]oxy}butanoic acid (E38)
Figure imgf000121_0001
Sodium hydroxide (63.4 mg) was added to a solution of ethyl 4-{[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-ethylphenyl]oxy}butanoate (D77) (73.5 mg) in tetrahydrofuran (THF) (10 ml_), ethanol (3 ml.) and water (1 ml_). The resulting mixture was stirred at room temperature overnight. The mixture was neutralized with 2 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed Auto Prep to afford 4-{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4- oxadiazol-3-yl)-2-ethylphenyl]oxy}butanoic acid (E38) (19.6 mg). δH (DMSO-Cf6, 400MHz): 1.15 (3H, t), 1.38 (6H, d), 2.01 (2H1 m), 2.45 (2H, t), 2.89 (2H, m), 4.07 (2H, t), 4.98 (1H, m), 7.19 (1 H, d), 7.35 (1H, t), 7.44 (1H, d), 7.56 (1H, d), 8.39 (1H, dd), 8.49 (1H1 d), 12.18 (1H1 br s). MS (ES): C24H25N3O5 requires 435; found 436.2 (M+H+).
Example-39
4-{[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2I4-oxadiazol-3-yl)-2- ethylphenyl]oxy}butanoic acid (E39)
Figure imgf000121_0002
Sodium hydroxide (71.5 mg) was added to a solution of ethyl 4-{[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-ethylphenyl]oxy}butanoate (D78) (84.5 mg) in tetrahydrofuran (THF) (10 mL), ethanol (3 ml_) and water (1 ml_). The resulting mixture was stirred at room temperature overnight. The mixture was neutralized with 2 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed Auto Prep to afford 4-{[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4- oxadiazol-3-yl)-2-ethylphenyl]oxy}butanoic acid (E39) (21 mg). δH (DMSO-cfe, 400MHz): 1.14 (3H, t), 1.36 (6H, d), 2.02 (2H, m), 2.45 (2H, t), 2.90 (2H, m), 4.07 (2H1 t), 4.88 (1H, m), 7.18 (1H, d), 7.34 (1H, t), 7.44 (2H, m), 8.09 (1H, dd), 8.16 (1 H, d), 12.17 (1H, br s). MS (ES): C23H25CIN2O5 requires 444; found 445.2 (M+H+).
Example-40
{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyl]oxy}acetic acid (E40)
Figure imgf000122_0001
Sodium hydroxide (50 mg) was added to a solution of ethyl {[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-ethylphenyl]oxy}acetate (D85) (35 mg) in isopropanol (3 mL) and water (1 ml_). The resulting mixture was stirred at room temperature for 2 h. The mixture was neutralized with 1 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed Auto Prep to afford {[3-(5-{3- cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-ethylphenyl]oxy}acetic acid (E40) (24 mg). δH (DMSOd6, 400MHz): 1.16 (3H, t), 1.38 (6H, d), 2.94 (2H, m), 4.81 (2H, s), 4.98 (1 H, m), 7.12 (1 H, d), 7.34 (1H, t), 7.45 (1H, d), 7.56 (1H, d), 8.40 (1H, dd), 8.50 (1 H, d), 13.05 (1 H, s). MS (ES): C22H2iN3O5 requires 407; found 408.2 (M+H+).
Example-41
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3,4-oxadiazol-2-yl)-2- ethylphenyl]butanoic acid (E41)
Figure imgf000122_0002
To a solution of ethyl 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3,4-oxadiazol- 2-yl)-2-ethylphenyl]butanoate (D88) (40 mg) in THF (5 mL) and water (0.5 mL) was added 2 M Sodium hydroxide (0.045 mL). The resulting mixture was stirred at room temperature overnight. The mixture was neutralized with 1 M HCI solution until pH was about 6. The solvent was evaporated, and the residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed Auto Prep to afford 4-[3-(5-{3- cyano-4-[(1-methylethyl)oxy]phenyl}-1,3,4-oxadiazol-2-yl)-2-ethylphenyl]butanoic acid (E41) (22 mg). δH (DMSO-d6, 400MHz): 1.17 (3H, t), 1.38 (6H, d), 1.80 (2H, m), 2.32 (2H, t), 2.73 (2H, t), 3.08 (2H, m), 4.95 (1H, m), 7.37 (1H, m), 7.45 (1H, d), 7.54 (1H, d), 7.89 (1H, dd), 8.32 (1 H, dd), 8.44 (1 H, d). MS (ES): C24H25N3O4 requires 419; found 420.2 (M+H+).
Example-42
4-[3-(5-{3-cyano^-[(1-methylethyl)oxy]phenyl}-1,3I4-thiadiazol-2-yl)-2- ethylphenyljbutanoic acid (E42)
Figure imgf000123_0001
To a solution of ethyl 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3,4-thiadiazol- 2-yl)-2-ethylphenyl]butanoate (D97) (57 mg) in tetrahydrofuran (THF) (3 mL) and water (3 mL) was added sodium hydroxide (50 mg). The reaction mixture was heated at 90 0C for 4 h and stirred at room temperature for 48 h. After cooling the reaction, the mixture was neutralized with 1 M HCI solution. The solvent was removed in vacuo. The residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed AutoPrep to give 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3,4- thiadiazol-2-yl)-2-ethylphenyl] butanoic acid (E42) (18 mg) as a pale yellow solid. δH (DMSO-Cf6, 400MHz): 1.09 (3H, t), 1.36 (6H, d), 1.80 (2H, m), 2.35 (2H, t), 2.71 (2H, m), 2.84 (2H, q), 4.93 (1H1 m), 7.31 (1 H, m), 7.40 (2H, m), 7.48 (1H, d), 8.28 (1 H, m), 8.38 (1 H, d). MS (ES): C24H25N3O3S requires 435; found 436.2 (M+H+).
Example-43
Λ/-{[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-2- ethylphenyl]methyl}-Λ/-methylglycine (E43)
Figure imgf000123_0002
To a mixture of 3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-2- ethylbenzaldehyde (D101) (100 mg) and Λ/-methylglycine (461 mg) in dichloromethane (DCM) (5 mL) was added one drop of acetic acid. The reaction mixture was sitrred at room temperature for 10 min. After that, sodium triacetoxyborohydride (164 mg) was added to the reaction mixture. The reaction mixture was stirred at room temperature overnight. Then water was added to the reaction mixture. Then the resulting solution extracted with EA. The combined organic solution was washed with water and dried over anhydrous sodium sulphate. After filtration and concentration, the residue was purified by Mass Directed AutoPrep to give Λ/-{[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-2- ethylphenyl]methyl}-Λ/-methylglycine (E43) (28.4 mg). δH (DMSO-d6, 400MHz): 1.08 (3H, t), 1.35 (6H, d), 2.66 (3H, s), 2.98 (2H, m), 3.95 (2H, s), 4.30 (2H, s), 4.84 (1H1 m), 7.38 (1H, d), 7.47 (1H, m), 7.67 (2H, m), 7.97 (1H, d), 8.10 (1H, d). δF (DMSO-Cf6, 376MHz): -73.6. MS (ES): C23H26CIN3O3S requires 459; found 460.2 (M+H+).
Example-44
4-[3-(3-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadiazol-5-yl)-2- ethylphenyl]butanoic acid (E44)
Figure imgf000124_0001
To a solution of ethyl 4-[3-(3-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol- 5-yl)-2-ethylphenyl]butanoate (D104) (60 mg) in isopropanol (3.00 mL) and water (3 mL) was added sodium hydroxide (50 mg). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was neutralized with 1 M HCI solution. The solvent was removed in vacuo. The residue was dissolved in THF and filtered. The filtrate was purified by Mass Directed AutoPrep to give 4-[3-(3-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-5-yl)-2-ethylphenyl]butanoic acid (E44) (2 mg) as a yellow gel. δH (DMSO-C6, 400MHz): 1.19 (3H, m), 1.37 (6H, d), 1.81 (2H, m), 2.34 (2H, t), 2.74 (2H, t), 2.96 (2H, d), 4.93 (1H, m), 7.35 (1H, t), 7.45 (1H, d), 7.50 (1H, d), 7.64 (1H, d), 8.50 (2H, m), 12.13 (1H, br s). δF (DMSO-d6, 376MHz): - 73.5. MS (ES): C24H25N3O3S requires 435; found 436.2 (M+H+).
Example-45 4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadiazol-3-yl)-2- ethylphenyl]butanoic acid (E45)
Figure imgf000125_0001
To a mixture of ethyl 4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol- 3-yl)-2-ethylphenyl]butanoate (D106) (51 mg) in isopropanol (40 mL) and water (5 ml_) at room temperature was added NaOH (8.62 mg). The mixture was The reaction vessel was sealed and heated under microwave at 80 0C for 2 h. After cooling the reaction, the mixture was neutralized with 1 M HCI solution. The solvent was removed in vacuo. The residue was dissolved in THF and filtered. The filtrate was purified by Mass Directed AutoPrep to give 4-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2-ethylphenyl]butanoic acid (E45) (31 mg) as a brown solid. δH (DMSO-Cf6, 400MHz): 1.10 (3H, t), 1.35 (6H, m), 1.81 (2H, m), 2.33 (2H, t), 2.72 (2H, t), 2.92 (2H, m), 4.86 (1H, m), 7.28 (1H, t), 7.33 (1H, d), 7.39 (1H1 d), 7.65 (1H, dd), 8.02 (1H, dd), 8.14 (1 H, d), 12.12 (1H, s). MS (ES): C23H25CIN2O3S requires 444; found 445.2 (M+H+).
Example-46
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2>4-thiadiazol-3-yl)-2- ethylphenyl]butanoic acid (E46)
Figure imgf000125_0002
To a solution of ethyl 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol- 3-yl)-2-ethylphenyl]butanoate (D108) (98 mg) in isopropanol (3.00 mL) and water (3 mL) was added sodium hydroxide (50 mg). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was neutralized with 1 M HCI solution. The solvent was removed in vacuo. The residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed AutoPrep to give 4-[3-(5-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2-ethylphenyl]butanoic acid (E46) (50 mg) as an off-white solid. δH (DMSO-Cf6, 400MHz): 1.09 (3H, t), 1.37 (6H1 d), 1.80 (2H, m), 2.33 (2H, t), 2.71 (2H, m), 2.91 (2H, d), 4.95 (1H, m), 7.28 (1 H, t), 7.35 (1 H, d), 7.50 (1H1 d), 7.65 (1H1 dd), 8.34 (1H, dd), 8.48 (1 H, d), 12.11 (1 H, s). MS (ES): C24H25N3O3S requires 435; found 436.2 (M+H+).
Example-47
Λ/-{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadiazol-3-yl)-2- ethylphenyl]methyl}-Λ/-methylglycine (E47)
Figure imgf000126_0001
To a solution of 5-[3-(2-ethyl-3-formylphenyl)-1,2,4-thiadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (D109) (80 mg) in dichloromethane (DCM) (5 ml_) and methanol (5.00 mL), was added Λ/-methylglycine (94 mg) and acetic acid (0.036 ml_). The resulting solution was stirred at ambient temperature for overnight. Sodium triacetoxyborohydride (135 mg) was added and the reaction solution was stirred for another 2 h. The solvent was removed in vacuo and the residue was purified by Mass Directed AutoPrep to give Λ/-{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}- 1 ,2,4-thiadiazol-3-yl)-2-ethylphenyl]methyl}-Λ/-methylglycine (E47) (22 mg) as a white solid. δH (DMSO-d6, 400MHz): 1.02 (3H, t), 1.31 (6H, d), 2.24 (3H1S)1 2.96 (2H,m ), 3.15 (2H1 s), 3.70 (2H, s), 4.89 (1 H, m), 7.25 (1H1 1), 7.44 (2H, m), 7.67 (1H, dd), 8.27 (1H, dd), 8.42 (1H, d). MS (ES): C24H26N4O3S requires 450; found 451.2 (M+H+).
Example-48
Λ/-{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadia2θl-3-yl)-2- ethylphenyl]methyl}-b-alanine (E48)
Figure imgf000126_0002
To a solution of 5-[3-(2-ethyl-3-formylphenyl)-1,2,4-thiadiazol-5-yl]-2-[(1- methylethyl)oxy]benzonitrile (D109) (110 mg) in ethanol (5.00 mL) and dichloromethane (DCM) (5 mL) was added hydrogen chloride - ethyl β-alaninate (1 :1) (81 mg) and sodium acetate (43.0 mg). The reaction solution was stirred at room temperature for overnight. Sodium triacetoxyborohydride (185 mg) was added and the reaction solution was stirred for another 2 h. The solvent was removed in vacuo and the residue was dissoved in ethyl acetate (50 mL) and washed with water (2*10 mL). After concentration, the residue was dissolved in isopropanol/water (1:1) 10 mL, heated to 90 0C for 2 h. lsopropanol was removed in vacuo and the residue was acidified to pH=6-7, extracted with ethyl acetate (2*15 mL). The combined organic phases were concentrated and the residue was purified by Mass Directed AutoPrep to give Λ/-{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2- ethylphenyl]methyl}-β-alanine (E48) (6 mg) as a white solid. δH (DMSOd6, 400MHz): 1.05 (3H ,t), 1.31 (6H, d), 2.31 (2H, t), 2.79 (2H, t), 2.90 (2H, m), 3.82 (2H, s), 4.89 (1H, m), 7.27 (1H, t), 7.45 (2H, m), 7.68 (1H1 d), 8.27 (1H, dd), 8.42 (1H, d). MS (ES): C24H26N4O3S requires 450; found 451.2 (M+H+).
Example-49
W-{2-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadiazol-3-yl)-2- ethylphenyl]ethyl}-Λ/-methylglycine (E49)
Figure imgf000127_0001
To a solution of [3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2- ethylphenyljacetaldehyde (D111) (100 mg), Λ/-methylglycine (44.4 mg) and acetic acid (1.428 μL) in dichloromethane (DCM) (8 mL) and Λ/,Λ/-dimethylformamide (DMF) (0.400 mL) stirred under nitrogen at room temperature for 20 min was added sodium triacetoxyborohydride (106 mg). The reaction mixture was stirred at room temperature for 5 h. Water was added to quench the reaction, the mixture was neutralized with acetic acid, the resulting solution was concentrated and the residue was purified by Mass Directed AutoPrep to afford Λ/-{2-[3-(5-{3-chloro-4-[(1- methylethyl)oxy]phenyl}-1,2,4-thiadiazol-3-yl)-2-ethylphenyl]ethyl}-Λ/-methylglycine (E49) (23 mg) as a white solid. δH (DMSO-Cf6, 400MHz): 1.13 (3H, t), 1.35 (6H, d), 2.93 (5H, m), 3.14 (2H, m), 3.32 (2H, m), 4.18 (2H, s), 4.86 (1 H, m), 7.34 (1H, t), 7.40 (2H, m), 7.72 (1 H1 d), 8.02 (1 H, dd), 8.14 (1 H, d). δF (DMSO-d6l 376MHz): -73.5. MS (ES): C24H28CIN3O3S requires 473; found 474.1 (M+H+).
Example-50 4-[3-(2-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2-ethylphenyl] butanoic acid (E50)
Figure imgf000128_0001
To a solution of ethyl 4-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)- 2-ethylphenyl]butanoate (D121) (320 mg) in isopropanol (8 ml_) and water (4.00 mL) at room temperature was added 2M sodium hydroxide (1.729 mL). The reaction mixture was stirred at room temperature overnight. After concentration, the residue was dissolved in water and acidified with 2N HCI to pH=5. The solvent was removed in vacuo, the residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed AutoPrep to give 4-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3- thiazol-5-yl)-2-ethylphenyl]butanoic acid (E50) (35 mg). δH (DMSO-Cf6, 400MHz): 1.05 (3H, t), 1.35 (6H, m), 1.78 (2H, m), 2.29 (2H, t), 2.68 (4H, m), 4.90 (1H, m), 7.22 (2H, m), 7.28 (1H, m), 7.43 (1H, d), 7.85 (1H1 s), 8.21 (1H, dd), 8.26 (1H, d). MS (ES): C25H26N2O3S requires 434; found 435.2 (M+H+).
Example-51
4-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-5-fluoro-2- (methyloxy)phenyl]butanoic acid (E51)
Figure imgf000128_0002
To a solution of ethyl 4-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)- 5-fluoro-2-(methyloxy)phenyl]butanoate (D122) (280 mg) in isopropanol (2 mL) and water (0.750 mL) at room temperature was added 2M sodium hydroxide (0.899 mL).
The reaction mixture was stirred at room temperature for 2 h. After concentration, the residue was dissolved in water and acidified with 1 N HCI to pH=5. The solvent was removed in vacuo, the residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed AutoPrep to give 4-[3-(2-{3-cyano-4-[(1- methylethyOoxyJpheny^-I.S-thiazol-S-yO-S-fluoro^-CmethyloxyJphenylJbutanoic acid (E51) (18 mg). δH (DMSO-Cf6, 400MHz): 1.36 (6H, d), 1.85 (2H1 m), 2.07 (1 H, s), 2.30 (2H, t), 2.69 (2H, t), 3.64 (3H, s), 4.90 (1 H, m), 7.14 (1 H, dd), 7.43 (1 H1 d), 7.65 (1 H, dd), 8.23 (1H1 dd), 8.30 (1H, d), 8.46 (1H, s). δF (DMSO-Cf6, 376MHz): -117.9. MS (ES): C24H23FN2O4S requires 454; found 455.1 (M+H+).
Example-52
4-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl] butanoic acid (E52)
Figure imgf000129_0001
To a solution of ethyl 4-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)- 2-ethylphenyl]butanoate (D125) (113 mg) in isopropanol (15 mL) and water (5 mL) at room temperature was added 2M sodium hydroxide (0.239 mL). The reaction mixture was stirred at room temperature overnight. After concentration, the residue was dissolved in water and acidified with 1N HCI to pH=5. The solvent was removed in vacuo, the residue was dissolved in THF1 and filtered. The filtrate was purified by Mass Directed AutoPrep to give 4-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3- thiazol-5-yl)-2-ethylphenyl] butanoic acid (E52) (30 mg). δH (DMSO-Cf6, 400MHz): 1.05 (3H, t), 1.34 (6H1 d), 1.79 (2H, m), 2.33 (2H1 t), 2.69 (4H, m), 4.79 (1 H, m), 7.22 (2H, m), 7.29 (2H1 m), 7.82 (1H, s), 7.87 (1 H1 dd), 7.98 (1 H, d), 12.12 (1 H, br s). MS (ES): C24H26CINO3S requires 443; found 444.0 (M+H+).
Example-53 /V-{2-[3-(2-{3-cyano-4-[(1 -methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2-ethylphenyl] ethyl}-Λ/-methylglycine (E53)
Figure imgf000129_0002
To a solution of methyl 1-{2-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-
5-yl)-2-ethylphenyl]ethyl}-3-azetidinecarboxylate (D132) (183 mg) in isopropanol (40 mL) and water (10 mL) stirred under nitrogen at room temperature was added a solution of NaOH (30.7 mg) in water in one charge. The reaction mixture was stirred at room temperature overnight, lsopropanol was removed in vacuo. The residue was dissolved in water and acidified with 1 N HCI to pH=5. The solvent was removed in vacuo, the residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed AutoPrep to give Λ/-{2-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}- 1 ,3-thiazol-5-yl)-2-ethylphenyl]ethyl}-Λ/-methylglycine (E53) (22 mg) as a white solid. δH (DMSO-d6, 400MHz): 1.10 (3H, t), 1.36 (6H, d), 2.71 (2H, m), 2.95 (3H, s), 3.13 (2H, m), 3.30 (2H, m), 4.18 (2 H, s), 4.91 (1H, m), 7.33 (3H, m), 7.44 (1H, d), 7.85 (1 H, s), 8.21 (1 H1 d), 8.28 (1 H, d), 9.95 (1H, br s). δF (DMSOd6, 376MHz): -73.6. MS (ES): C26H29N3O3S requires 463; found 464.2 (M+H+).
Example-54
Λ/-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5.yl)-2-ethylphenyl] methyl}-/V-methylglycine (ES4)
Figure imgf000130_0001
To a solution of methyl Λ/-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5- yl)-2-ethylphenyl]methyl}-Λ/-methylglycinate (D133) (160 mg) in isopropanol (40 mL) and water (10 mL) stirred under nitrogen at room temperature was added a solution of NaOH (27.1 mg) in water in one charge. The reaction mixture was stirred at room temperature overnight. Isopropanol was removed in vacuo. The residue was dissolved in water and acidified with 1N HCI to pH=5. The solvent was removed in vacuo, the residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed AutoPrep to give Λ/-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3- thiazol-5-yl)-2-ethylphenyl] methyl}-Λ/-methylglycine (E54) (48 mg) as a white solid. δH (DMSO-d6, 400MHz): 1.03 (3H, t), 1.34 (6H1 d), 2.77 (3H1 s), 2.86 (2H, m), 4.17 (2H1 s), 4.43 (2H, s), 4.80 (1 H, m), 7.32 (1H, d), 7.41 (1H, t), 7.50 (1H1 d), 7.62 (1 H, d), 7.87 (2H, m), 7.99 (1H1 d), 9.99 (1H1 br s). δF (DMSO-d6, 376MHz): -74.1. MS (ES): C24H27CIN2O3S requires 458; found 459.0 (M+H+).
Example-55
Λ/-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl] methyl}-Λ/-methylglycine (E55)
Figure imgf000131_0001
To a solution of methyl Λ/-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5- yl)-2-ethylphenyl]methyl}-Λ/-methylglycinate (D134) (140 mg) in isopropanol (40 ml_) and water (10 ml_) stirred under nitrogen at room temperature was added a solution of NaOH (24.2 mg) in water in one charge. The reaction mixture was stirred at room temperature overnight. Isopropanol was removed in vacuo. The residue was dissolved in water and acidified with 1N HCI to pH=5. The solvent was removed in vacuo, the residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed AutoPrep to give Λ/-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3- thiazol-5-yl)-2-ethylphenyl] methyl}-Λ/-methylglycine (E55) (58 mg) as a white solid. δH (DMSO-Cf6, 400MHz): 1.03 (3H, t), 1.36 (6H, d), 2.76 (3H, s), 2.87 (2H, m), 4.15 (2H, s), 4.41 (2H, s), 4.91 (1H, m), 7.45 (3H, m), 7.62 (1H1 d), 7.89 (1 H, s), 8.22 (1 H, dd), 8.28 (1 H, d), 10.11 (1H1 br s), 14.19 (1H1 br s). δF (DMSO-d6l 376MHz): -74.0. MS (ES): C25H27N3O3S requires 449; found 450.2 (M+H+).
Example-56
W-{2-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2- ethylphenyl] ethyl}-/V-methylglycine (E56)
Figure imgf000131_0002
To a solution of methyl Λ/-{2-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol- 5-yl)-2-ethylphenyl]ethyl}-Λ/-methylglycinate (D135) (120 mg) in isopropanol (40 ml_) and water (10 mL) stirred under nitrogen at room temperature was added a solution of NaOH (19.7 mg) in water in one charge. The reaction mixture was stirred at room temperature overnight. Isopropanol was removed in vacuo. The residue was dissolved in water and acidified with 1N HCI to pH=5. The solvent was removed in vacuo, the residue was dissolved in THF, and filtered. The filtrate was purified by Mass Directed AutoPrep to give Λ/-{2-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}- 1 ,3-thiazol-5-yl)-2-ethylphenyl] ethyl}-Λ/-methylglycine (E56) (29 mg) as a white solid. δH (DMSOd6, 400MHz): 1.09 (3H, t), 1.34 (6H, d), 2.73 (2H, d), 2.96 (3H, s), 3.13 (2H, m), 3.30 (2H1 m), 4.19 (2H1 s), 4.79 (1H, m), 7.31 (4H, m), 7.82 (1H, s), 7.87 (1 H1 dd), 7.99 (1 H, d), 10.02 (1 H, br S)1 14.13 (1H1 br s). δF (DMSO-d6, 376MHz): -73.7. MS (ES): C25H29CIN2O3S requires 472; found 473.0 (M+H+).
Example-57
Λ/-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl] methyl}-/V-methyl-β-alanine (E57)
Figure imgf000132_0001
A solution of 5-[5-(2-ethyl-3-formylphenyl)-1,3-thiazol-2-yl]-2-[(1- methylethyl)oxy]benzonitrile (D126) (200 mg), ethyl beta-alaninate (163 mg) and acetic acid (0.1 ml.) in dichloromethane (DCM) (10 mL) was stirred at room temperature for 15 min, then sodium triacetoxyborohydride (338 mg) was added. The mixture was stirred at room temperature for 2 h, then formaldehyde (0.146 mL) was added. The mixture was stirred at room temperature overnight. After concentration, the residue was partitioned between ethyl acetate and water, the organic phase was washed with saturated brine and concentrated, the residue was dissolved in DMF (5 mL) and aqueous 2M NaOH (2 mL) was added. The mixture was stirred at 50 0C for 1 h. After cooling the reaction, the reaction mixture was acidified with aqueous 2M HCI to Ph= 5-6, extracted with ethyl acetate for two times. The combined organic phases were concentrated and the residue was purified by mass Directed AutoPrep to afford Λ/-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2- ethylphenyl]methyl}-Λ/-methyl-β-alanine (E57) (155 mg). δH (DMSO-d6, 400MHz): 1.05 (3H, t), 1.36 (6H1 d), 2.76 (3H, s), 2.82 (4H, m), 3.41 (2H, s), 4.44 (2 H, s), 4.91 (1H, m), 7.46 (3H, m), 7.63 (1H, dd), 7.88 (1H, s), 8.22 (1H, dd), 8.28 (1H, d), 9.36 (1H1 br s). δF (DMSO-d6, 376MHz): -73.8. MS (ES): C26H29N3O3S requires 463; found 464.2 (M+H+).
Example-58
4-[4-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-3-ethyl-2- pyridinyl]butanoic acid (E58)
Figure imgf000133_0001
To a suspension of 5-[5-(2-chloro-3-ethyl-4-pyridinyl)-1,3-thiazol-2-yl]-2-[(1- methylethyl)oxy]benzonitrile (D136) (200 mg), tris(1 ,1-dimethylethyl)phosphane (30.2 mg), Pd2(ClDa)3 (95 mg) and Cs2CO3 (67.9 mg) in tetrahydrofuran (THF) (5 ml_) was added 0.5M bromo[4-(ethyloxy)-4-oxobutyl]zinc (5 ml.) in THF. The reaction was stirred at 60 0C under nitrogen for 1 h. After that, the reaction was quenched with aqueous ammonium chloride, partitioned between ethyl acetate and water. The organic phase was washed with water and saturated brine. After removing solvent, the residue was dissolved in DMF (5 mL) and aqueous 2M NaOH (2 mL) was added. The mixure was stirred at 50 0C for 1 h. After cooling the reaction, the mixture was partitioned between ethyl acetate and water. The aqueous phase was separated and colleceted, acidified with aqueous 2M HCI to Ph= 4-5, extracted with ethyl acetate. The combined organic phase was evaporated to give the crude product, which was purified by Mass Directed AutoPrep to afford 4-[4-(2-{3-cyano-4-[(1- methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-3-ethyl-2-pyridinyl]butanoic acid (E58) (40 mg). δH (DMSO-Oe, 400MHz): 1.14 (3H, t), 1.33 (6H, d), 1.94 (2H, m), 2.39 (2H, t), 2.88 (2H, m), 2.98 (2H, t), 4.92 (1H, m), 7.46 (1H, d), 7.67 (1H, d), 8.21 (1H, s), 8.26 (1H, dd), 8.35 (1 H, d), 8.59 (1H, d). δF (DMSO-Cf6, 376MHz): -74.5. MS (ES): C24H25N3O3S requires 435; found 436.2 (M+H+).
Example-59
W-{2-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1(3-thia2Ol-5-yl)-2- ethylphenyl]ethyl}-Λ/-methyl-b-alanine (E59)
Figure imgf000133_0002
A solution of 5-{5-[2-ethyl-3-(2-oxoethyl)phenyl]-1,3-thiazol-2-yl}-2-[(1- methylethyl)oxy]benzonitrile (D129) (100 mg), ethyl beta-alaninate (79 mg) and acetic acid (0.1 mL) in dichloromethane (DCM) (10 mL) was stirred at room temperature for 15 min, then sodium triacetoxyborohydride (163 mg) was added. The mixture was stirred at room temperature for 2 h, then formaldehyde (0.071 mL) was added. The mixture was stirred at room temperature overnight. After concentration, the residue was partitioned between ethyl acetate and water, washed with saturated brine. The organic phase was collected and evaporated, the residue was dissolved in DMF (5 mL) and 2M NaOH (2 ml_) solution was added. The mixture was stirred at 50 0C for 1 h, then cooled to room temperature. This reaction mixture was acidified with 2M HCI to pH 5-6, extracted with ethyl acetate for three times. The combined organic phase was concentrated and the residue purified by Mass Directed AutoPrep to afford Λ/-{2-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2- ethylphenyl]ethyl}-Λ/-methyl-β-alanine (E59) (145 mg). δH (DMSOd6, 400MHz): 1.10 (3H, t), 1.36 (6H, d), 2.72 (2H, m), 2.81 (2H, m), 2.90 (3H, s), 3.44 (4H, m), 4.90 (1 H, m), 7.31 (2H, m), 7.38 (1H, m), 7.44 (1H, d), 7.85 (1H, s), 8.21 (1H, dd), 8.27 (1H, d), 9.68 (1 H, br s), 12.82 (1H, br s). δF (DMSOd6, 376MHz): -73.7. MS (ES): C27H3IN3O3S requires 477; found 478.2 (M+H+).
Example-60 3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3- yl)phenyl]propanoic acid (E60)
Figure imgf000134_0001
TFA (1 mL, 12.98 mmol) was added dropwise to an ice cooled solution of 1,1- dimethylethyl 3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2l4-oxadiazol-3- yl)phenyl]propanoate (D140; 1.93 g, 4.36 mmol) in dichloromethane (DCM) (40 mL), and the reaction mixture was stirred for an hour. The reaction mixture was evaporated to yield a light yellow solid which was triturated under diethyl ether to give the title compound as a white coloured solid (1.2 g) MS: (+ve ion electrospray) m/z 387 [MH+];
1H NMR (400 MHz, CDCI3) δ ppm 8.25 (d, J=2.Q Hz, 1 H), 8.06 (dd, J=8.5, 2.0 Hz, 1 H), 8.02 (s, 1 H), 7.99 - 8.03 (m, 1 H), 7.44 (t, J=8.0 Hz, 1 H), 7.38 (d, J=7.5 Hz, 1 H), 7.06 (d, J=8.5 Hz, 1 H), 4.72 (spt, J=6.0 Hz, 1 H), 3.06 (t, J=8.0 Hz, 2 H), 2.77 (t, J=8.0 Hz, 2 H), 1.45 (d, J=6.0 Hz, 6 H)
S1P1 Tango assay - 96 well format
Recombinant EDG1-bla/U2OS cells (contain the human Endothelial Differentiation Gene 1 (EDG1) linked to a TEV protease site and a Gal4-VP16 transcription factor stably integrated into the Tango GPCR-bla U2OS parental cell line) were suspended in assay medium (Invitrogen Freestyle Expression Medium) at a density of 312, 500 cells/ml. Add 100μl/well of the assay medium to the cell-free control wells (column 12) and 100μl/well of the cell suspension to the test compound wells (row 2-8, column 1- 10), the unstimulated control wells (DMSO) (column 11), and stimulated control wells (S1P) (row 1, column 1-10) in a Coming black-well, clear bottom 96-well plate. Cells were incubated at 370C, 5% CO2 for 44-48h. Add 25μl of 5* stock solution of test compounds in assay medium with 0.5% DMSO to the test compound wells, 25μl of 5* stock solution of agonist (S1 P) in assay medium with 0.5% DMSO to the stimulated compound wells, and 25μl of 5χ stock solution of 0.5% DMSO in assay medium to the unstimulated control and cell-free control wells. After incubation at 370C, 5% CO2 for 5h, 25μl of 6χ substrate mixture (6μl Solution A (1mg LiveBLAzer™-FRET B/G substrate (CCF4-AM) in 912μl DMSO) plus 60μl Solution B plus 934μl Solution C) was added to each well and incubate at room temperature for 2h in dark. The plate was finally read on EnVision for two emission channels (460 nm and 530 nm). All test compounds were dissolved in DMSO at a concentration of 1OmM and were prepared in 100% DMSO using a 1 in 5 dilution step to provide 10 point dose response curves. The dilutions were transferred to the assay plates ensuring that the DMSO concentration was constant across the plate for all assays. Calculate the blue/green emission ratio (460 nm/530 nm) for each well, by dividing the background-subtracted Blue emission values by the background-subtracted Green emission values. The dose response curve is based on sigmoidal dose- response model. All ratio data was normalized based upon the maximum emission ratio of positive control (S1P) and minimum emission ratio of negative control (DMSO) on each plate. The intrinsic activity (IA) of each compound would be the normalized percentage of its maximum response after curve fitting. Examples 1 to 27 had a pEC50 > 6.0 in this assay Except for Examples 3, 4 and 21 with a pEC50 <6.
S1P1 Tango assay - 384 well format
Recombinant EDG1-bla/U2OS cells (contain the human Endothelial Differentiation Gene 1 (EDG1) linked to a TEV protease site and a Gal4-VP16 transcription factor stably integrated into the Tango GPCR-bla U2OS parental cell line) were harvested from growth medium and passaged into assay medium (Invitrogen Freestyle Expression Medium). The cells were starved for 24 hours at 370C, 5% CO2, harvested and resuspended in assay medium at a density of ~200,000 cells/ml. All test compounds were dissolved in DMSO at a concentration of 1OmM and were prepared in 100% DMSO to provide 10 point dose response curves. Test compounds prepared by Bravo (Velocity11) were added to wells in columns 2-11 and 13-22; DMSO was added to wells in columns 12 and 23 as unstimulated controls and assay medium was added to wells in columns 1 and 24 as cell-free controls. An S1P1 agonist was added to wells in row 2, columns 2-11 as stimulated controls and test compounds were added to wells in row 2, columns 13-22 and rows 3-15, columns 2- 11/13-22 (row 1 and 16 were empty and not used). Compounds in solution were added to the assay plate (Greiner 781090) using an Echo (Labcyte) dose-response program (50nl/well). The unstimulated and cell-free controls were loaded with 50nl/well pure DMSO to ensure that the DMSO concentration was constant across the plate for all assays. 50 μl of the cell suspension was added to each well in columns 2-23 of the plate (-10,000 cells per well). 50 μl of assay medium was added to each well in the cell- free controls (columns 1 and 24). The cells were incubated overnight at 37°C/5% CO2.
10μl of 6* substrate mixture (LiveBLAzer™-FRET B/G substrate (CCF4-AM) Cat # K1096 from Invitrogen, Inc.) was added to each well using Bravo and the plates incubated at room temperature for 2h in the dark. The plate was finally read on EnVision using one excitation channel (409 nm) and two emission channels (460 nm and 530 nm).
The blue/green emission ratio (460 nm/530 nm) was calculated for each well, by dividing the background-subtracted Blue emission values by the background- subtracted Green emission values. The dose response curve is based on sigmoidal dose-response model. All ratio data was normalized based upon the maximum emission ratio of positive control and minimum emission ratio of negative control (DMSO) on each plate. The intrinsic activity (IA) of each compound would be the normalized percentage of its maximum response after curve fitting. Examples 20, 22, 23, 54 and 58 had a pEC50 >6 in this assay. Examples 25, 33, 57, 55 and 57 had a pEC50 > 7.0 in this assay. Examples 7, 8, 14, 24, 32, 34, 41, 36, 37, 38, 40, 41, 144, 145, 146, 48, 50, 51, 52, 53, 56 had a pEC50 > 8 in this assay. Examples 11, 12, 15, 17, 28, 29, 30, 31 , 35, 39, 49 and 59 had a pEC50 >9 in this assay.
S1P3 GeneBlazer assay
GeneBLAzer EDG3-Ga15-NFAT-bla HEK 293T cells (contain the human Endothelial Differentiation G-protein Coupled Receptor 3 (EDG3) and a beta-lactamase reporter gene under control of a NFAT response element and a promiscuous G Protein, Ga15, stably integrated into the GeneBLAzer Ga15-NFAT-bla HEK 293T cell line) were suspended in assay medium (99% DMEM, 1% Dialyzed FBS, 0.1mM NEAA, 25mM HEPES (pH 7.3), 100U/ml penicillin, 100μg/ml streptomycin) at a density of 312, 500 cells/ml. Add 100μl/well of the assay medium to the cell-free control wells (column 12) and 100μl/well of the cell suspension to the test compound wells (row 2-8, column 1- 10), the unstimulated control wells (DMSO) (column 11), and stimulated control wells (S1P) (row 1, column 1-10) in a Coming black-well, clear bottom 96-well plate. Cells were incubated at 370C, 5% CO2 for 24h.
Add 25μl of 5* stock solution of test compounds in assay medium with 0.5% DMSO to the test compound wells, 25μl of 5χ stock solution of agonist (S1P) in assay medium with 0.5% DMSO to the stimulated compound wells, and 25μl of 5* stock solution of 0.5% DMSO in assay medium to the unstimulated control and cell-free Control wells.
After incubation at 370C, 5% CO2 for 5h, 25μl of 6* substrate mixture (6μl Solution A (1mg LiveBLAzer™-FRET B/G Substrate (CCF4-AM) in 912μl DMSO) plus 60μl Solution B plus 934μl Solution C) was added to each well and incubate at room temperature for 2h in dark. The plate was finally read on EnVision for two emission channels (460 nm and 530 nm).
All test compounds were dissolved in DMSO at a concentration of 1OmM and were prepared in 100% DMSO using a 1 in 5 dilution step to provide 10 point dose response curves. The dilutions were transferred to the assay plates ensuring that the DMSO concentration was constant across the plate for all assays. Calculate the blue/green emission ratio (460 nm/530 nm) for each well, by dividing the background-subtracted Blue emission values by the background-subtracted green emission values. The dose response curve is based on sigmoidal dose- response model. All ratio data was normalized based upon the maximum emission ratio of positive control (S 1P) and minimum emission ratio of negative control (DMSO) on each plate. The intrinsic activity (IA) of each compound would be the normalized percentage of its maximum response after curve fitting.
S1P3 GeneBlazer assay - 384 well format GeneBLAzer EDG3-Ga15-NFAT-bla HEK 293T cells (contain the human Endothelial Differentiation G-protein Coupled Receptor 3 (EDG3) and a beta-lactamase reporter gene under control of a NFAT response element and a promiscuous G Protein, Ga15, stably integrated into the GeneBLAzer Ga15-NFAT-bla HEK 293T cell line) were harvested from growth medium and resuspended in thawing medium (90% DMEM, 10% Charcoal-stripped FBS, 0.1mM NEAA, 25mM HEPES (pH 7.3), 100U/ml penicillin, 100μg/ml streptomycin) at a density of -200,000 cells/ml. All test compounds were dissolved in DMSO at a concentration of 1OmM and were prepared in 100% DMSO to provide 10 point dose response curves. Test compounds prepared by Bravo (Velocity11) were added to wells in columns 2-11 and 13-22; DMSO was added to wells in columns 12 and 23 as unstimulated controls and assay medium was added to wells in columns 1 and 24 as cell-free controls. An S1P3 agonist was added to wells in row 2, columns 2-11 as stimulated controls and test compounds were added to wells in row 2, columns 13-22 and rows 3-15, columns 2- 11/13-22 (row 1 and 16 were empty and not used). Compounds in solution were added to the assay plate (Greiner 781090) using an Echo (Labcyte) dose-response program (50nl/well). The unstimulated and cell-free controls were loaded with 50nl/well pure DMSO to ensure that the DMSO concentration was constant across the plate for all assays. 50 μl of the cell suspension was added to each well in columns 2-23 of the plate (-10,000 cells per well). 50 μl of thawing medium was added to each well in the cell- free controls (columns 1 and 24). The cells were incubated overnight at 37°C/5% CO2.
10μl of 6χ substrate mixture (LiveBLAzer™-FRET B/G substrate (CCF4-AM) Cat # K1096 from Invitrogen, Inc.) was added to each well using Bravo and the plates incubated at room temperature for 2h in the dark. The plate was finally read on EnVision using one excitation channel (409 nm) and two emission channels (460 nm and 530 nm).
The blue/green emission ratio (460 nm/530 nm) was calculated for each well, by dividing the background-subtracted Blue emission values by the background- subtracted Green emission values. The dose response curve is based on sigmoidal dose-response model. All ratio data was normalized based upon the maximum emission ratio of positive control and minimum emission ratio of negative control (DMSO) on each plate. The intrinsic activity (IA) of each compound would be the normalized percentage of its maximum response after curve fitting.
Exemplified compounds of the invention tested in at least one of the above assays had a pEC50 < 5.5

Claims

Claims
1. A compound of formula (I) or a salt thereof:
Figure imgf000140_0001
(D
wherein
X is CH or N;
Y is CR5 or N;
Z is C(0-5)alkyl optionally interrupted by O, S or N and optionally substituted by C0-
3)alkyl or OH; B is a 5-membered heteroaryl ring selected from:
Figure imgf000140_0002
(a) (b) (C) (d) (e)
Figure imgf000140_0003
(f)
R1 is C(i-4)alkoxy;
R2 is cyano or chloro;
R3 is hydrogen, halogen, trifluoromethyl, C^alkyl, C(i-5)alkoxy or CN;
R4 is hydrogen, halogen, trifluoromethyl, C(i.3)alkyl or C(1.3)alkoxy; and R5 is hydrogen, halogen, trifluoromethyl, C(i-3)alkyl or C(1-3)alkoxy, with the proviso that the compound is not 3-(3-(5-(3-cyano-4-isopropoxyphenyl)-1 ,2,4-oxadiazol-3-yl)- 5-methylphenyl)propanoic acid.
2. A compound according to claim 1 or a salt thereof, wherein:
Y is CR5 or N;
Z is C(o-5)alkyl optionally interrupted by O or N and optionally substituted by C(1-3)alkyl; B is (a), (b), (C), (d) or (f); R1 is C(i-4)alkoxy; R2 is cyano or chloro;
R3 is hydrogen, methyl, ethyl, propyl, methoxy, chloro or triflouromethyl; R4 is hydrogen or fluoro; and R5 is hydrogen.
3. A compound selected from:
3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- methylphenyl]propanoic acid
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-methylphenyl] butanoic acid (2f?)-3-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-2- methylphenyl]-2-methylpropanoic acid
4-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-2- methylphenyl]butanoic acid
3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- methylphenyl]propanoic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- methylphenyljbutanoic acid
4-[4-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-3-methyl-2- pyridinyljbutanoic acid 3-[2-chloro-3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3- yl)phenyl]propanoic acid
4-[2-chloro-3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3- yl)phenyl]butanoic acid
3-[2-chloro-3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3- yl)phenyl]propanoic acid
4-[2-chloro-3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3- yl)phenyl]butanoic acid 6-[2-chloro-3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3- yl)phenyl]hexanoic acid
3-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-y|)-2- ethylphenyl]propanoic acid 4-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyljbutanoic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- ethylphenyl]butanoic acid
3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2l4-oxadiazol-3-yl)-2- (methyloxy)phenyl]propanoic acid
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-
(methyloxy)phenyl]butanoic acid
3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-
(methyloxy)phenyl]propanoic acid 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-
(methyloxy)phenyljbutanoic acid
3-[4-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- pyridinyl]propanoic acid
4-[4-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- pyridinyl]butanoic acid
3-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- fluorophenyl]propanoic acid
4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- fluorophenyl]butanoic acid 3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2-
(trifluoromethyl)phenyl]propanoic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-
(trifluoromethyl)phenyl]butanoic acid
3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2-methylbenzoic acid
{[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-2- methylphenyl]oxy}acetic acid
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-2- ethylphenyl]butanoic acid S-tS-Cδ^S-chloro^-KI-methylethylJoxyJphenyl^i^^-oxadiazol-S-yl)^- ethylphenyl]propanoic acid 3-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-5-fluoro-2- (methyloxy)phenyl]propanoic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-5-fluoro-2-
(methyloxy)phenyl]butanoic acid 4-[3-(5-{5-chloro-6-[(1 -methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-5-fluoro-2-
(methyloxy)phenyl]butanoic acid
3-[3-(5-{5-chloro-6-[(1-methylethyl)oxy]-3-pyridinyl}-1 ,2,4-oxadiazol-3-yl)-5-fluoro-2-
(methyloxy)phenyl]propanoic acid
3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5-fluoro-2- (methyloxy)phenyljpropanoic acid
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-5-fluoro-2-
(methyloxy)phenyl]butanoic acid
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- propylphenyl]butanoic acid 4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- propylphenyl]butanoic acid
4-{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- ethylphenyl]oxy}butanoic acid
4-{[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-oxadiazol-3-yl)-2- ethylphenyl]oxy}butanoic acid
{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]pheny^1 ,2,4-oxadiazol-3-yl)-2- ethylphenyl]oxy}acetic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3,4-oxadiazol-2-yl)-2- ethylphenyl]butanoic acid 4-[3-(5-{3-cyano-4-[( 1 -methylethyl)oxy]phenyl}- 1 , 3, 4-thiadiazol-2-yl)-2- ethylphenyl]butanoic acid
Λ/-{[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3,4-thiadiazol-2-yl)-2- ethylphenyl]methyl}-Λ/-methylglycine
4-[3-(3-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-5-yl)-2- ethylphenyl]butanoic acid
4-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2- ethylphenyl]butanoic acid
4-[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2- ethylphenyl]butanoic acid Λ/-{[3-(5-{3-cyano-4-[( 1 -methylethyl)oxy]phenyl}- 1,2, 4-thiadiazol-3-y l)-2- ethylphenyl]methyl}-Λ/-methylglycine Λ/-{[3-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadiazol-3-yl)-2- ethylphenyl]methyl}-b-alanine
Λ/-{2-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,2,4-thiadiazol-3-yl)-2- ethylphenyl]ethyl}-Λ/-methylglycine 4-[3-(2-{3-cyano-4-[( 1 -methylethyl)oxy]phenyl}- 1 , 3-thiazol-5-yl)-2-ethylphenyl] butanoic acid
4-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-5-fluoro-2-
(methyloxy)phenyl]butanoic acid
4-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2-ethylphenyl] butanoic acid
/\/-{2-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2-ethylphenyl] ethyl}- Λ/-methylglycine
Λ/-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2-ethylphenyl] methyl}- /V-methylglycine Λ/-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl] methyl}- Λ/-methylglycine
Λ/-{2-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2-ethylphenyl] ethyl}- Λ/-methylglycine
Λ/-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2-ethylphenyl] methyl}-Λ/-methyl-β-alanine
4-[4-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-3-ethyl-2- pyridinyl]butanoic acid
Λ/-{2-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1 ,3-thiazol-5-yl)-2- ethylphenyl]ethyl}-Λ/-methyl-b-alanine 3-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)phenyl]propanoic acid and salts thereof.
4. Use of a compound of formula (I) as defined in claim 1 or a compound according to any one of claims 1 to 3 or a salt thereof for the treatment of conditions or disorders mediated by S1P1 receptors.
5. Use according to claim 4, wherein the condition or disorder is multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non- insulin dependant diabetes.
6. Use according to claim 5, wherein the condition is multiple sclerosis.
7. Use of a compound of formula (I) as defined in claim 1 or a compound according to any one of claims 1 to 3 or a salt thereof to manufacture a medicament for use in the treatment of conditions or disorders mediated by S1 P1 receptors.
8. Use according to claim 7, wherein the condition or disorder multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non- insulin dependant diabetes.
9. Use according to claim 8, wherein the condition is multiple sclerosis.
10. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or a compound according any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof.
11. A method of treatment for conditions or disorders in mammals including humans which can be mediated via the S1P1 receptor comprising administering to the sufferer a therapeutically safe and effective amount of a compound of formula (I) as defined in claim 1 or a compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof.
12. A method of treatment according to claim 11 , wherein the condition is multiple sclerosis.
PCT/CN2010/000939 2009-06-26 2010-06-24 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists WO2010148649A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/379,431 US20120101134A1 (en) 2009-06-26 2010-06-24 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
EP10791156A EP2445891A4 (en) 2009-06-26 2010-06-24 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
JP2012516485A JP2012530728A (en) 2009-06-26 2010-06-24 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0911126A GB0911126D0 (en) 2009-06-26 2009-06-26 Novel compounds
GB0911126.1 2009-06-26
GB0918473A GB0918473D0 (en) 2009-10-21 2009-10-21 Compounds
GB0918473.0 2009-10-21

Publications (1)

Publication Number Publication Date
WO2010148649A1 true WO2010148649A1 (en) 2010-12-29

Family

ID=43385890

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/000939 WO2010148649A1 (en) 2009-06-26 2010-06-24 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists

Country Status (7)

Country Link
US (1) US20120101134A1 (en)
EP (1) EP2445891A4 (en)
JP (1) JP2012530728A (en)
AR (1) AR077227A1 (en)
TW (1) TW201107302A (en)
UY (1) UY32734A (en)
WO (1) WO2010148649A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658675B2 (en) 2009-07-16 2014-02-25 Actelion Pharmaceuticals Ltd. Pyridin-4-yl derivatives
KR20140114340A (en) * 2011-12-23 2014-09-26 메이지 세이카 파루마 가부시키가이샤 Novel s1p receptor modulator
US9133179B2 (en) 2011-01-19 2015-09-15 Actelion Pharmaceuticals Ltd. 2-methoxy-pyridin-4-yl-derivatives
US9540362B2 (en) 2013-02-20 2017-01-10 Lg Life Sciences Ltd. Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
US10385043B2 (en) 2015-05-20 2019-08-20 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
WO2021175225A1 (en) * 2020-03-04 2021-09-10 南京明德新药研发有限公司 Tricyclic compounds and use thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0911130D0 (en) * 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
MX2017011389A (en) * 2015-03-05 2018-03-16 Bayer Cropscience Ag Process for preparing 3-chloro-2-vinylphenylsulfonates.
AR116635A1 (en) * 2018-10-15 2021-05-26 Servier Lab PROCESS FOR THE SYNTHESIS OF PIPERAZINIL-ETOXY-BROMOPHENIL DERIVATIVES AND THEIR APPLICATION IN THE PRODUCTION OF COMPOUNDS CONTAINING THEM
CN112745270B (en) * 2020-12-30 2023-02-24 河北医科大学 Novel compound and method for preparing topramezone intermediate by using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029370A1 (en) * 2006-09-08 2008-03-13 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
WO2009043889A2 (en) * 2007-10-04 2009-04-09 Merck Serono S.A. Oxadiazole derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2547198A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029370A1 (en) * 2006-09-08 2008-03-13 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
WO2009043889A2 (en) * 2007-10-04 2009-04-09 Merck Serono S.A. Oxadiazole derivatives

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658675B2 (en) 2009-07-16 2014-02-25 Actelion Pharmaceuticals Ltd. Pyridin-4-yl derivatives
US9133179B2 (en) 2011-01-19 2015-09-15 Actelion Pharmaceuticals Ltd. 2-methoxy-pyridin-4-yl-derivatives
CN104144927B (en) * 2011-12-23 2016-08-24 明治制果药业株式会社 S1p receptor modulators
CN104144927A (en) * 2011-12-23 2014-11-12 明治制果药业株式会社 Novel S1P receptor modulator
EP2796459A4 (en) * 2011-12-23 2015-03-18 Meiji Seika Pharma Co Ltd Novel s1p receptor modulator
EP2796459A1 (en) * 2011-12-23 2014-10-29 Meiji Seika Pharma Co., Ltd. Novel s1p receptor modulator
KR20140114340A (en) * 2011-12-23 2014-09-26 메이지 세이카 파루마 가부시키가이샤 Novel s1p receptor modulator
KR101889131B1 (en) 2011-12-23 2018-09-20 메이지 세이카 파루마 가부시키가이샤 Novel s1p receptor modulator
US9540362B2 (en) 2013-02-20 2017-01-10 Lg Life Sciences Ltd. Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
US10385043B2 (en) 2015-05-20 2019-08-20 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
US10836754B2 (en) 2015-05-20 2020-11-17 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
US11390615B2 (en) 2015-05-20 2022-07-19 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenox
US11834443B2 (en) 2015-05-20 2023-12-05 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
WO2021175225A1 (en) * 2020-03-04 2021-09-10 南京明德新药研发有限公司 Tricyclic compounds and use thereof

Also Published As

Publication number Publication date
TW201107302A (en) 2011-03-01
AR077227A1 (en) 2011-08-10
US20120101134A1 (en) 2012-04-26
JP2012530728A (en) 2012-12-06
UY32734A (en) 2010-11-30
EP2445891A4 (en) 2012-11-14
EP2445891A1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
EP2445891A1 (en) 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
AU2007336224B2 (en) Indole derivatives as S1P1 receptor agonists
US8324254B2 (en) Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists
US8217028B2 (en) 1,2,4-oxadiazole indole compounds
JP2012530108A (en) S1P1 agonists containing nitrogen-containing heterocyclyl rings
US20120094979A1 (en) Thiazole or thiadizaloe derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
EP2445892A1 (en) 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
EP2443115B1 (en) Pyrrolo-pyridine derivatives useful to treat diseases connected to S1P1 receptors
US20130012491A1 (en) Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
WO2011134280A1 (en) Compounds as agonists of s1p1 receptors
US8389508B2 (en) Heterocyclic compounds
US20120101124A1 (en) 1,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
AU2013201157B2 (en) Indole derivatives as s1p1 receptor agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10791156

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010791156

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13379431

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012516485

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE